<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10341809</article-id><article-id pub-id-type="pmcid-ver">PMC10341809.1</article-id><article-id pub-id-type="pmcaid">10341809</article-id><article-id pub-id-type="pmcaiid">10341809</article-id><article-id pub-id-type="pmid">37445714</article-id><article-id pub-id-type="doi">10.3390/ijms241310537</article-id><article-id pub-id-type="publisher-id">ijms-24-10537</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Urinary Tract Infections Caused by Uropathogenic <italic toggle="yes">Escherichia coli</italic>: Mechanisms of Infection and Treatment Options</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0556-7228</contrib-id><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yang</given-names></name><xref rid="af1-ijms-24-10537" ref-type="aff">1</xref><xref rid="af2-ijms-24-10537" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4879-7621</contrib-id><name name-style="western"><surname>Zhou</surname><given-names initials="Z">Zuying</given-names></name><xref rid="af1-ijms-24-10537" ref-type="aff">1</xref><xref rid="af2-ijms-24-10537" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="L">Lin</given-names></name><xref rid="af1-ijms-24-10537" ref-type="aff">1</xref><xref rid="af2-ijms-24-10537" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2074-9476</contrib-id><name name-style="western"><surname>Gong</surname><given-names initials="Z">Zipeng</given-names></name><xref rid="af1-ijms-24-10537" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yueting</given-names></name><xref rid="af1-ijms-24-10537" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="Y">Yang</given-names></name><xref rid="af1-ijms-24-10537" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yong</given-names></name><xref rid="af1-ijms-24-10537" ref-type="aff">1</xref><xref rid="af2-ijms-24-10537" ref-type="aff">2</xref><xref rid="c1-ijms-24-10537" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chi</surname><given-names initials="M">Mingyan</given-names></name><xref rid="af1-ijms-24-10537" ref-type="aff">1</xref><xref rid="af2-ijms-24-10537" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Verani&#269;</surname><given-names initials="P">Peter</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-24-10537"><label>1</label>State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, 4 Beijing Road, Guiyang 550004, China; <email>zy225300@163.com</email> (Y.Z.); <email>zu_ing@163.com</email> (Z.Z.); <email>zhengl2020@126.com</email> (L.Z.); <email>gzp4012607@126.com</email> (Z.G.); <email>nhwslyt@163.com</email> (Y.L.); <email>jinyang4791@163.com</email> (Y.J.); <email>naoko_568@sina.com</email> (M.C.)</aff><aff id="af2-ijms-24-10537"><label>2</label>School of Pharmaceutical Sciences, Guizhou Medical University, 4 Beijing Road, Guiyang 550004, China</aff><author-notes><corresp id="c1-ijms-24-10537"><label>*</label>Correspondence: <email>mailofhy@gmc.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2023</year></pub-date><volume>24</volume><issue>13</issue><issue-id pub-id-type="pmc-issue-id">440664</issue-id><elocation-id>10537</elocation-id><history><date date-type="received"><day>24</day><month>5</month><year>2023</year></date><date date-type="rev-recd"><day>20</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>14</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-06 17:25:14.040"><day>06</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-24-10537.pdf"/><abstract><p>Urinary tract infections (UTIs) are common bacterial infections that represent a severe public health problem. They are often caused by <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">E. coli</italic>), <italic toggle="yes">Klebsiella pneumoniae</italic> (<italic toggle="yes">K. pneumonia</italic>), <italic toggle="yes">Proteus mirabilis</italic> (<italic toggle="yes">P. mirabilis</italic>), <italic toggle="yes">Enterococcus faecalis</italic> (<italic toggle="yes">E. faecalis</italic>), and <italic toggle="yes">Staphylococcus saprophyticus</italic> (<italic toggle="yes">S. saprophyticus</italic>). Among these, uropathogenic <italic toggle="yes">E. coli</italic> (UPEC) are the most common causative agent in both uncomplicated and complicated UTIs. The adaptive evolution of UPEC has been observed in several ways, including changes in colonization, attachment, invasion, and intracellular replication to invade the urothelium and survive intracellularly. While antibiotic therapy has historically been very successful in controlling UTIs, high recurrence rates and increasing antimicrobial resistance among uropathogens threaten to greatly reduce the efficacy of these treatments. Furthermore, the gradual global emergence of multidrug-resistant UPEC has highlighted the need to further explore its pathogenesis and seek alternative therapeutic and preventative strategies. Therefore, a thorough understanding of the clinical status and pathogenesis of UTIs and the advantages and disadvantages of antibiotics as a conventional treatment option could spark a surge in the search for alternative treatment options, especially vaccines and medicinal plants. Such options targeting multiple pathogenic mechanisms of UPEC are expected to be a focus of UTI management in the future to help combat antibiotic resistance.</p></abstract><kwd-group><kwd>urinary tract infections</kwd><kwd>uropathogenic <italic toggle="yes">Escherichia coli</italic></kwd><kwd>alternative treatment options</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>82274203</award-id><award-id>U1812403</award-id></award-group><award-group><funding-source>Guizhou Science and Technology Department</funding-source><award-id>GCC(2022)031-1</award-id></award-group><funding-statement>This work was supported by the National Natural Science Foundation of China (grant number 82274203/U1812403) and the Guizhou Science and Technology Department (grant number GCC(2022)031-1).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-24-10537"><title>1. Introduction</title><p>Urinary tract infections (UTIs) are the most common bacterial infections and affect one million people globally each year [<xref rid="B1-ijms-24-10537" ref-type="bibr">1</xref>,<xref rid="B2-ijms-24-10537" ref-type="bibr">2</xref>,<xref rid="B3-ijms-24-10537" ref-type="bibr">3</xref>]. Among nosocomial infections, UTIs are second only to lower respiratory tract infections, which represent 24% of such cases in developing countries [<xref rid="B4-ijms-24-10537" ref-type="bibr">4</xref>]. A UTI requires the presence of more than 10<sup>5</sup>/mL of bacteria in the urine. The symptoms of UTIs are variable, ranging from no symptoms to a severely unwell patient with a high temperature and, sometimes, secondary bacteremia. UTIs can be divided into three categories: acute pyelonephritis, acute cystitis, and asymptomatic bacteriuria [<xref rid="B5-ijms-24-10537" ref-type="bibr">5</xref>]. Pyelonephritis is a type of kidney infection, the symptoms of which include the presence of bacteriuria and pyuria. Cystitis is a type of bladder infection, the symptoms of which include frequent urination, dysuria, suprapubic pain, lower abdominal discomfort, and foul-smelling urine. The vast majority of UTIs present as asymptomatic bacteriuria, primarily affecting the lower urinary tract. In some people, such as pregnant or menopausal women, the elderly, diabetics, prepubertal children, and patients with vesicoureteral reflux, bacteria can ascend to the bladder and kidney, making upper UTIs more likely.</p><p>Distressingly, UTIs are not only common but also have a high recurrence rate. Usually, a recurring UTI refers to three or more UTIs within one year, as well as two or more recurrences within six months. The abovementioned population is especially susceptible to chronic recurrent UTIs, which leads to the increased use of antibiotics. Women have a high risk of a UTI over their lifetime, and over 20% experience UTI recurrence in the next 6 months after being cured [<xref rid="B6-ijms-24-10537" ref-type="bibr">6</xref>,<xref rid="B7-ijms-24-10537" ref-type="bibr">7</xref>]. Recurrent UTIs can be especially frequent during pregnancy and may cause severe adverse consequences for the mother and infant, including preterm birth [<xref rid="B8-ijms-24-10537" ref-type="bibr">8</xref>]. Recurrent UTIs are a common problem in the elderly [<xref rid="B9-ijms-24-10537" ref-type="bibr">9</xref>]. Menopausal women are more likely to experience recurrent UTIs, as lower levels of estrogen lead to adverse changes in the urogenital epithelium and urogenital microbiome [<xref rid="B10-ijms-24-10537" ref-type="bibr">10</xref>]. In addition, UTIs affect nearly one-third of children within one year of birth, and about 30% develop recurrent UTIs [<xref rid="B11-ijms-24-10537" ref-type="bibr">11</xref>,<xref rid="B12-ijms-24-10537" ref-type="bibr">12</xref>]. Among the causative factors, bladder and bowel dysfunction (BBD) and vesicoureteral reflux (VUR) are risk factors for recurrent UTIs, especially when they occur simultaneously [<xref rid="B13-ijms-24-10537" ref-type="bibr">13</xref>,<xref rid="B14-ijms-24-10537" ref-type="bibr">14</xref>]. Bacteria re-emerging in the bladder epithelium also cause UTI recurrence [<xref rid="B15-ijms-24-10537" ref-type="bibr">15</xref>].</p><p>UTIs are caused by a wide range of pathogens, including Gram-negative and Gram-positive bacteria, as well as fungi. According to the epidemiology of UTIs (<xref rid="ijms-24-10537-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B1-ijms-24-10537" ref-type="bibr">1</xref>,<xref rid="B16-ijms-24-10537" ref-type="bibr">16</xref>], uropathogenic <italic toggle="yes">E. coli</italic> (UPEC) are the main pathogenic factor for UTIs, accounting for about 75% of uncomplicated UTI cases; however, less common pathogens, such as <italic toggle="yes">Klebsiella pneumoniae</italic> (<italic toggle="yes">K. pneumonia</italic>), <italic toggle="yes">Staphylococcus saprophyticus</italic> (<italic toggle="yes">S. saprophyticus</italic>), <italic toggle="yes">Enterococcus faecalis</italic> (<italic toggle="yes">E. faecalis</italic>), group B <italic toggle="yes">Streptococcus</italic> (GBS), <italic toggle="yes">Proteus mirabilis</italic> (<italic toggle="yes">P. mirabilis</italic>), <italic toggle="yes">Pseudomonas aeruginosa</italic> (<italic toggle="yes">P. aeruginosa</italic>), <italic toggle="yes">Staphylococcus aureus</italic> (<italic toggle="yes">S. aureus</italic>), and other pathogenic bacteria cause opportunistic UTIs. UPEC UTIs account for more than half of complicated UTI cases [<xref rid="B1-ijms-24-10537" ref-type="bibr">1</xref>]. Therefore, in patients suffering from UPEC UTI, maintenance therapy is ensured by antibiotic prophylaxis. Furthermore, UTIs need to be treated by surgery in some cases, especially when UPEC UTIs develop into recurrent UTIs. However, invalid traditional treatments, antibiotic resistance, and the trauma of surgery have made seeking alternative and complementary treatments urgent, with vaccines and medicinal plants showing significant potential. Therefore, UTIs are a major challenge faced by humans worldwide, and ascertaining their causes and finding the most effective treatments are crucial.</p><p>&#8220;In this review, the UPEC of concern are the most common pathogenic pathogen for UTIs. The properties of UPEC are summarized, including adherence, motility, toxin production, metal acquisition, intracellular bacterial communities (IBCs), and the evasion of host immune defenses, which can help to understand the pathogenesis of UPEC UTI. In addition, the treatment of UTIs is described, including conventional drugs and complementary and alternative medicines, as well as the presence of antibiotic resistance and the great potential of vaccines and medicinal plants. Finally, we present an outlook, with the hope that this paper will draw attention to recent advances in the field of UTI therapeutics&#8221;.</p></sec><sec id="sec2-ijms-24-10537"><title>2. Mechanisms of UPEC UTIs</title><p>The urethra has a self-defense function and usually prevents UTIs. The urethral mucosa and epithelial cells can resist the invasion of pathogenic bacteria, maintaining a balance between the urethra and bacteria. However, when the pathogenicity of bacteria is very strong, or the body suffers from external damage, this balance is disturbed, and the defense function of the body is compromised. Subsequently, a series of inflammatory reactions occur in the urinary tract, such as urethritis, cystitis, and pyelonephritis. Certain factors of UPEC often play an important role in these reactions, such as lipopolysaccharides (LPSs), polysaccharide capsules, flagella, outer-membrane vesicles, fimbriae, curli, non-fimbrial adhesins, outer-membrane proteins (OMPs), and iron-acquisition receptors [<xref rid="B16-ijms-24-10537" ref-type="bibr">16</xref>,<xref rid="B17-ijms-24-10537" ref-type="bibr">17</xref>]. UPEC are more likely to infect the host from the lower urinary tract. When the impact of UPEC on the body cannot be ignored, the host suffers from a UTI or even more serious disease. Usually, the physiological process of UPEC in the host body can be roughly divided into six steps (<xref rid="ijms-24-10537-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B18-ijms-24-10537" ref-type="bibr">18</xref>].</p><p>The first step is UPEC-induced periurethral and vaginal invasion and colonization. Various fimbriae and adhesins on the surface of UPEC play a pivotal role in mediating adhesion and colonization. The second step is ascension into the bladder lumen and growth as planktonic cells in the urine. The third step is adherence to the surface and interaction with the defensive system of the bladder epithelium. The fourth step is biofilm formation. UPEC proliferate and accumulate to a certain degree to form the biofilm. The biofilm is important in ensuring that bacterial pathogens can colonize the urinary tract and cause infection. Once the biofilm is formed, it may elude immune defense mechanisms. At the same time, the biofilm also exhibits strong drug resistance, and it is difficult for drugs to penetrate the biofilm, leading to chronic and recurrent UTIs [<xref rid="B1-ijms-24-10537" ref-type="bibr">1</xref>,<xref rid="B19-ijms-24-10537" ref-type="bibr">19</xref>,<xref rid="B20-ijms-24-10537" ref-type="bibr">20</xref>]. The fifth step is invasion and replication via the formation of IBCs in the bladder, where quiescent intracellular reservoirs (QIRs) arise in the underlying urothelium. Bacterial replication in these IBCs can easily reach as high as 10<sup>5</sup> bacteria per cell. Additionally, bacteria in the IBCs undergo morphological changes, emerge from the infected cell, and enter neighboring cells, which spreads the infection. The sixth step is kidney colonization. UPEC destroy host tissues by releasing toxins, causing upper UTIs, and severe cases may lead to dangerous conditions, including bacteremia, septicemia, urosepsis, and even death [<xref rid="B18-ijms-24-10537" ref-type="bibr">18</xref>,<xref rid="B21-ijms-24-10537" ref-type="bibr">21</xref>]. These cascade stages occur when UPEC successfully attach to host urothelial cells. In the abovementioned process of UPEC action, adhesins, virulence, IBCs, and other factors have important research significance. In general, the strategies of pathogenesis employed by UPEC include adherence, motility, the acquisition of metals, toxin production, and immune evasion. The bacterial adhesins and their receptors on the host&#8217;s cells mediate the processes of bacterial colonization, biofilm formation, replication, secretion of toxins, internalization, and invasion [<xref rid="B18-ijms-24-10537" ref-type="bibr">18</xref>,<xref rid="B22-ijms-24-10537" ref-type="bibr">22</xref>,<xref rid="B23-ijms-24-10537" ref-type="bibr">23</xref>]. In this section, we discuss several of the main factors in UPEC pathogenesis, particularly chaperone&#8211;usher fimbrial adhesins, to provide a clearer understanding of the pathogenesis of UPEC UTIs.</p><sec id="sec2dot1-ijms-24-10537"><title>2.1. UPEC Adhesins</title><p>Adhesins, a wide range of adhesive proteins assembled by bacteria, can mediate binding to receptors and the colonization of surfaces. Over the past two decades, the whole-genome sequencing of several standard library UPEC strains has revealed the presence of multiple known and putative adhesins in each strain, some of which have been demonstrated to enhance the ability to colonize the urinary tract (<xref rid="ijms-24-10537-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B24-ijms-24-10537" ref-type="bibr">24</xref>,<xref rid="B25-ijms-24-10537" ref-type="bibr">25</xref>,<xref rid="B26-ijms-24-10537" ref-type="bibr">26</xref>,<xref rid="B27-ijms-24-10537" ref-type="bibr">27</xref>,<xref rid="B28-ijms-24-10537" ref-type="bibr">28</xref>,<xref rid="B29-ijms-24-10537" ref-type="bibr">29</xref>]. Among these, adhesive fibers called pili or fimbriae have attracted widespread attention. Fimbriae are long fibers that extend beyond the bacterial capsule. In diverse genera of Gram-negative bacteria, a molecular machine known as the chaperone&#8211;usher pathway (CUP) mediates the assembly of fimbriae on the bacterial outer membrane [<xref rid="B24-ijms-24-10537" ref-type="bibr">24</xref>]. At the tips of fimbriae, adhesins are thought to play an important role in the adherence of bacteria to host epithelial receptors [<xref rid="B25-ijms-24-10537" ref-type="bibr">25</xref>,<xref rid="B26-ijms-24-10537" ref-type="bibr">26</xref>,<xref rid="B27-ijms-24-10537" ref-type="bibr">27</xref>]. Each sequenced UPEC strain encodes a multitude of CUP operons [<xref rid="B28-ijms-24-10537" ref-type="bibr">28</xref>]. At present, several CUP operons, including Auf, Dr, F1C, S, type 9, type 3, type 1, and P fimbriae, have been recognized in UPEC pathotypes (<xref rid="ijms-24-10537-f003" ref-type="fig">Figure 3</xref>), but of those that are broadly conserved among UPEC isolates, only two (type 1 and P fimbriae) have so far been strongly implicated in UTI pathogenesis [<xref rid="B29-ijms-24-10537" ref-type="bibr">29</xref>,<xref rid="B30-ijms-24-10537" ref-type="bibr">30</xref>,<xref rid="B31-ijms-24-10537" ref-type="bibr">31</xref>]. CUP adhesins are known to recognize certain receptors with stereochemical specificity, elucidating causative factors and possible drug mechanisms.</p><p>As well-known mannose-sensitive organelles, type 1 fimbriae can generate stable bonds with mannosylated glycoproteins of uroplakins (UPs) [<xref rid="B32-ijms-24-10537" ref-type="bibr">32</xref>], as well as N-linked oligosaccharides on <italic toggle="yes">&#945;</italic>3 and <italic toggle="yes">&#946;</italic>1 integrins [<xref rid="B33-ijms-24-10537" ref-type="bibr">33</xref>] and the pattern-recognition Toll-like receptor 4 (TLR4) [<xref rid="B34-ijms-24-10537" ref-type="bibr">34</xref>], all of which are expressed in the urine bladder to cause successful UTIs. FimH as the tip adhesin of type 1 fimbriae encompasses a lectin domain on the N-terminal head and a fimbrin domain on the C-terminal end, which has a pathogen-associated molecular pattern (PAMP) role [<xref rid="B35-ijms-24-10537" ref-type="bibr">35</xref>,<xref rid="B36-ijms-24-10537" ref-type="bibr">36</xref>]. As another important fimbrial organelle for UPEC cell adhesion, P fimbriae can bind to <italic toggle="yes">&#945;</italic>-D-galactopyranosyl-1,4-<italic toggle="yes">&#946;</italic>-D-galactopyranoside in the globo-series glycolipids [<xref rid="B37-ijms-24-10537" ref-type="bibr">37</xref>], whose tip adhesin is PapG. Therefore, it is important to understand type 1 and P fimbriae and their respective characteristic adhesins.</p><sec id="sec2dot1dot1-ijms-24-10537"><title>2.1.1. Type 1 Fimbriae and FimH</title><p>Considerable evidence suggests that type 1 fimbriae are a critical virulence factor in UPEC-derived UTIs in humans [<xref rid="B29-ijms-24-10537" ref-type="bibr">29</xref>,<xref rid="B30-ijms-24-10537" ref-type="bibr">30</xref>,<xref rid="B31-ijms-24-10537" ref-type="bibr">31</xref>,<xref rid="B38-ijms-24-10537" ref-type="bibr">38</xref>]. In addition, type 1 fimbriae have also been shown to play a critical role in establishing cystitis in an experimental murine UTI model [<xref rid="B39-ijms-24-10537" ref-type="bibr">39</xref>,<xref rid="B40-ijms-24-10537" ref-type="bibr">40</xref>], and they are required for UPEC adherence to human urothelial tissue culture cells [<xref rid="B41-ijms-24-10537" ref-type="bibr">41</xref>,<xref rid="B42-ijms-24-10537" ref-type="bibr">42</xref>]. Many studies have found that nearly five hundred right-handed helical rod-shaped type 1 fimbriae exist on the surface of UPEC [<xref rid="B23-ijms-24-10537" ref-type="bibr">23</xref>,<xref rid="B38-ijms-24-10537" ref-type="bibr">38</xref>,<xref rid="B43-ijms-24-10537" ref-type="bibr">43</xref>]. Furthermore, they can be up to 2 &#956;m in length and 10 nm in width, which guarantees successful bacterial attachment. Meanwhile, numerous studies have found that over 50% of women with an acute UTI show strong positive type 1 fimbriae via the immunostaining of urine sediments [<xref rid="B44-ijms-24-10537" ref-type="bibr">44</xref>], with results comparable to those obtained in acutely infected mice [<xref rid="B45-ijms-24-10537" ref-type="bibr">45</xref>]. Interestingly, a study found that urine decreases the UPEC expression of type 1 fimbriae [<xref rid="B46-ijms-24-10537" ref-type="bibr">46</xref>,<xref rid="B47-ijms-24-10537" ref-type="bibr">47</xref>], which may explain the results above. Normally, type 1 fimbrial adhesin subunits are bound to uroplakin molecules in urothelial cells. After successful binding, the phosphorylation processes follow [<xref rid="B48-ijms-24-10537" ref-type="bibr">48</xref>]. During phosphorylation procedures, certain signaling pathways associated with bacterial invasion, apoptosis, and the regulation of intracellular ions of calcium within urothelial cells and tissues are complete [<xref rid="B48-ijms-24-10537" ref-type="bibr">48</xref>]. At the same time, the kidney cells secrete Tamm&#8211;Horsfall protein molecules into the urine [<xref rid="B49-ijms-24-10537" ref-type="bibr">49</xref>]. As an 8.7 kbp operon, <italic toggle="yes">fimBEAICDFGH</italic>, which encodes type 1 fimbriae, is highly conserved. Accordingly, proteins with various functions are produced: regulatory proteins (FimB and FimE); a major subunit (FimA); minor subunits/adaptor subunits (FimI, FimF, and FimG); a chaperone (FimC); an usher (FimD); and an adhesin (FimH) (<xref rid="ijms-24-10537-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B50-ijms-24-10537" ref-type="bibr">50</xref>].</p><p>As a distal adhesin subunit of type 1 fimbriae, when FimH attaches to the superficial urothelial receptors, it may lead to inflammatory responses, such as dysuria and other painful symptoms in the urinary tract [<xref rid="B36-ijms-24-10537" ref-type="bibr">36</xref>]. Numerous studies have found that the expression of FimH is required for bacterial adherence to human bladder tissue in situ [<xref rid="B41-ijms-24-10537" ref-type="bibr">41</xref>,<xref rid="B42-ijms-24-10537" ref-type="bibr">42</xref>], and the vaccination of mice and cynomolgus monkeys with FimH has protected them against experimental cystitis [<xref rid="B39-ijms-24-10537" ref-type="bibr">39</xref>,<xref rid="B40-ijms-24-10537" ref-type="bibr">40</xref>]. Interestingly, the receptor for type 1 fimbriae appears to vary depending on the state of urothelial cell differentiation. In mature superficial umbrella cells, the FimH receptor is the mannosylated uroplakin protein UPIa [<xref rid="B32-ijms-24-10537" ref-type="bibr">32</xref>]. After binding to UPIa, the phosphorylation of UPIIIa occurs. UPIIIa is the only one of the four major uroplakins with a potential cytoplasmic signaling domain, leading to increased intracellular calcium and enhanced invasion [<xref rid="B51-ijms-24-10537" ref-type="bibr">51</xref>,<xref rid="B52-ijms-24-10537" ref-type="bibr">52</xref>]. However, in vitro studies found that some immature urothelial cells, such as 5637 bladder transitional carcinoma cells, generally do not express uroplakins on the cell surface, while mannosylated <italic toggle="yes">&#945;</italic>3 and <italic toggle="yes">&#946;</italic>1 integrins are expressed and have been shown to bind to FimH [<xref rid="B33-ijms-24-10537" ref-type="bibr">33</xref>]. Simultaneously, bacterial invasion after FimH binding has been reported to involve components of clathrin-coated pits (for example, the cargo-adaptor protein AP-2 [<xref rid="B53-ijms-24-10537" ref-type="bibr">53</xref>]). The adhesin subunit of FimH encompasses a lectin domain on the N-terminal head, contributing to fimbrial polymerization by attaching to the related fimbrial subunit. On the other hand, the C-terminal end is a fimbrin domain, which links to superficial glycan molecules acting as the host&#8217;s urothelial cell receptors [<xref rid="B50-ijms-24-10537" ref-type="bibr">50</xref>]. In addition, several amino-acid residues of FimH have been found to be under positive selection [<xref rid="B54-ijms-24-10537" ref-type="bibr">54</xref>,<xref rid="B55-ijms-24-10537" ref-type="bibr">55</xref>,<xref rid="B56-ijms-24-10537" ref-type="bibr">56</xref>]. Further studies have found that FimH mediates pathoadaptive mutations in UPEC clinical isolates. When mutations of these residues occurred, the virulence in a murine model of cystitis was reduced, which suggested that FimH plays an important role in human UTIs in vivo [<xref rid="B56-ijms-24-10537" ref-type="bibr">56</xref>]. </p></sec><sec id="sec2dot1dot2-ijms-24-10537"><title>2.1.2. P Fimbriae and PapG</title><p>The role of P fimbriae in UTIs is complex and has not yet been fully explored, but a substantial amount of evidence demonstrates its importance to UPEC [<xref rid="B57-ijms-24-10537" ref-type="bibr">57</xref>,<xref rid="B58-ijms-24-10537" ref-type="bibr">58</xref>]. Several studies have reported that P fimbriae are strongly related to pyelonephritis in children [<xref rid="B14-ijms-24-10537" ref-type="bibr">14</xref>,<xref rid="B59-ijms-24-10537" ref-type="bibr">59</xref>] but are not highly expressed in women with acute and recurrent UTIs, only accounting for 40% to 50% in isolates [<xref rid="B60-ijms-24-10537" ref-type="bibr">60</xref>]. This is likely due to the occurrence of inflammation in acute pyelonephritis and the reduced requirement for P fimbriae in kidney colonization during severe or recurrent UTIs [<xref rid="B50-ijms-24-10537" ref-type="bibr">50</xref>,<xref rid="B61-ijms-24-10537" ref-type="bibr">61</xref>]. The linkage of the overwhelming majority of UPEC on urothelial cells is mediated by P fimbriae. &#945;-D-galactopyranosyl-1,4-<italic toggle="yes">&#946;</italic>-D-galactopyranoside, present in the globo-series glycolipids including GbO3, GbO4, and GbO5, is the receptor for urothelial cells and links with P fimbriae [<xref rid="B43-ijms-24-10537" ref-type="bibr">43</xref>]. In humans who are non-secretors of ABO antigens, P fimbriae receptors are found more abundantly on the surface of the kidneys and lower urogenital tract urothelial cells [<xref rid="B62-ijms-24-10537" ref-type="bibr">62</xref>]. Recent studies have revealed that many glyco(galacto)lipids exist on the surface of the kidneys&#8217; urothelial cells, indicating the connection between the tip adhesins of P fimbriae and the superficial di-galactose molecules of glycolipid receptors in the kidneys [<xref rid="B23-ijms-24-10537" ref-type="bibr">23</xref>]. The above connection may lead to the production of sphingolipid ceramide molecules, which activate the TLR4 signaling pathway [<xref rid="B23-ijms-24-10537" ref-type="bibr">23</xref>]. In addition, sphingolipid ceramide molecules regulate certain immune system responses such as proinflammatory cytokines, chemokines (IL-6 and IL-8), and the activation of some groups of leukocytes [<xref rid="B63-ijms-24-10537" ref-type="bibr">63</xref>]. Therefore, the occurrence of inflammation can contribute to the elimination of UPEC cells, but it may also harm kidney tissues, prompting the occurrence of acute pyelonephritis. This could explain why the secretor/non-secretor status of ABO antigens is a significant risk factor for UTIs. However, the chronic inflammatory changes in patients with severe or recurrent UTIs may lessen the requirement for P fimbriae when colonizing the kidney [<xref rid="B61-ijms-24-10537" ref-type="bibr">61</xref>].</p><p>The number of <italic toggle="yes">papIBAHCDJKEFG</italic>&#8212;10 kbp operons located on pathogenicity islands (PAIs) [<xref rid="B64-ijms-24-10537" ref-type="bibr">64</xref>]&#8212;depends on various classes of adhesin subunits (ranging from 9 to 12 genes). Accordingly, P fimbrial proteins with different functions encoded by <italic toggle="yes">papIBAHCDJKEFG</italic> are produced: a tip adhesin (PapG), adapter proteins (PapF, PapE, and PapK), a major subunit (PapA), and a terminator subunit (PapH) [<xref rid="B50-ijms-24-10537" ref-type="bibr">50</xref>,<xref rid="B65-ijms-24-10537" ref-type="bibr">65</xref>]. Other proteins encoded by <italic toggle="yes">papIBAHCDJKEFG</italic> include regulator molecules (PapI and PapB), an usher molecule (PapC), a chaperone molecule (PapD), and a minor subunit (PapJ) (<xref rid="ijms-24-10537-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B50-ijms-24-10537" ref-type="bibr">50</xref>,<xref rid="B65-ijms-24-10537" ref-type="bibr">65</xref>]. Three alleles of the <italic toggle="yes">papG</italic> gene (PapGI, PapGII, and PapGIII) are recognized among UPEC pathotypes, which differ in their binding specificity to globosides. Among these, PapGII, the most common in UPEC strains, is identified through its receptor isotype, GbO4, and is required for the establishment of pyelonephritis and bacteremia in mammals [<xref rid="B65-ijms-24-10537" ref-type="bibr">65</xref>,<xref rid="B66-ijms-24-10537" ref-type="bibr">66</xref>]. PapGIII, which binds to GbO5, is involved in acute cystitis. A recent clinical study found that horizontally acquired papGII-containing pathogenicity islands underlie the emergence of invasive UPEC lineages [<xref rid="B57-ijms-24-10537" ref-type="bibr">57</xref>]. However, in a CBA murine model of infection, a lack of PapGII did not affect pathogenesis [<xref rid="B67-ijms-24-10537" ref-type="bibr">67</xref>]. PapGII was found to be unnecessary for robust bladder infection in a primate model of uncomplicated cystitis [<xref rid="B2-ijms-24-10537" ref-type="bibr">2</xref>]. Alternative adhesins capable of colonizing the kidney epithelium may have influenced the above studies. Additionally, the GbO4 receptor may not be highly expressed in non-mammals [<xref rid="B68-ijms-24-10537" ref-type="bibr">68</xref>]. Live multiphoton studies suggest that P and type 1 fimbriae may work together to colonize renal tubules by promoting bacterial attachment and biofilm growth [<xref rid="B69-ijms-24-10537" ref-type="bibr">69</xref>]. Thus, although P fimbriae are not highly conserved and are only expressed in about half of UTI isolates, drugs targeting both type 1 and P fimbriae may provide broad bladder and kidney protection.</p></sec><sec id="sec2dot1dot3-ijms-24-10537"><title>2.1.3. Other Fimbriae and Non-Fimbrial Adhesins</title><p>The Auf fimbriae are the products of the CUP, in which periplasmic chaperones cooperate with outer-membrane usher proteins to polymerize fimbrin (pilin) subunits and produce these fimbrial organelles. More CUP-assembled pilus operons have been found in UPEC than in commensal bacteria, in addition to those expressing type 1 and P fimbriae. However, the receptors and activities of these extra UPEC-associated fimbriae have not been fully validated, and neither have those of type 1 and P fimbriae. S, F1C, and type 9 fimbriae are enriched in UPEC but less well conserved and provide a weaker contribution to biofilm formation than type 1 and P fimbriae. In frozen tissue sections, they have been shown to have the ability to bind to human kidney epithelia, and they may have different functions during different UTI phases [<xref rid="B70-ijms-24-10537" ref-type="bibr">70</xref>,<xref rid="B71-ijms-24-10537" ref-type="bibr">71</xref>,<xref rid="B72-ijms-24-10537" ref-type="bibr">72</xref>]. F1C fimbriae, part of the S fimbriae superfamily, are found in about 30% of UPEC strains [<xref rid="B29-ijms-24-10537" ref-type="bibr">29</xref>]. The adhesive virulence factor of S fimbriae has been identified in UPEC [<xref rid="B50-ijms-24-10537" ref-type="bibr">50</xref>]. Additionally, the binding ability of S fimbriae with sialic acid molecules has led to urosepsis [<xref rid="B38-ijms-24-10537" ref-type="bibr">38</xref>]. Type 9 fimbriae play a significant role in the formation of biofilms on abiotic surfaces, which may explain their contribution to CAUTIs [<xref rid="B73-ijms-24-10537" ref-type="bibr">73</xref>,<xref rid="B74-ijms-24-10537" ref-type="bibr">74</xref>]. Like Auf, F1C, S, and type 9 fimbriae, type 3 fimbriae contribute to bacterial colonization and biofilm formation processes in UPEC [<xref rid="B50-ijms-24-10537" ref-type="bibr">50</xref>]. In addition, the Ygi pilus provided a slight advantage during kidney colonization, whereas the Yad pilus was found to contribute to the adhesion of UPEC to bladder epithelial cells in vitro but was not necessary for experimental UTI in mice [<xref rid="B75-ijms-24-10537" ref-type="bibr">75</xref>]. While fimbriae are essential in the initial attachment of UPEC to the mucosa of the urinary tract, the bacteria also produce many outer-membrane vesicles, which may be crucial in the pathophysiology of the illness. Gram-negative bacteria produce outer-membrane vesicles at all phases of their development [<xref rid="B76-ijms-24-10537" ref-type="bibr">76</xref>]. The creation of membrane vesicles is thought to be a &#8220;smart&#8221; technique for bacteria to protect their toxins and an effective way to transport them to the host cell [<xref rid="B77-ijms-24-10537" ref-type="bibr">77</xref>]. TosA, a new adhesin released by a related type 1 secretion pathway, was recently reported [<xref rid="B78-ijms-24-10537" ref-type="bibr">78</xref>]. About 30% of urinary tract isolates include TosA, which is expressed during UTIs [<xref rid="B78-ijms-24-10537" ref-type="bibr">78</xref>,<xref rid="B79-ijms-24-10537" ref-type="bibr">79</xref>,<xref rid="B80-ijms-24-10537" ref-type="bibr">80</xref>]. However, the function of TosA in UTIs remains unknown. FdeC, another adhesin, is allegedly produced exclusively when in contact with host cells and is well conserved across all pathotypes of <italic toggle="yes">E. coli</italic> and intestinal commensals [<xref rid="B81-ijms-24-10537" ref-type="bibr">81</xref>]. The presence of FdeC provided the mouse model with a competitive edge in bladder and kidney colonization, while the immunization of mice with FdeC antigens had no effect on bladder infection and only protected against kidney infection. UpaG, another autotransporter, promoted cell aggregation and the formation of biofilms and provided adherence to epithelial cells of the human bladder. However, UpaG may not be required for colonization [<xref rid="B82-ijms-24-10537" ref-type="bibr">82</xref>]. In addition, the iron-regulated adhesin Iha was demonstrated to mediate adhesion to bladder epithelial cells and grant UPEC a significant advantage in a mouse model of a UTI [<xref rid="B83-ijms-24-10537" ref-type="bibr">83</xref>]. An additional structure, the curli protein, is usually produced by <italic toggle="yes">E. coli</italic> and contributes to adhesion, host colonization, biofilm formation, and invasion [<xref rid="B84-ijms-24-10537" ref-type="bibr">84</xref>,<xref rid="B85-ijms-24-10537" ref-type="bibr">85</xref>,<xref rid="B86-ijms-24-10537" ref-type="bibr">86</xref>]. The extracellular nucleation/precipitation mechanism is included in the pathway for curli assembly on the bacterial surface, which differs from CUP and other pilus assembly systems. Through this mechanism, curli subunit proteins are first secreted onto the cell surface, before being incorporated into the growing fiber. Several studies have demonstrated that curli recognition is mediated by TLR2, which can result in the activation of pro-inflammatory molecules such as IL-6, IL-8, and TNF-&#945; [<xref rid="B87-ijms-24-10537" ref-type="bibr">87</xref>,<xref rid="B88-ijms-24-10537" ref-type="bibr">88</xref>]. Consistent with the above results, a study of the murine urinary tract reported that the curli shows multiple functions, including a pro-inflammatory response [<xref rid="B89-ijms-24-10537" ref-type="bibr">89</xref>]. In summary, although the roles of other fimbriae and non-fimbrial adhesins have been explored, P fimbriae and type 1 fimbriae play the most important role in bacterial action.</p></sec></sec><sec id="sec2dot2-ijms-24-10537"><title>2.2. Flagella-Mediated Motility</title><p>In addition to adherence, bacterial motility is another characteristic that is usually associated with the virulence of bacterial infections. Flagella are complex surface structures that mediate motility and contribute to fitness during UPEC UTIs [<xref rid="B90-ijms-24-10537" ref-type="bibr">90</xref>,<xref rid="B91-ijms-24-10537" ref-type="bibr">91</xref>]. The regulation of flagella and fimbriae has been shown to be coordinated. A transcriptional regulator called PapX was found to be present at the 3&#8242; end of the P fimbrial operon in UPEC. The flagellin protein (FlaA), flagella production, and the motility of bacteria were all decreased by the overexpression of PapX [<xref rid="B92-ijms-24-10537" ref-type="bibr">92</xref>]. In addition, as a transcriptional repressor, PapX inhibited the transcription of the <italic toggle="yes">flhDC</italic> gene, which acts as a sort of master regulator of flagellar motility [<xref rid="B17-ijms-24-10537" ref-type="bibr">17</xref>]. Therefore, the flagella and fimbriae in <italic toggle="yes">E. coli</italic> are connected.</p><p>Furthermore, flagella-related gene expression was regulated during the growth phase of <italic toggle="yes">E. coli</italic>, indicating that flagella are involved in several functions during the processes of adhesion, maturation, and proliferation [<xref rid="B93-ijms-24-10537" ref-type="bibr">93</xref>,<xref rid="B94-ijms-24-10537" ref-type="bibr">94</xref>]. During the processes of adhesion and colonization, a torsional change in the outer membrane of bacteria happens after contact with a urinary catheter. This kind of change can be sensed by regulators of the flagellar master operon proteins, which induce the expression of flagella to produce the highly flagellated bacteria that are required for swarming during UTIs [<xref rid="B1-ijms-24-10537" ref-type="bibr">1</xref>,<xref rid="B90-ijms-24-10537" ref-type="bibr">90</xref>,<xref rid="B91-ijms-24-10537" ref-type="bibr">91</xref>]. On the other hand, flagella participate in the formation of a multicellular bacterial community that is protected from immune responses, antimicrobial agents, and other stresses. Therefore, bacteria can mature and proliferate rapidly [<xref rid="B1-ijms-24-10537" ref-type="bibr">1</xref>,<xref rid="B90-ijms-24-10537" ref-type="bibr">90</xref>,<xref rid="B91-ijms-24-10537" ref-type="bibr">91</xref>]. Additionally, the ascent of UPEC to the upper urinary system, which reaches its peak in the murine kidney, coincided with the growth of flagella [<xref rid="B95-ijms-24-10537" ref-type="bibr">95</xref>]. The importance of flagella for kidney colonization has not been proven, though several mutants with decreased flagellar motility were not found to be consistently deficient during kidney colonization in competitive infection studies [<xref rid="B90-ijms-24-10537" ref-type="bibr">90</xref>,<xref rid="B96-ijms-24-10537" ref-type="bibr">96</xref>].</p></sec><sec id="sec2dot3-ijms-24-10537"><title>2.3. Toxins</title><p>Three main types of toxins are produced by UPEC and secreted into their surroundings: hemolysin, cytotoxic necrotizing factor 1 (CNF1), and secreted autotransporter toxins. Hemolysin, encoded by the <italic toggle="yes">hlyCABD</italic> operon, is a prototypical calcium-dependent repeats in toxin secreted protein that can penetrate uroepithelial cell membranes. Although hemolysin has not been shown to be necessary for colonization in experimental UTI, it does contribute to virulence because it is associated with renal damage and scarring. According to reports, it induces Ca<sup>2+</sup> oscillations in renal tubular epithelial cells at small physiological doses, further disrupting normal urine flow, thereby enhancing UPEC ascension and colonization in the ureters and kidney parenchyma [<xref rid="B97-ijms-24-10537" ref-type="bibr">97</xref>]. Furthermore, hemolysin was also found to induce pro-inflammatory caspase-1/caspase-4-dependent cell death in bladder epithelial cells, resulting in cell exfoliation. In addition, hemolysin can attenuate UPEC strains during acute infections in mice, suggesting that acute bladder exfoliation is a host defense mechanism [<xref rid="B98-ijms-24-10537" ref-type="bibr">98</xref>]. CNF1 activity causes the Rho family of GTP-binding proteins to be constitutively activated, which induces host cells to remodel their cytoskeletons [<xref rid="B99-ijms-24-10537" ref-type="bibr">99</xref>]. CNF1 has been linked to host cell invasion and cellular adhesion, which might represent fitness factors in hosts [<xref rid="B100-ijms-24-10537" ref-type="bibr">100</xref>,<xref rid="B101-ijms-24-10537" ref-type="bibr">101</xref>]. In addition, UPEC strains positively expressing CNF1 increase inflammation and bladder cell apoptosis through the activation of the Rho GTP-binding proteins Rac1, RhoA, and CDC42, suggesting that CNF1 might stimulate the exfoliation of bladder cells in vivo, thereby exposing underlying tissues [<xref rid="B102-ijms-24-10537" ref-type="bibr">102</xref>]. Other UPEC toxins, i.e., serine protease autotransporters of <italic toggle="yes">Enterobacteriaceae</italic> (SPATEs) including Sat, Pic, and Tsh, have been proven to contribute to renal pathology [<xref rid="B103-ijms-24-10537" ref-type="bibr">103</xref>,<xref rid="B104-ijms-24-10537" ref-type="bibr">104</xref>]. Sat (secreted autotransporter toxin) mediates cytopathic effects on bladder and kidney cells in vitro and elongates kidney cells with the apparent impairment of cellular junctions [<xref rid="B104-ijms-24-10537" ref-type="bibr">104</xref>,<xref rid="B105-ijms-24-10537" ref-type="bibr">105</xref>]. In addition, it can degrade human coagulation factor V [<xref rid="B106-ijms-24-10537" ref-type="bibr">106</xref>] and induce autophagic cell detachment [<xref rid="B107-ijms-24-10537" ref-type="bibr">107</xref>]. Pic, acting as a mucinase, is expressed during infection. However, it is unnecessary for colonization [<xref rid="B103-ijms-24-10537" ref-type="bibr">103</xref>,<xref rid="B108-ijms-24-10537" ref-type="bibr">108</xref>]. Tsh, also called vat, (vacuolating autotransporter toxin) in CFT073, is again expressed during infection and contributes to UTIs [<xref rid="B103-ijms-24-10537" ref-type="bibr">103</xref>,<xref rid="B109-ijms-24-10537" ref-type="bibr">109</xref>,<xref rid="B110-ijms-24-10537" ref-type="bibr">110</xref>].</p></sec><sec id="sec2dot4-ijms-24-10537"><title>2.4. Metal Acquisition</title><p>Iron, an essential nutrient, is ingested by hosts and can be acquired by bacterial pathogens. Iron acquisition is another requirement for bacterial virulence [<xref rid="B111-ijms-24-10537" ref-type="bibr">111</xref>,<xref rid="B112-ijms-24-10537" ref-type="bibr">112</xref>]. The most diverse and broadly distributed iron acquisition mechanisms used by bacteria are siderophore acquisition systems. The primary function of siderophores, which are small chelating molecules with a very high affinity for iron, is assumed to be scavenging ferric iron (Fe<sup>3+</sup>) [<xref rid="B113-ijms-24-10537" ref-type="bibr">113</xref>]. Deleting rhyB in CFT073 reduced siderophore production and decreased bladder and kidney colonization [<xref rid="B114-ijms-24-10537" ref-type="bibr">114</xref>]. A small regulatory noncoding RNA, rhyB, plays a role in the regulation of siderophore production in <italic toggle="yes">E. coli.</italic> Direct host iron capture occurs either from free heme or from proteins containing heme, such as hemoglobin. Heme is a direct source of iron in vivo that can be obtained via the direct heme uptake systems in UPEC. Hma and ChuA, which are iron-binding receptors, bind to heme and transport it to the periplasm. An ATP-binding cassette (ABC) transporter is then used by ChuT to mediate further transfer to the cytoplasm [<xref rid="B115-ijms-24-10537" ref-type="bibr">115</xref>,<xref rid="B116-ijms-24-10537" ref-type="bibr">116</xref>]. ChuA is extensively expressed in IBCs, and a deletion mutant deficient in this heme transporter greatly shrinks IBCs in vivo [<xref rid="B114-ijms-24-10537" ref-type="bibr">114</xref>]. Additionally, microbes can sequester host iron through siderophores with high affinity, such as enterobactin, salmochelins, aerobactin, and yersiniabactin [<xref rid="B117-ijms-24-10537" ref-type="bibr">117</xref>]. Enterobactin is broadly conserved among <italic toggle="yes">E. coli</italic> strains, whereas the production of yersiniabactin, salmochelin, and aerobactin is concentrated in UPEC. Salmochelins are encoded by the <italic toggle="yes">iroBCDEN</italic> gene cluster. By escaping the effects of the host lipocalin-2 molecule, this siderophore increases the pathogenicity of ExPEC strains [<xref rid="B118-ijms-24-10537" ref-type="bibr">118</xref>]. Salmochelins exhibit greater affinity than enterobactin and are highly expressed at a low pH [<xref rid="B119-ijms-24-10537" ref-type="bibr">119</xref>]. IroN, the salmochelin receptor, may have numerous functions, as it has been demonstrated to facilitate the bacterial invasion of bladder epithelial cells in vitro, and a mutant UPEC strain lacking IroN was inhibited in a cystitis mouse model [<xref rid="B120-ijms-24-10537" ref-type="bibr">120</xref>,<xref rid="B121-ijms-24-10537" ref-type="bibr">121</xref>]. Yersiniabactin, a known siderophore, also contributes to UPEC resistance to urine copper toxicity [<xref rid="B122-ijms-24-10537" ref-type="bibr">122</xref>]. In addition, the harmful effects of copper (II) ions are sequestered by yersiniabactin, perhaps improving resistance to phagocyte killing [<xref rid="B122-ijms-24-10537" ref-type="bibr">122</xref>]. Enterobactin, a highly conserved siderophore, contributes to copper sensitivity, indicating that the seeming redundancy of siderophores may be a bacterial adaptation to inhabiting different host niches.</p><p>In short, nearly all common iron-acquisition-associated genes are significantly positively selected in UPEC clinical isolates [<xref rid="B28-ijms-24-10537" ref-type="bibr">28</xref>,<xref rid="B123-ijms-24-10537" ref-type="bibr">123</xref>]. In the urine, bladder, and kidneys of mice, the asymptomatic bacteriuria isolate UPEC 83972 outcompeted a mutant strain lacking salmochelin and enterobactin [<xref rid="B124-ijms-24-10537" ref-type="bibr">124</xref>]. Aerobactin appears to be crucial for bladder fitness in the pyelonephritis isolate CFT073, which does not manufacture yersiniabactin, indicating that these two siderophores may have overlapping roles [<xref rid="B125-ijms-24-10537" ref-type="bibr">125</xref>]. As a result, multiple bacterial iron acquisition mechanisms have been chosen for UPEC, perhaps in part because of their function in IBC formation, which may make targeting them with vaccines or therapeutics difficult. This problem might be solved by including multiple siderophore receptor antigens in a single vaccination. However, the TonB inner-membrane protein is necessary for all siderophore receptors to transmit the energy required for import. TonB deletion from a UPEC strain was reported to significantly decrease pathogenicity in the kidney and, to a lesser extent, the bladder [<xref rid="B126-ijms-24-10537" ref-type="bibr">126</xref>]. Therefore, discovering small molecules or medicinal plants to target TonB inhibition may be a successful anti-infection strategy.</p></sec><sec id="sec2dot5-ijms-24-10537"><title>2.5. Intracellular Bacterial Communities (IBCs)</title><p><italic toggle="yes">E. coli</italic> can enter the cytoplasm after adhering to and being taken up by the host cell, where they multiply rapidly. The bacteria eventually multiply excessively over several generations and form IBCs, which are distinctive in the acute stage of infection [<xref rid="B127-ijms-24-10537" ref-type="bibr">127</xref>]. Additionally, dispersal from the IBC is essential for bacterial persistence. During the first 12&#8211;16 h of an experimental mouse bladder infection, an only partially understood differentiation program contributed to IBC maturation. The rapidly multiplying bacteria initially adopted a coccoid morphology, then changed back to a rod-like shape as the IBC matured, and finally fluxed away from the IBC. Then, frequently in the form of filaments, UPEC protruded from the dying urothelial cells and colonized and invaded nearby cells, initiating a second round of IBC formation (<xref rid="ijms-24-10537-f005" ref-type="fig">Figure 5</xref>) [<xref rid="B127-ijms-24-10537" ref-type="bibr">127</xref>]. Experimental UPEC infection in mice did not fully recapitulate IBC development. In urine sediments from women with recurrent cystitis, IBCs have been identified through translational investigations, while evidence of IBCs was not found when the UTI pathogen was a Gram-positive organism [<xref rid="B128-ijms-24-10537" ref-type="bibr">128</xref>]. In addition, the IBC pathway is also used by other Gram-negative uropathogens expressing type 1 fimbriae, including <italic toggle="yes">Klebsiella pneumonia</italic>, <italic toggle="yes">Enterobacter</italic> spp., and <italic toggle="yes">Citrobacter freundii</italic> [<xref rid="B96-ijms-24-10537" ref-type="bibr">96</xref>]. These findings collectively imply that the IBC pathway is a key mechanism for the establishment of UTIs in mammalian bladders by Gram-negative uropathogens expressing type 1 fimbriae. Additionally, IBCs with biofilm-like structures are shielded from components of the host immune response, including neutrophils and antibiotics [<xref rid="B129-ijms-24-10537" ref-type="bibr">129</xref>]. Less differentiated cells in the lower levels of the urothelium become exposed to bacteria at the luminal surface because of the loss of superficial cells during the exfoliation process. As a result of the denser actin network in these cells, UPEC cells are not able to replicate at these sites [<xref rid="B130-ijms-24-10537" ref-type="bibr">130</xref>]. These aggregates of quiescent UPEC cells have been called quiescent intracellular reservoirs (QIRs) [<xref rid="B131-ijms-24-10537" ref-type="bibr">131</xref>]. The emergence of either IBCs or QIRs contributes to the recurrence of UTIs, owing to bacteria fluxing out of infected host cells and invading new cells [<xref rid="B127-ijms-24-10537" ref-type="bibr">127</xref>]. In conclusion, the IBC pathway is a significant target for therapeutic intervention.</p></sec><sec id="sec2dot6-ijms-24-10537"><title>2.6. Strategies for Evading Host Defenses</title><p>The infection causes the host to have a significant pro-inflammatory reaction, which is followed by an inflow of neutrophils and attempted eradication of bacteria. Unlike commensal strains, UPEC may be able to block this induction of pro-inflammatory mediators in addition to colonizing the host and causing damage to the nearby tissue. Another strategy is escaping from immune recognition by either hiding intracellularly or masking the immunogenic surface structures.</p><p>Some fitness and virulence factors may have characteristics that shield UPEC from the host immune response. For instance, as mentioned above, iron is a crucial nutrient that UPEC must collect during infection, and the siderophore enterobactin is one route of iron acquisition. However, the neutrophil-expressed and neutrophil-released host protein lipocalin-2 specifically binds to and sequesters enterobactin, preventing it from providing UPEC with iron [<xref rid="B132-ijms-24-10537" ref-type="bibr">132</xref>]. Enterobactin can be modified by UPEC through glycosylation, and this modified enterobactin, called salmochelin, is not bound by the host protein lipocalin-2 and thus is not inhibited in its iron-sequestering function [<xref rid="B133-ijms-24-10537" ref-type="bibr">133</xref>,<xref rid="B134-ijms-24-10537" ref-type="bibr">134</xref>].</p><p>The major component of the cell wall in Gram-negative bacteria is LPS (also called endotoxin), which is highly immunogenic. The hydrophobic lipid A, core oligosaccharide, and repeats of O-antigen subunits make up the structure of LPS [<xref rid="B135-ijms-24-10537" ref-type="bibr">135</xref>]. The highly conserved outer leaflet of the membrane contains the hydrophobic lipid A, which mediates the toxicity of LPS. The O antigen, which is exposed at the surface of the bacteria and constitutes the major immunogen, is bound to the oligosaccharide core [<xref rid="B136-ijms-24-10537" ref-type="bibr">136</xref>]. Thanks to several LPS O antigens, UPEC has the capacity to dampen the induction of cytokines and chemokines in epithelial cells [<xref rid="B137-ijms-24-10537" ref-type="bibr">137</xref>,<xref rid="B138-ijms-24-10537" ref-type="bibr">138</xref>]. The ability of UPEC strains to inhibit the induction of interleukin-6 (IL-6) and IL-8 is neutralized by the disruption of the <italic toggle="yes">rfa</italic> operon, particularly the deletion of <italic toggle="yes">waaL</italic>, which codes for the O-antigen ligase [<xref rid="B137-ijms-24-10537" ref-type="bibr">137</xref>,<xref rid="B138-ijms-24-10537" ref-type="bibr">138</xref>]. In vivo, this process is accompanied by increased neutrophil recruitment and elimination [<xref rid="B137-ijms-24-10537" ref-type="bibr">137</xref>]. Additionally, serum resistance is linked to a few O antigens that are often detected in UPEC [<xref rid="B139-ijms-24-10537" ref-type="bibr">139</xref>]. For instance, the cystitis strains UTI89 and NU14 belong to the O18 serotype, while the pyelonephritis strains CFT073 and 536 belong to the O6 serotype. The O18 and O6 serotypes are both associated with serum resistance [<xref rid="B139-ijms-24-10537" ref-type="bibr">139</xref>].</p><p>Biofilm and extracellular matrix components have also been implicated as contributors to evading host defenses. In biofilms, bacterial communities are formed and embedded in an extracellular matrix, which is mainly composed of exopolysaccharides, nucleic acids, and proteins. Bacteria within biofilms are effectively sheltered against adverse environmental conditions, including antimicrobial treatment and endogenous host immune defense [<xref rid="B140-ijms-24-10537" ref-type="bibr">140</xref>]. Therefore, the ability of bacteria to form a biofilm could be attributed to the combined action of adhesion, the production of an extracellular matrix, and growth characteristics. The pathogenesis of several diseases, including chronic mastitis and pyelonephritis, is associated with the formation of biofilms by bacteria [<xref rid="B141-ijms-24-10537" ref-type="bibr">141</xref>]. Additionally, UPEC produce more biofilms in vitro than commensal fecal isolates, proving that biofilm contributes to <italic toggle="yes">E. coli</italic> urovirulence [<xref rid="B89-ijms-24-10537" ref-type="bibr">89</xref>]. Moreover, the increasing production of exopolysaccharides and biofilms in UPEC can result in more severe and persistent infections [<xref rid="B142-ijms-24-10537" ref-type="bibr">142</xref>,<xref rid="B143-ijms-24-10537" ref-type="bibr">143</xref>,<xref rid="B144-ijms-24-10537" ref-type="bibr">144</xref>,<xref rid="B145-ijms-24-10537" ref-type="bibr">145</xref>]. It is surprising that persisting UPEC isolates do not consistently produce more biofilms in vitro than isolates from sporadic infections, suggesting that in vitro biofilm formation does not necessarily reflect the in vivo situation [<xref rid="B145-ijms-24-10537" ref-type="bibr">145</xref>]. Generally, exopolysaccharides can promote the long-term colonization and persistence of UPEC in the urinary tract. Among them, the most noteworthy exopolysaccharides are capsular polysaccharides [<xref rid="B146-ijms-24-10537" ref-type="bibr">146</xref>], poly-<italic toggle="yes">N</italic>-acetyl glucosamine [<xref rid="B147-ijms-24-10537" ref-type="bibr">147</xref>], and cellulose [<xref rid="B89-ijms-24-10537" ref-type="bibr">89</xref>]. By covering highly immunogenic structures, cellulose can reduce the immune response to bacteria, and other exopolysaccharides may have similar functions.</p><p>Interestingly, the phase variation of type 1 fimbrial genes may help UPEC evade immune system recognition [<xref rid="B17-ijms-24-10537" ref-type="bibr">17</xref>]. A promoter on an invertible element upstream of the target genes in UPEC regulates the expression of type 1 fimbrial operons, and the orientation of the promoter is controlled by multiple recombinase enzymes. Two of these enzymes, FimB and FimE, are encoded upstream of the fimbrial operon [<xref rid="B148-ijms-24-10537" ref-type="bibr">148</xref>]. In addition, IpuA and IpbA, two additional recombinases, mediate the switching of the invertible element independent of FimB and FimE [<xref rid="B149-ijms-24-10537" ref-type="bibr">149</xref>]. In contrast to FimE and IpbA, which can only turn expression off and on, respectively, FimB and IpuA can mediate the bidirectional switching of the promoter. This process is regulated in a complex manner and is influenced by a multitude of environmental factors, such as temperature, osmolarity, pH, and oxygen levels. Furthermore, at least three regulatory proteins are also involved, including Lrp, IHF, and H-NS [<xref rid="B17-ijms-24-10537" ref-type="bibr">17</xref>]. When the promoters are in the &#8216;on&#8217; position, the genes expressing fimbriae are transcribed, and the bacteria can be recognized by antibodies. On the contrary, bacteria with their promoters in the &#8216;off&#8217; position are not recognized by these antibodies, thus essentially evading the host defense.</p></sec></sec><sec id="sec3-ijms-24-10537"><title>3. Treatment of Urinary Tract Infections</title><p>Antibiotics have been used to combat UTIs since the introduction of sulfonamides in the 1940s. Until now, antibiotics have remained the most recommended therapeutic for UTIs [<xref rid="B150-ijms-24-10537" ref-type="bibr">150</xref>]. However, increasing antibiotic resistance and high recurrence rates have significantly impacted the social burden of UTIs. In addition, the excessive use of antibiotics can cause long-term changes in the normal microbiota of the vagina and gastrointestinal tract and lead to liver and kidney damage, a flora imbalance, and other problems. Ideally, alternative therapies will be developed to combat the development of resistance and increase the effectiveness of antibiotics. Many promising approaches are under development, ranging from leveraging UTI pathogenesis to targeting virulence pathways. In theory, these antimicrobial therapies should be effective in reducing the ability of UTI pathogens to cause disease without causing other adverse effects. Furthermore, alternative therapies should target specific processes critical to UTI pathogenesis.</p><p>Below, we summarize the status of the use of antibiotics as traditional pharmacologic therapies and discuss the current challenges that have arisen from the emergence of multidrug-resistant bacterial strains. We emphasize the significant potential of vaccines and medicinal plants with antibacterial activity as anti-UTI medicines.</p><sec id="sec3dot1-ijms-24-10537"><title>3.1. Antibiotics and Multidrug Resistance</title><p>Currently, patients with clinically symptomatic UTIs are usually treated with antibiotics. Several factors should be considered in the selection of the appropriate therapy, including host factors (such as sex, the potential for adverse effects, a compromised immune system, or urologic abnormalities), the severity of the illness (such as the duration of therapy), and the risk of multidrug resistance (such as the activity spectrum of the antimicrobial agent and resistance prevalence for the community). In addition, the management of UTIs is influenced by the increasing prevalence of resistant organisms and the potential for the spread of resistance among normal host flora with the use of broad-spectrum antibiotics [<xref rid="B151-ijms-24-10537" ref-type="bibr">151</xref>,<xref rid="B152-ijms-24-10537" ref-type="bibr">152</xref>].</p><p>Four agents are recommended for first-line therapy: nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX), pivmecillinam, and fosfomycin tromethamine. Two alternative agents are also recommended: <italic toggle="yes">&#946;</italic>-lactams and fluoroquinolones (<xref rid="ijms-24-10537-t001" ref-type="table">Table 1</xref>) [<xref rid="B151-ijms-24-10537" ref-type="bibr">151</xref>,<xref rid="B152-ijms-24-10537" ref-type="bibr">152</xref>,<xref rid="B153-ijms-24-10537" ref-type="bibr">153</xref>]. An important recommendation should be noted. Owing to the risk of serious harm outweighing the benefits, fluoroquinolones (for example, ciprofloxacin) have been transferred to the latter category of agents and should only be used when no other effective oral options are available. Nitrofurantoin has been an option for the management of UTIs for more than 70 years. However, nitrofurantoin does not achieve high serum concentrations and has poor tissue penetration. Therefore, it should be avoided if pyelonephritis is possible and is contraindicated in patients with renal failure [<xref rid="B153-ijms-24-10537" ref-type="bibr">153</xref>]. The adverse effect profile of nitrofurantoin includes nausea, headache, and gastrointestinal effects. Higher doses or longer durations of use may lead to significant hepatic and pulmonary toxicity [<xref rid="B153-ijms-24-10537" ref-type="bibr">153</xref>]. Nitrofurantoin affords comparable efficacy to TMP-SMX for UTIs in terms of both clinical and microbiological cures [<xref rid="B154-ijms-24-10537" ref-type="bibr">154</xref>,<xref rid="B155-ijms-24-10537" ref-type="bibr">155</xref>]. TMP, with or without SMX, has been the mainstay therapy for UTIs for the past 40 years. It is also the first-line drug for acute UTIs and pyelonephritis. However, the main limitation of using TMP&#8211;SMX is the increasing rate of resistance among uropathogens [<xref rid="B156-ijms-24-10537" ref-type="bibr">156</xref>]. The efficacy of pivmecillinam for the empirical treatment of acute uncomplicated UTIs was initially reported in clinical trials published in the 1970s [<xref rid="B157-ijms-24-10537" ref-type="bibr">157</xref>]. Several studies have confirmed earlier reports and clinical experience suggesting that pivmecillinam is effective and well tolerated for the treatment of acute cystitis in women [<xref rid="B157-ijms-24-10537" ref-type="bibr">157</xref>]. Furthermore, the resistance rate of pivmecillinam is lower than that of other recommended agents and is relatively stable over time [<xref rid="B158-ijms-24-10537" ref-type="bibr">158</xref>]. Fosfomycin tromethamine, a soluble salt of fosfomycin, is approved for the treatment of uncomplicated UTIs in women. Although surveys show that it remains active against other antibiotic-resistant Gram-negative organisms, data supporting its efficacy for the treatment of MDR-uropathogens are limited [<xref rid="B159-ijms-24-10537" ref-type="bibr">159</xref>,<xref rid="B160-ijms-24-10537" ref-type="bibr">160</xref>]. Given the concerns that its widespread use will increase drug resistance, it is not a popular first-line choice in the treatment of complicated UTIs [<xref rid="B161-ijms-24-10537" ref-type="bibr">161</xref>]. <italic toggle="yes">&#946;</italic>-lactams and fluoroquinolones are second-line therapies. <italic toggle="yes">&#946;</italic>-lactams show increased adverse effects compared with other choices, while the risk of fluoroquinolones may outweigh their benefits for treatment [<xref rid="B151-ijms-24-10537" ref-type="bibr">151</xref>,<xref rid="B161-ijms-24-10537" ref-type="bibr">161</xref>].</p><p>However, owing to the widespread emergence of antibiotic-resistance mechanisms (<xref rid="ijms-24-10537-f006" ref-type="fig">Figure 6</xref>), the treatment of UTIs is becoming increasingly difficult [<xref rid="B3-ijms-24-10537" ref-type="bibr">3</xref>,<xref rid="B150-ijms-24-10537" ref-type="bibr">150</xref>,<xref rid="B162-ijms-24-10537" ref-type="bibr">162</xref>,<xref rid="B163-ijms-24-10537" ref-type="bibr">163</xref>,<xref rid="B164-ijms-24-10537" ref-type="bibr">164</xref>,<xref rid="B165-ijms-24-10537" ref-type="bibr">165</xref>,<xref rid="B166-ijms-24-10537" ref-type="bibr">166</xref>,<xref rid="B167-ijms-24-10537" ref-type="bibr">167</xref>]. Currently, UPEC isolated from clinics contain various types of plasmids encoding extended-spectrum <italic toggle="yes">&#946;</italic>-lactamases (ESBLs), which include temoniera (TEM), sulfhydryl variables (SHVs), oxacillinases (OXAs), cefotaximases (CTX-Ms), AmpC-type <italic toggle="yes">&#946;</italic>-lactamases, and carbapenemases. Originating in <italic toggle="yes">Klebsiella pneumoniae</italic> and <italic toggle="yes">Escherichia coli</italic>, ESBLs are now widespread across the family of Enterobacteriaceae. ESBLs are <italic toggle="yes">&#946;</italic>-lactamases with broad activity against penicillins and cephalosporins. They are encoded by plasmids or chromosomes and function by splitting the amide bond of the <italic toggle="yes">&#946;</italic>-lactam ring, thus inactivating <italic toggle="yes">&#946;</italic>-lactam antibiotics [<xref rid="B166-ijms-24-10537" ref-type="bibr">166</xref>]. Among them, TEM and SHVs are common in Asia [<xref rid="B168-ijms-24-10537" ref-type="bibr">168</xref>], and CTX-Ms are the most prevalent <italic toggle="yes">&#946;</italic>-lactamases in community-associated isolates [<xref rid="B166-ijms-24-10537" ref-type="bibr">166</xref>]. OXAs are typically encoded by plasmids, which can hydrolyze <italic toggle="yes">&#946;</italic>-lactam rings, thereby increasing the resistance of ampicillin, cephalothin, and oxacillin [<xref rid="B163-ijms-24-10537" ref-type="bibr">163</xref>]. AmpC enzymes, typically encoded by chromosomes, hydrolyze almost all third-generation and extended-spectrum cephalosporins and are resistant to <italic toggle="yes">&#946;</italic>-lactamase inhibitors [<xref rid="B166-ijms-24-10537" ref-type="bibr">166</xref>]. The carbapenemase ESBLs confer resistance to carbapenems and extended-spectrum cephalosporins [<xref rid="B166-ijms-24-10537" ref-type="bibr">166</xref>]. These plasmids have rapidly spread resistance to third-generation cephalosporins and other antibiotics [<xref rid="B162-ijms-24-10537" ref-type="bibr">162</xref>,<xref rid="B164-ijms-24-10537" ref-type="bibr">164</xref>,<xref rid="B165-ijms-24-10537" ref-type="bibr">165</xref>,<xref rid="B167-ijms-24-10537" ref-type="bibr">167</xref>,<xref rid="B169-ijms-24-10537" ref-type="bibr">169</xref>]. Several studies have reported that UPEC isolates are resistant to ampicillin [<xref rid="B166-ijms-24-10537" ref-type="bibr">166</xref>], oral first-generation cephalosporins, TMP-SMX [<xref rid="B156-ijms-24-10537" ref-type="bibr">156</xref>], cefuroxime [<xref rid="B170-ijms-24-10537" ref-type="bibr">170</xref>], cotrimoxazole [<xref rid="B171-ijms-24-10537" ref-type="bibr">171</xref>], amoxicillin-clavulanate [<xref rid="B169-ijms-24-10537" ref-type="bibr">169</xref>], nalidixic acid [<xref rid="B172-ijms-24-10537" ref-type="bibr">172</xref>], cefradine [<xref rid="B173-ijms-24-10537" ref-type="bibr">173</xref>], and aminopenicillins [<xref rid="B174-ijms-24-10537" ref-type="bibr">174</xref>]. <xref rid="ijms-24-10537-f007" ref-type="fig">Figure 7</xref> depicts the representative antibiotic structural formulations whose resistance to UPEC has been demonstrated (orange background) and those showing susceptibility to UPEC (purple background). All in all, the troubling trend toward a high prevalence of multidrug-resistant uropathogens has stimulated the development of alternative control measures and treatment options. </p><p>In short, with the widespread use of antimicrobial drugs and the increasing number of drug-resistant strains, the &#8220;golden age&#8221; of antibiotics is waning, and fewer antibiotics are available. To minimize the above problems, antibiotic selection should be based on local sensitivity patterns and adjusted once culture results are available. Furthermore, the unnecessary treatment of asymptomatic bacteriuria should be avoided. In addition, the disturbing trend toward a high prevalence of multidrug-resistant uropathogens has stimulated the development of complementary and alternative medicines. </p></sec><sec id="sec3dot2-ijms-24-10537"><title>3.2. Preventative Strategies and Alternative Therapeutics for Urinary Tract Infections</title><p>Antibiotics will continue to be an unavoidable resource for the treatment of UTIs on a case-by-case basis. However, numerous effective strategies have been developed by bacteria to overcome therapeutic procedures and survive in the urinary system [<xref rid="B175-ijms-24-10537" ref-type="bibr">175</xref>]. Moreover, excessive use of antibiotics can lead to the occurrence of drug resistance and interfere with the intestinal microbiota [<xref rid="B176-ijms-24-10537" ref-type="bibr">176</xref>]. Therefore, it is necessary to search for preventative strategies and alternative remedies. In recent years, a plethora of potential drugs have been found to inhibit bacterial adhesion or weaken the effect of siderophores&#8212;such as vitamin D, estrogens, and probiotics. However, these drugs are still in the preclinical research stage as a means of preventing or treating UTIs. Therefore, the advantages of vaccines and medicinal plants are being considered. Medicinal plants, used in many countries as an alternative treatment for UTIs, contain a wide variety of phytochemicals and secondary metabolites, which are the most promising sources of compounds exerting antibacterial activity. Here, we summarize the most effective alternative remedies against UPEC, focusing on vaccines and medicinal plants.</p><sec id="sec3dot2dot1-ijms-24-10537"><title>3.2.1. Vaccines</title><p>The creation of vaccines to prevent UPEC UTIs is of great clinical and academic importance due to the serious consequences of these infections and the current dearth of efficient, nonantibiotic prophylactic measures. These immunizations will likely help certain patient populations. UPEC vaccination would undoubtedly be a major benefit for patients, particularly those who suffer from recurrent infections or are more likely to develop infections. The following elements should be considered when developing an effective UPEC vaccine strategy: (a) the heterogeneity of UPEC strains; (b) the production of multiple virulence factors by UPEC strains; (c) potential adverse effects on the commensal microbiota of the intestine; and (d) comprehensive and efficient drug effects for both the upper and lower urinary tract [<xref rid="B102-ijms-24-10537" ref-type="bibr">102</xref>,<xref rid="B177-ijms-24-10537" ref-type="bibr">177</xref>]. An efficient vaccine should be able to generate a protective immune response against important virulence factors during particular phases of UTI pathogenesis, such as colonization, invasion, and the formation of IBCs [<xref rid="B177-ijms-24-10537" ref-type="bibr">177</xref>]. Among the steps involved in UPEC infections, adhesins, antimicrobial peptides (AMPs), and siderophores are the most likely candidates for target antigens [<xref rid="B20-ijms-24-10537" ref-type="bibr">20</xref>].</p><p>In general, vaccines to prevent UPEC can be divided into two categories: whole-cell vaccines and antigen-specific vaccines (<xref rid="ijms-24-10537-t002" ref-type="table">Table 2</xref>). The most effective vaccinations created to date are whole-cell vaccines. Whether attenuated or inactivated, vaccines containing intact uropathogens expose the host to a variety of virulence factors that trigger the body&#8217;s immune response, thus achieving the goal of vaccination. Solco-Urovac, a polyvalent inactivated vaccine, was developed for humans after several decades of research in animals. It consists of ten distinct strains of heat-inactivated bacteria: six from UPEC and one strain each from <italic toggle="yes">Enterococcus faecalis</italic>, <italic toggle="yes">Proteus mirabilis</italic>, <italic toggle="yes">Morganella morganii</italic>, and <italic toggle="yes">Klebsiella pneumoniae</italic>. The vaccine was reported to protect Europeans from recurrent UTIs in a clinical trial [<xref rid="B178-ijms-24-10537" ref-type="bibr">178</xref>]. However, it produced significant adverse effects, such as nausea, fever, burning, bleeding, and vaginal itching [<xref rid="B179-ijms-24-10537" ref-type="bibr">179</xref>], which might have led to its abandonment. StroVac, currently available for use in humans, is another intramuscular polyvalent inactivated UTI vaccine that comprises the same ten UPEC strains in a different formulation and produces few side effects in the nonantibiotic prophylaxis of recurrent UTIs [<xref rid="B180-ijms-24-10537" ref-type="bibr">180</xref>,<xref rid="B181-ijms-24-10537" ref-type="bibr">181</xref>]. Another oral inactivated UTI vaccine, Uro-vaxom, comprises membrane proteins of 18 UPEC strains. It can protect women from recurrent UTIs, has few side effects, and has been approved for use in Europe since 1994 [<xref rid="B182-ijms-24-10537" ref-type="bibr">182</xref>,<xref rid="B183-ijms-24-10537" ref-type="bibr">183</xref>,<xref rid="B184-ijms-24-10537" ref-type="bibr">184</xref>]. However, its major drawback is poor patient compliance because it requires repeated injections every three months, which limits its promotion [<xref rid="B185-ijms-24-10537" ref-type="bibr">185</xref>]. Other inactivated vaccines against UTIs include Urvakol, Urostim [<xref rid="B186-ijms-24-10537" ref-type="bibr">186</xref>,<xref rid="B187-ijms-24-10537" ref-type="bibr">187</xref>], ExPEC9V [<xref rid="B188-ijms-24-10537" ref-type="bibr">188</xref>], and CP923 [<xref rid="B189-ijms-24-10537" ref-type="bibr">189</xref>], which promote immunogenicity in animals but have not completed clinical trials. NU14 &#8710;<italic toggle="yes">waal</italic>, the representative attenuated vaccine for UPEC, is a whole-cell vaccine. It was identified from a mutant of the UPEC strain NU14 that lacks the O-antigen ligase <italic toggle="yes">waal</italic>. In a murine UTI model, NU14 &#8710;<italic toggle="yes">waal</italic> was considerably less virulent and more inflammatory than wild-type NU14. When challenged with infection by NU14, CFT073, and four other UPEC isolates, mice were protected from infection by vaccination with NU14 &#8710;<italic toggle="yes">waal</italic> [<xref rid="B190-ijms-24-10537" ref-type="bibr">190</xref>]. However, the potential of NU14 &#8710;<italic toggle="yes">waal</italic> was diminished by the discovery that serial infections with NU14 &#8710;<italic toggle="yes">waal</italic> cause chronic bladder pain [<xref rid="B191-ijms-24-10537" ref-type="bibr">191</xref>].</p><p>In addition, antigen-specific vaccines have been investigated as potential prevention targets, including capsular- or LPS-based, fimbrial, and non-fimbrial adhesin, iron-scavenger-receptor-based, and toxin-based vaccines [<xref rid="B2-ijms-24-10537" ref-type="bibr">2</xref>,<xref rid="B205-ijms-24-10537" ref-type="bibr">205</xref>]. ExPEC4V, a polysaccharide-based vaccine containing the O antigens of four <italic toggle="yes">E. coli</italic> serotypes (O1A, O2, O6A, and O25B), induced significant IgG responses and significantly reduced the incidence of UTIs caused by UPEC even with higher bacterial doses compared with the placebo group in phase II clinical trial [<xref rid="B196-ijms-24-10537" ref-type="bibr">196</xref>,<xref rid="B197-ijms-24-10537" ref-type="bibr">197</xref>,<xref rid="B205-ijms-24-10537" ref-type="bibr">205</xref>]. Adhesins that promote the UPEC colonization of the bladder epithelium also cause host immune reactions. Therefore, adhesins can be used to create a desirable antigen candidate that can prevent adhesin-host cell-receptor interaction and obstruct the bacterial colonization of the host [<xref rid="B50-ijms-24-10537" ref-type="bibr">50</xref>]. In animal models, the FimH adhesin from type 1 fimbriae played a crucial role in the pathogenesis of UPEC in the lower urinary tract. It has proven to be highly efficient in treating mice when challenged with bacteria cultured under conditions that induce type 1 fimbriae [<xref rid="B206-ijms-24-10537" ref-type="bibr">206</xref>]. FimH can be purified either in its mannose-binding native form or attached to its periplasmic chaperone FimC (FimCH) [<xref rid="B44-ijms-24-10537" ref-type="bibr">44</xref>]. In a mouse model, both antigens were effective at preventing the colonization of various UPEC strains [<xref rid="B206-ijms-24-10537" ref-type="bibr">206</xref>]. Numerous preclinical investigations have demonstrated the effectiveness of FimH vaccinations in triggering an immune response and preventing UPEC. Both approaches were reported to be effective at preventing cystitis when a recombinant FimH vaccine was administered to mice either intranasally or intramuscularly [<xref rid="B207-ijms-24-10537" ref-type="bibr">207</xref>]. Another report showed that the subcutaneous administration of recombinant FimH coupled to the flagellin subunit FliC, a TLR5 agonist and potential adjuvant, shielded mice from cystitis when challenged with a type 1 pilus-expressing clinical strain [<xref rid="B198-ijms-24-10537" ref-type="bibr">198</xref>]. Additionally, in murine and primate models, a FimH vaccination with alum and MF59 adjuvants or with FliC and Montanide ISA 206 adjuvants induced an immune response to UPEC and inhibited colonization [<xref rid="B199-ijms-24-10537" ref-type="bibr">199</xref>,<xref rid="B208-ijms-24-10537" ref-type="bibr">208</xref>]. Last, a team created a FimH plasmid construct with mammalian codon optimization for use in a DNA vaccine, allowing for the induction of a protective immune response in mice when plasmid DNA was injected [<xref rid="B209-ijms-24-10537" ref-type="bibr">209</xref>,<xref rid="B210-ijms-24-10537" ref-type="bibr">210</xref>]. Mice that received the DNA vaccination through footpad injection presented much less extensive bladder colonization and significantly higher urine IgA titers [<xref rid="B211-ijms-24-10537" ref-type="bibr">211</xref>]. However, most of these vaccines were later rejected due to the lack of efficacy in humans after FimH vaccination tests in clinical trials. The failure of the FimH-based vaccination was due to several factors. UPEC strains are not consistently detected by the immune system due to the variable expression of type 1 fimbriae in animal and human models [<xref rid="B200-ijms-24-10537" ref-type="bibr">200</xref>]. In addition, antigens developed against the fimbriae do not target their mannose-binding region. Multiple studies utilizing a range of target antigens in animal urinary tract models may be necessary to develop an efficient UTI vaccine [<xref rid="B2-ijms-24-10537" ref-type="bibr">2</xref>,<xref rid="B200-ijms-24-10537" ref-type="bibr">200</xref>]. A TLR ligand-based vaccine using FimH adhesin is currently being explored, with the fusion of FimH adhesin to the flagellin of UPEC as a TLR5 ligand able to elicit an immune response and shield mice from UTIs [<xref rid="B198-ijms-24-10537" ref-type="bibr">198</xref>,<xref rid="B201-ijms-24-10537" ref-type="bibr">201</xref>,<xref rid="B202-ijms-24-10537" ref-type="bibr">202</xref>]. A study reported that cynomolgus monkeys receiving the FimCH vaccination intramuscularly were shielded from pyuria and bacteriuria [<xref rid="B39-ijms-24-10537" ref-type="bibr">39</xref>]. In addition, in mouse and primate models, the FimCH vaccine with Freund&#8217;s adjuvant induced an immune response against UPEC and inhibited colonization [<xref rid="B199-ijms-24-10537" ref-type="bibr">199</xref>,<xref rid="B208-ijms-24-10537" ref-type="bibr">208</xref>]. However, the development of the FimCH vaccine was abandoned during phase II trials despite its safety being confirmed in phase I studies. Evidently, whether a vaccine is composed of truncated FimH or a complex of FimH with the chaperone FimC, it will eventually be rejected due to a lack of efficacy or adverse reactions in clinical trials. Moreover, the PapG adhesin from P fimbriae also plays an important role in UPEC pathogenesis. Analogous to the FimH and FimCH vaccines, a vaccine composed of truncated PapG or a complex of PapG with the chaperone PapD (PapDG) was able to protect cynomolgus monkeys from pyelonephritis [<xref rid="B212-ijms-24-10537" ref-type="bibr">212</xref>]. In addition, PapDG vaccines with Freund&#8217;s adjuvants were also shown to generate immune responses and reduce UPEC colonization in a mouse model [<xref rid="B20-ijms-24-10537" ref-type="bibr">20</xref>].</p><p>The use of siderophore&#8211;protein conjugates was found to induce immune responses targeted at bacterial siderophores and to successfully protect against UTIs [<xref rid="B213-ijms-24-10537" ref-type="bibr">213</xref>], meaning that <italic toggle="yes">E. coli</italic> iron acquisition systems have the same potential as UPEC vaccine candidates. IroN, IutA, IreA, and FyuA increased protection in the urinary tracts of mice in a study using an attenuated Salmonella vaccine delivery system to assess the efficacy of a multi-epitope vaccine comprising siderophore receptors [<xref rid="B214-ijms-24-10537" ref-type="bibr">214</xref>,<xref rid="B215-ijms-24-10537" ref-type="bibr">215</xref>]. In a mouse model, researchers discovered that systemic vaccination with the salmochelin receptor IroN or IroN with Freund&#8217;s adjuvant could offer protection against UTIs [<xref rid="B121-ijms-24-10537" ref-type="bibr">121</xref>], while the aerobactin receptor IutA conjugated with cholera toxin also produced potent immune responses and provided defense against UPEC infection [<xref rid="B203-ijms-24-10537" ref-type="bibr">203</xref>]. The intranasal administration of the yersiniabactin receptor FyuA prevented mice from contracting pyelonephritis after exposure to UPEC strain 536, which expresses FyuA. FyuA also produced potent immune responses and provided defense against UPEC infection in mouse models when used with alum as an adjuvant [<xref rid="B204-ijms-24-10537" ref-type="bibr">204</xref>]. Additionally, the potential antigen Hma, a heme receptor, exhibited kidney protection against challenge infection [<xref rid="B216-ijms-24-10537" ref-type="bibr">216</xref>]. In a similar vein, UTI symptoms were reduced in murine experimental infection models by a toxin-based vaccine including antigens such as hemolysin HlyA, recombinant hemolysin, and mutant CNF1 and HlyA toxins [<xref rid="B2-ijms-24-10537" ref-type="bibr">2</xref>,<xref rid="B200-ijms-24-10537" ref-type="bibr">200</xref>]. As potential vaccine targets, autotransporter toxins such as FdeC from UPEC strains have also been studied. Identifying whether these results extend to human UTI patients should undoubtedly be a future study objective.</p></sec><sec id="sec3dot2dot2-ijms-24-10537"><title>3.2.2. Medicinal Plants for the Management and Treatment of Urinary Tract Infections</title><p>With the increasing prevalence of UTIs and the economic burden for both patients and governments, developing effective anti-UTI drugs that can be quickly applied in clinical settings is important. Vaccines and small molecule formulations may be a promising option; however, the high cost (over one billion USD) and lengthy process of developing new antibacterial agents (more than 10 years) must be taken into consideration [<xref rid="B217-ijms-24-10537" ref-type="bibr">217</xref>]. Therefore, medicinal plants have attracted increasing interest within the scientific community. In fact, research on medicinal plants has grown significantly since the beginning of the 21st century, touching on their effectiveness in treating and preventing UTIs, their therapeutic material basis, and their mechanisms of action [<xref rid="B218-ijms-24-10537" ref-type="bibr">218</xref>].</p><p>The superiority of medicinal plants has also attracted increasing research interest. As plant extracts contain a variety of phytochemicals that act against different molecular targets within bacterial cells, bacteria are less likely to develop resistance to medicinal plants, and thus they can maintain increased efficacy and decreased side effects [<xref rid="B219-ijms-24-10537" ref-type="bibr">219</xref>,<xref rid="B220-ijms-24-10537" ref-type="bibr">220</xref>,<xref rid="B221-ijms-24-10537" ref-type="bibr">221</xref>]. Medicinal plants contain a wide variety of phytochemicals and secondary metabolites and are classified according to their chemical composition, including alkaloids, coumarins, flavonoids, lectins, polypeptides, quinones, tannins, and terpenoids [<xref rid="B222-ijms-24-10537" ref-type="bibr">222</xref>]. The parts of the plant used to treat UTIs vary substantially, as do the chemical compositions of these parts. In addition, the plant extraction and processing methods also impact the chemical composition. Generally, the plant part, form, and dosage depend on information gathered from folk medicine or the experience of ethnophysicians. Therefore, fully developing and applying medicinal plants is a significant challenge.</p><p>Although the exact mechanisms by which plants offer curative or preventative effects against UTIs are unclear, substantial research is ongoing in this field. Studies have shown that many medicinal plants exert antibacterial activity against a variety of bacterial pathogens, and combined use with antibiotics can enhance bactericidal and bacteriostatic effects [<xref rid="B223-ijms-24-10537" ref-type="bibr">223</xref>]. In some cases, medicinal plants can even reverse antibiotic resistance. In addition to bactericidal and bacteriostatic effects, medicinal plants have been reported to present other mechanisms, such as antiadhesive activity [<xref rid="B224-ijms-24-10537" ref-type="bibr">224</xref>,<xref rid="B225-ijms-24-10537" ref-type="bibr">225</xref>,<xref rid="B226-ijms-24-10537" ref-type="bibr">226</xref>], the inhibition of bacterial growth [<xref rid="B227-ijms-24-10537" ref-type="bibr">227</xref>,<xref rid="B228-ijms-24-10537" ref-type="bibr">228</xref>], anti-biofilm-formation activity [<xref rid="B229-ijms-24-10537" ref-type="bibr">229</xref>,<xref rid="B230-ijms-24-10537" ref-type="bibr">230</xref>], the inhibition of motility [<xref rid="B231-ijms-24-10537" ref-type="bibr">231</xref>,<xref rid="B232-ijms-24-10537" ref-type="bibr">232</xref>], the protection of host urinary cells [<xref rid="B233-ijms-24-10537" ref-type="bibr">233</xref>], and the enhancement of antibacterial immunity. In <xref rid="ijms-24-10537-t003" ref-type="table">Table 3</xref>, we summarize recently studied plants that achieved positive results against UPEC. We hope that this will help in the selection of clinical anti-UPEC drugs.</p></sec></sec></sec><sec id="sec4-ijms-24-10537"><title>4. Conclusion and Future Prospects</title><p>In this review, we described an interaction network comprising UPEC, the host, and antibiotics. Vaccines and medicinal plants were also included as preventative strategies and alternative therapeutic methods for UPEC. The main pathogen of UTIs is UPEC, which can survive within the urinary tract and cause infection through a wide range of virulence factors, including fimbrial and non-fimbrial adhesins, flagella, toxins, lipopolysaccharides, surface vesicles, polysaccharide capsules, and the iron acquisition system. Hence, as vital organs, the urethra, bladder, and kidneys are often attacked by UPEC. The pathogenesis of a UTI starts with the contamination and colonization of the urethral area with UPEC. The bladder epithelium is then invaded by UPEC. Finally, UPEC release toxins that damage host tissues, resulting in upper UTIs. Severe cases can also result in life-threatening illnesses, such as bacteremia, septicemia, and urosepsis. Since the 1940s, when sulfonamides were first introduced, various antibiotics have been employed to treat UTIs and then UPEC. Until now, antibiotics have remained the most frequently recommended treatment for UTIs. However, as new and more severe diseases have emerged, the growing resistance to antibiotics has led to the recurrence and chronicity of infection, making treatment challenging and complicated.</p><p>Therefore, the highest priority in UTI research should be the development of new, effective alternative therapies, as these therapies have the potential to significantly improve the quality of life for millions of humans and reduce the overall use of antibiotics. However, the promotion of vaccines faces numerous obstacles. The notion that any novel vaccine or therapy by itself can entirely eradicate recurrent UTIs in all patients is doubtful due to the substantial contribution of the host to recurrent UTIs unless the vaccine/therapy is also able to alter the innate mucosal-immune response to uropathogens. In the urogenital niche of hosts, UPEC can predominate in the absence of immunization, but after vaccination, other uropathogens may take the position of UPEC. Furthermore, the process of developing new vaccines for the market is relatively lengthy and expensive.</p><p>Thus, a new, more efficacious, and cost-effective strategy should be developed to combat UTIs caused by UPEC. Some of the most promising sources of compounds that exert antibacterial activity against UPEC are medicinal plants. Plants have been used extensively to treat and prevent diseases for a long time. The development of reliable and efficient plant-based medicinal treatments would undoubtedly necessitate a complete understanding of the mechanisms through which medicinal plants affect UPEC and the human body. An overview of the antibacterial activities of medicinal plants that work against UPEC was provided in this review. However, to completely understand how these plants prevent or treat UTIs caused by UPEC, more research is required.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: Y.Z. and Z.Z.; writing&#8212;original draft preparation: Y.Z.; writing&#8212;review and editing: Y.H. and M.C.; supervision: L.Z. and Z.G.; project administration: Y.L. and Y.J.; funding acquisition: L.Z. and Y.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-24-10537"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flores-Mireles</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Caparon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Urinary tract infections: Epidemiology, mechanisms of infection and treatment options</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>269</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3432</pub-id><pub-id pub-id-type="pmid">25853778</pub-id><pub-id pub-id-type="pmcid">PMC4457377</pub-id></element-citation></ref><ref id="B2-ijms-24-10537"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Hannan</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>H.V.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections</article-title><source>Microbiol. Spectr.</source><year>2016</year><volume>4</volume><fpage>589</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.UTI-0013-2012</pub-id><pub-id pub-id-type="pmid">26999391</pub-id><pub-id pub-id-type="pmcid">PMC4887100</pub-id></element-citation></ref><ref id="B3-ijms-24-10537"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foxman</surname><given-names>B.</given-names></name></person-group><article-title>Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2014</year><volume>28</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2013.09.003</pub-id><pub-id pub-id-type="pmid">24484571</pub-id></element-citation></ref><ref id="B4-ijms-24-10537"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tandogdu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wagenlehner</surname><given-names>F.M.</given-names></name></person-group><article-title>Global epidemiology of urinary tract infections</article-title><source>Curr. Opin. Infect. Dis.</source><year>2016</year><volume>29</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000228</pub-id><pub-id pub-id-type="pmid">26694621</pub-id></element-citation></ref><ref id="B5-ijms-24-10537"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tullus</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>N.</given-names></name></person-group><article-title>Urinary tract infections in children</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1659</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30676-0</pub-id><pub-id pub-id-type="pmid">32446408</pub-id></element-citation></ref><ref id="B6-ijms-24-10537"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liska</surname><given-names>D.</given-names></name><name name-style="western"><surname>Talan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>M.</given-names></name></person-group><article-title>Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis</article-title><source>J. Nutr.</source><year>2017</year><volume>147</volume><fpage>2282</fpage><lpage>2288</lpage><pub-id pub-id-type="doi">10.3945/jn.117.254961</pub-id><pub-id pub-id-type="pmid">29046404</pub-id></element-citation></ref><ref id="B7-ijms-24-10537"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chughtai</surname><given-names>B.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Hickling</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kenton</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline</article-title><source>J. Urol.</source><year>2019</year><volume>202</volume><fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1097/JU.0000000000000296</pub-id><pub-id pub-id-type="pmid">31042112</pub-id></element-citation></ref><ref id="B8-ijms-24-10537"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneeberger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Geerlings</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crowther</surname><given-names>C.A.</given-names></name></person-group><article-title>Interventions for preventing recurrent urinary tract infection during pregnancy</article-title><source>Cochrane Database Syst. Rev.</source><year>2015</year><volume>2015</volume><fpage>Cd009279</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD009279.pub3</pub-id><pub-id pub-id-type="pmid">26221993</pub-id><pub-id pub-id-type="pmcid">PMC6457953</pub-id></element-citation></ref><ref id="B9-ijms-24-10537"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthews</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>J.W.</given-names></name></person-group><article-title>Urinary tract infections in the elderly population</article-title><source>Am. J. Geriatr. Pharmacother.</source><year>2011</year><volume>9</volume><fpage>286</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.amjopharm.2011.07.002</pub-id><pub-id pub-id-type="pmid">21840265</pub-id></element-citation></ref><ref id="B10-ijms-24-10537"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brubaker</surname><given-names>L.</given-names></name></person-group><article-title>The etiology and management of recurrent urinary tract infections in postmenopausal women</article-title><source>Climacteric</source><year>2019</year><volume>22</volume><fpage>242</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1080/13697137.2018.1551871</pub-id><pub-id pub-id-type="pmid">30624087</pub-id><pub-id pub-id-type="pmcid">PMC6629580</pub-id></element-citation></ref><ref id="B11-ijms-24-10537"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becknell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schober</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korbel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>J.D.</given-names></name></person-group><article-title>The diagnosis, evaluation and treatment of acute and recurrent pediatric urinary tract infections</article-title><source>Expert Rev. Anti-Infect. Ther.</source><year>2015</year><volume>13</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1586/14787210.2015.986097</pub-id><pub-id pub-id-type="pmid">25421102</pub-id><pub-id pub-id-type="pmcid">PMC4652790</pub-id></element-citation></ref><ref id="B12-ijms-24-10537"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim&#245;es</surname><given-names>E.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>R.H.</given-names></name></person-group><article-title>Urinary tract infection in pediatrics: An overview</article-title><source>J. Pediatr. (Rio. J.)</source><year>2020</year><volume>96</volume><fpage>65</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jped.2019.10.006</pub-id><pub-id pub-id-type="pmid">31783012</pub-id><pub-id pub-id-type="pmcid">PMC9432043</pub-id></element-citation></ref><ref id="B13-ijms-24-10537"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keren</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pohl</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gravens-Mueller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zaoutis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Berardinis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Risk Factors for Recurrent Urinary Tract Infection and Renal Scarring</article-title><source>Pediatrics</source><year>2015</year><volume>136</volume><fpage>e13</fpage><lpage>e21</lpage><pub-id pub-id-type="doi">10.1542/peds.2015-0409</pub-id><pub-id pub-id-type="pmid">26055855</pub-id><pub-id pub-id-type="pmcid">PMC4485012</pub-id></element-citation></ref><ref id="B14-ijms-24-10537"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattoo</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C.P.</given-names></name></person-group><article-title>Contemporary Management of Urinary Tract Infection in Children</article-title><source>Pediatrics</source><year>2021</year><volume>147</volume><fpage>e2020012138</fpage><pub-id pub-id-type="doi">10.1542/peds.2020-012138</pub-id><pub-id pub-id-type="pmid">33479164</pub-id></element-citation></ref><ref id="B15-ijms-24-10537"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silverman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>H.L.T.</given-names></name><name name-style="western"><surname>Hooton</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>From physiology to pharmacy: Developments in the pathogenesis and treatment of recurrent urinary tract infections</article-title><source>Curr. Urol. Rep.</source><year>2013</year><volume>14</volume><fpage>448</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1007/s11934-013-0354-5</pub-id><pub-id pub-id-type="pmid">23832844</pub-id><pub-id pub-id-type="pmcid">PMC3797163</pub-id></element-citation></ref><ref id="B16-ijms-24-10537"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hannan</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Totsika</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mansfield</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Schembri</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic <italic toggle="yes">Escherichia coli</italic> bladder infection</article-title><source>FEMS Microbiol. Rev.</source><year>2012</year><volume>36</volume><fpage>616</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2012.00339.x</pub-id><pub-id pub-id-type="pmid">22404313</pub-id><pub-id pub-id-type="pmcid">PMC3675774</pub-id></element-citation></ref><ref id="B17-ijms-24-10537"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielubowicz</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Host-pathogen interactions in urinary tract infection</article-title><source>Nat. Rev. Urol.</source><year>2010</year><volume>7</volume><fpage>430</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2010.101</pub-id><pub-id pub-id-type="pmid">20647992</pub-id></element-citation></ref><ref id="B18-ijms-24-10537"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terlizzi</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gribaudo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maffei</surname><given-names>M.E.</given-names></name></person-group><article-title>UroPathogenic <italic toggle="yes">Escherichia coli</italic> (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>1566</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.01566</pub-id><pub-id pub-id-type="pmid">28861072</pub-id><pub-id pub-id-type="pmcid">PMC5559502</pub-id></element-citation></ref><ref id="B19-ijms-24-10537"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhakal</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Kulesus</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Mulvey</surname><given-names>M.A.</given-names></name></person-group><article-title>Mechanisms and consequences of bladder cell invasion by uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Eur. J. Clin. Investig.</source><year>2008</year><volume>38</volume><fpage>2</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2008.01986.x</pub-id><pub-id pub-id-type="pmid">18616559</pub-id></element-citation></ref><ref id="B20-ijms-24-10537"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spaulding</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Adhesive Pili in UTI Pathogenesis and Drug Development</article-title><source>Pathogens</source><year>2016</year><volume>5</volume><elocation-id>30</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens5010030</pub-id><pub-id pub-id-type="pmid">26999218</pub-id><pub-id pub-id-type="pmcid">PMC4810151</pub-id></element-citation></ref><ref id="B21-ijms-24-10537"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Totsika</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moriel</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Idris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Wurpel</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Schembri</surname><given-names>M.A.</given-names></name></person-group><article-title>Uropathogenic <italic toggle="yes">Escherichia coli</italic> mediated urinary tract infection</article-title><source>Curr. Drug Targets</source><year>2012</year><volume>13</volume><fpage>1386</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.2174/138945012803530206</pub-id><pub-id pub-id-type="pmid">22664092</pub-id></element-citation></ref><ref id="B22-ijms-24-10537"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name></person-group><article-title>Pathogenomics of uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Indian J. Med. Microbiol.</source><year>2012</year><volume>30</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.4103/0255-0857.96657</pub-id><pub-id pub-id-type="pmid">22664427</pub-id></element-citation></ref><ref id="B23-ijms-24-10537"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribi&#263;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Me&#353;trovi&#263;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Neuberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kozina</surname><given-names>G.</given-names></name></person-group><article-title>Effective anti-adhesives of uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Acta Pharm.</source><year>2018</year><volume>68</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.2478/acph-2018-0004</pub-id><pub-id pub-id-type="pmid">29453908</pub-id></element-citation></ref><ref id="B24-ijms-24-10537"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pakharukova</surname><given-names>N.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tuittila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paavilainen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malmi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Parilova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zavialov</surname><given-names>A.V.</given-names></name></person-group><article-title>Archaic and alternative chaperones preserve pilin folding energy by providing incomplete structural information</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>17070</fpage><lpage>17080</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.004170</pub-id><pub-id pub-id-type="pmid">30228191</pub-id><pub-id pub-id-type="pmcid">PMC6222105</pub-id></element-citation></ref><ref id="B25-ijms-24-10537"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuehn</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Heuser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Normark</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>P pili in uropathogenic <italic toggle="yes">E. coli</italic> are composite fibres with distinct fibrillar adhesive tips</article-title><source>Nature</source><year>1992</year><volume>356</volume><fpage>252</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/356252a0</pub-id><pub-id pub-id-type="pmid">1348107</pub-id></element-citation></ref><ref id="B26-ijms-24-10537"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Remaut</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Pirker</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Lebedev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Geibel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Volkan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate</article-title><source>Nature</source><year>2011</year><volume>474</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/nature10109</pub-id><pub-id pub-id-type="pmid">21637253</pub-id><pub-id pub-id-type="pmcid">PMC3162478</pub-id></element-citation></ref><ref id="B27-ijms-24-10537"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waksman</surname><given-names>G.</given-names></name></person-group><article-title>Structural and Molecular Biology of a Protein-Polymerizing Nanomachine for Pilus Biogenesis</article-title><source>J. Mol. Biol.</source><year>2017</year><volume>429</volume><fpage>2654</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2017.05.016</pub-id><pub-id pub-id-type="pmid">28551336</pub-id></element-citation></ref><ref id="B28-ijms-24-10537"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reigstad</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Magrini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sabo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blasiar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bieri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Ozersky</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Identification of genes subject to positive selection in uropathogenic strains of <italic toggle="yes">Escherichia coli</italic>: A comparative genomics approach</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>5977</fpage><lpage>5982</lpage><pub-id pub-id-type="doi">10.1073/pnas.0600938103</pub-id><pub-id pub-id-type="pmid">16585510</pub-id><pub-id pub-id-type="pmcid">PMC1424661</pub-id></element-citation></ref><ref id="B29-ijms-24-10537"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behzadi</surname><given-names>P.</given-names></name></person-group><article-title>Classical chaperone-usher (CU) adhesive fimbriome: Uropathogenic <italic toggle="yes">Escherichia coli</italic> (UPEC) and urinary tract infections (UTIs)</article-title><source>Folia Microbiol.</source><year>2020</year><volume>65</volume><fpage>45</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s12223-019-00719-x</pub-id><pub-id pub-id-type="pmid">31165977</pub-id></element-citation></ref><ref id="B30-ijms-24-10537"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Beatson</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Totsika</surname><given-names>M.</given-names></name><name name-style="western"><surname>Forestier</surname><given-names>C.</given-names></name><name name-style="western"><surname>McEwan</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Schembri</surname><given-names>M.A.</given-names></name></person-group><article-title>Molecular analysis of type 3 fimbrial genes from <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Klebsiella</italic> and <italic toggle="yes">Citrobacter species</italic></article-title><source>BMC Microbiol.</source><year>2010</year><volume>10</volume><elocation-id>183</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-10-183</pub-id><pub-id pub-id-type="pmid">20576143</pub-id><pub-id pub-id-type="pmcid">PMC2900259</pub-id></element-citation></ref><ref id="B31-ijms-24-10537"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zavialov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zav&#8217;yalova</surname><given-names>G.</given-names></name><name name-style="western"><surname>Korpela</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zav&#8217;yalov</surname><given-names>V.</given-names></name></person-group><article-title>FGL chaperone-assembled fimbrial polyadhesins: Anti-immune armament of Gram-negative bacterial pathogens</article-title><source>FEMS Microbiol. Rev.</source><year>2007</year><volume>31</volume><fpage>478</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00075.x</pub-id><pub-id pub-id-type="pmid">17576202</pub-id></element-citation></ref><ref id="B32-ijms-24-10537"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Sebbel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Min</surname><given-names>G.</given-names></name><name name-style="western"><surname>Neubert</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Glockshuber</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X.P.</given-names></name></person-group><article-title>Uroplakin Ia is the urothelial receptor for uropathogenic <italic toggle="yes">Escherichia coli</italic>: Evidence from in vitro FimH binding</article-title><source>J. Cell Sci.</source><year>2001</year><volume>114</volume><fpage>4095</fpage><lpage>4103</lpage><pub-id pub-id-type="doi">10.1242/jcs.114.22.4095</pub-id><pub-id pub-id-type="pmid">11739641</pub-id></element-citation></ref><ref id="B33-ijms-24-10537"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eto</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Sundsbak</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Mulvey</surname><given-names>M.A.</given-names></name></person-group><article-title>Integrin-mediated host cell invasion by type 1-piliated uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>PLoS Pathog.</source><year>2007</year><volume>3</volume><elocation-id>e100</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0030100</pub-id><pub-id pub-id-type="pmid">17630833</pub-id><pub-id pub-id-type="pmcid">PMC1914067</pub-id></element-citation></ref><ref id="B34-ijms-24-10537"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mossman</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Mian</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Lauzon</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Gyles</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Lichty</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mackenzie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ashkar</surname><given-names>A.A.</given-names></name></person-group><article-title>Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>6702</fpage><lpage>6706</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.10.6702</pub-id><pub-id pub-id-type="pmid">18981086</pub-id></element-citation></ref><ref id="B35-ijms-24-10537"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behzadi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Behzadi</surname><given-names>P.</given-names></name></person-group><article-title>The role of toll-like receptors (TLRs) in urinary tract infections (UTIs)</article-title><source>Cent. Eur. J. Urol.</source><year>2016</year><volume>69</volume><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.5173/ceju.2016.871</pub-id><pub-id pub-id-type="pmcid">PMC5260452</pub-id><pub-id pub-id-type="pmid">28127459</pub-id></element-citation></ref><ref id="B36-ijms-24-10537"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spaulding</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Ruer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kau</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Cusumano</surname><given-names>Z.T.</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Fremont</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Janetka</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Selective depletion of uropathogenic <italic toggle="yes">E. coli</italic> from the gut by a FimH antagonist</article-title><source>Nature</source><year>2017</year><volume>546</volume><fpage>528</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/nature22972</pub-id><pub-id pub-id-type="pmid">28614296</pub-id><pub-id pub-id-type="pmcid">PMC5654549</pub-id></element-citation></ref><ref id="B37-ijms-24-10537"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lund</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lindberg</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marklund</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Normark</surname><given-names>S.</given-names></name></person-group><article-title>The PapG protein is the alpha-D-galactopyranosyl-(1----4)-beta-D-galactopyranose-binding adhesin of uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1987</year><volume>84</volume><fpage>5898</fpage><lpage>5902</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.16.5898</pub-id><pub-id pub-id-type="pmid">2886993</pub-id><pub-id pub-id-type="pmcid">PMC298970</pub-id></element-citation></ref><ref id="B38-ijms-24-10537"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klemm</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schembri</surname><given-names>M.A.</given-names></name></person-group><article-title>Fimbrial adhesins from extraintestinal <italic toggle="yes">Escherichia coli</italic></article-title><source>Environ. Microbiol. Rep.</source><year>2010</year><volume>2</volume><fpage>628</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1111/j.1758-2229.2010.00166.x</pub-id><pub-id pub-id-type="pmid">23766248</pub-id></element-citation></ref><ref id="B39-ijms-24-10537"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langermann</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#246;llby</surname><given-names>R.</given-names></name><name name-style="western"><surname>Burlein</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Palaszynski</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Auguste</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>DeFusco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strouse</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schenerman</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Infect. Dis.</source><year>2000</year><volume>181</volume><fpage>774</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1086/315258</pub-id><pub-id pub-id-type="pmid">10669375</pub-id></element-citation></ref><ref id="B40-ijms-24-10537"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Seed</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Development of intracellular bacterial communities of uropathogenic <italic toggle="yes">Escherichia coli</italic> depends on type 1 pili</article-title><source>Cell Microbiol.</source><year>2007</year><volume>9</volume><fpage>2230</fpage><lpage>2241</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2007.00952.x</pub-id><pub-id pub-id-type="pmid">17490405</pub-id></element-citation></ref><ref id="B41-ijms-24-10537"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaeffer</surname><given-names>A.J.</given-names></name></person-group><article-title>Structural basis of tropism of <italic toggle="yes">Escherichia coli</italic> to the bladder during urinary tract infection</article-title><source>J. Urol.</source><year>2003</year><volume>170</volume><fpage>335</fpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)63509-4</pub-id><pub-id pub-id-type="pmid">14567339</pub-id></element-citation></ref><ref id="B42-ijms-24-10537"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Mulvey</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Type 1 pilus-mediated bacterial invasion of bladder epithelial cells</article-title><source>EMBO J.</source><year>2000</year><volume>19</volume><fpage>2803</fpage><lpage>2812</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.12.2803</pub-id><pub-id pub-id-type="pmid">10856226</pub-id><pub-id pub-id-type="pmcid">PMC203355</pub-id></element-citation></ref><ref id="B43-ijms-24-10537"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Sticky fibers and uropathogenesis: Bacterial adhesins in the urinary tract</article-title><source>Future Microbiol.</source><year>2006</year><volume>1</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.2217/17460913.1.1.75</pub-id><pub-id pub-id-type="pmid">17661687</pub-id></element-citation></ref><ref id="B44-ijms-24-10537"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarowar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Werneburg</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Thanassi</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>The <italic toggle="yes">Escherichia coli</italic> P and Type 1 Pilus Assembly Chaperones PapD and FimC Are Monomeric in Solution</article-title><source>J. Bacteriol.</source><year>2016</year><volume>198</volume><fpage>2360</fpage><lpage>2369</lpage><pub-id pub-id-type="doi">10.1128/JB.00366-16</pub-id><pub-id pub-id-type="pmid">27353649</pub-id><pub-id pub-id-type="pmcid">PMC4984555</pub-id></element-citation></ref><ref id="B45-ijms-24-10537"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salda&#241;a</surname><given-names>Z.</given-names></name><name name-style="western"><surname>De la Cruz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Carrillo-Casas</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Dur&#225;n</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Castro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Puente</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Daaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gir&#243;n</surname><given-names>J.A.</given-names></name></person-group><article-title>Production of the <italic toggle="yes">Escherichia coli</italic> common pilus by uropathogenic <italic toggle="yes">E. coli</italic> is associated with adherence to HeLa and HTB-4 cells and invasion of mouse bladder urothelium</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e101200</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0101200</pub-id><pub-id pub-id-type="pmid">25036370</pub-id><pub-id pub-id-type="pmcid">PMC4103759</pub-id></element-citation></ref><ref id="B46-ijms-24-10537"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sidaway</surname><given-names>P.</given-names></name></person-group><article-title>Infection: Exposure to human urine decreases type 1 pili expression in uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Nat. Rev. Urol.</source><year>2015</year><volume>12</volume><fpage>422</fpage><pub-id pub-id-type="doi">10.1038/nrurol.2015.172</pub-id><pub-id pub-id-type="pmid">26171804</pub-id></element-citation></ref><ref id="B47-ijms-24-10537"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greene</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Hibbing</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Janetka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>mBio</source><year>2015</year><volume>6</volume><fpage>e00820</fpage><pub-id pub-id-type="doi">10.1128/mBio.00820-15</pub-id><pub-id pub-id-type="pmid">26126855</pub-id><pub-id pub-id-type="pmcid">PMC4488945</pub-id></element-citation></ref><ref id="B48-ijms-24-10537"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zav&#8217;yalov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zavialov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zav&#8217;yalova</surname><given-names>G.</given-names></name><name name-style="western"><surname>Korpela</surname><given-names>T.</given-names></name></person-group><article-title>Adhesive organelles of Gram-negative pathogens assembled with the classical chaperone/usher machinery: Structure and function from a clinical standpoint</article-title><source>FEMS Microbiol. Rev.</source><year>2010</year><volume>34</volume><fpage>317</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2009.00201.x</pub-id><pub-id pub-id-type="pmid">20070375</pub-id></element-citation></ref><ref id="B49-ijms-24-10537"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conover</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Ruer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taganna</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kalas</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Greve</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Remaut</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Inflammation-Induced Adhesin-Receptor Interaction Provides a Fitness Advantage to Uropathogenic, <italic toggle="yes">E. coli</italic> during Chronic Infection</article-title><source>Cell Host Microbe</source><year>2016</year><volume>20</volume><fpage>482</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.08.013</pub-id><pub-id pub-id-type="pmid">27667696</pub-id><pub-id pub-id-type="pmcid">PMC5294914</pub-id></element-citation></ref><ref id="B50-ijms-24-10537"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chahales</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thanassi</surname><given-names>D.G.</given-names></name></person-group><article-title>Structure, Function, and Assembly of Adhesive Organelles by Uropathogenic Bacteria</article-title><source>Microbiol. Spectr.</source><year>2015</year><volume>3</volume><fpage>277</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.UTI-0018-2013</pub-id><pub-id pub-id-type="pmcid">PMC4638162</pub-id><pub-id pub-id-type="pmid">26542038</pub-id></element-citation></ref><ref id="B51-ijms-24-10537"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thumbikat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Billips</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Yaggie</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Zaichuk</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Klumpp</surname><given-names>D.J.</given-names></name></person-group><article-title>Bacteria-induced uroplakin signaling mediates bladder response to infection</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000415</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000415</pub-id><pub-id pub-id-type="pmid">19412341</pub-id><pub-id pub-id-type="pmcid">PMC2669708</pub-id></element-citation></ref><ref id="B52-ijms-24-10537"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Min</surname><given-names>G.</given-names></name><name name-style="western"><surname>Glockshuber</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X.P.</given-names></name></person-group><article-title>Uropathogenic, <italic toggle="yes">E. coli</italic> adhesin-induced host cell receptor conformational changes: Implications in transmembrane signaling transduction</article-title><source>J. Mol. Biol.</source><year>2009</year><volume>392</volume><fpage>352</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2009.06.077</pub-id><pub-id pub-id-type="pmid">19577575</pub-id><pub-id pub-id-type="pmcid">PMC2755582</pub-id></element-citation></ref><ref id="B53-ijms-24-10537"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eto</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Dhakal</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Mulvey</surname><given-names>M.A.</given-names></name></person-group><article-title>Clathrin, AP-2, and the NPXY-binding subset of alternate endocytic adaptors facilitate FimH-mediated bacterial invasion of host cells</article-title><source>Cell Microbiol.</source><year>2008</year><volume>10</volume><fpage>2553</fpage><lpage>2567</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2008.01229.x</pub-id><pub-id pub-id-type="pmid">18754852</pub-id></element-citation></ref><ref id="B54-ijms-24-10537"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schembri</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sokurenko</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Klemm</surname><given-names>P.</given-names></name></person-group><article-title>Functional flexibility of the FimH adhesin: Insights from a random mutant library</article-title><source>Infect. Immun.</source><year>2000</year><volume>68</volume><fpage>2638</fpage><lpage>2646</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.5.2638-2646.2000</pub-id><pub-id pub-id-type="pmid">10768955</pub-id><pub-id pub-id-type="pmcid">PMC97470</pub-id></element-citation></ref><ref id="B55-ijms-24-10537"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokurenko</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Courtney</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Maslow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siitonen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hasty</surname><given-names>D.L.</given-names></name></person-group><article-title>Quantitative differences in adhesiveness of type 1 fimbriated <italic toggle="yes">Escherichia coli</italic> due to structural differences in fimH genes</article-title><source>J. Bacteriol.</source><year>1995</year><volume>177</volume><fpage>3680</fpage><lpage>3686</lpage><pub-id pub-id-type="doi">10.1128/jb.177.13.3680-3686.1995</pub-id><pub-id pub-id-type="pmid">7601831</pub-id><pub-id pub-id-type="pmcid">PMC177083</pub-id></element-citation></ref><ref id="B56-ijms-24-10537"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Cusumano</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bouckaert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>22439</fpage><lpage>22444</lpage><pub-id pub-id-type="doi">10.1073/pnas.0902179106</pub-id><pub-id pub-id-type="pmid">20018753</pub-id><pub-id pub-id-type="pmcid">PMC2794649</pub-id></element-citation></ref><ref id="B57-ijms-24-10537"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biggel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Frimodt-M&#248;ller</surname><given-names>N.</given-names></name><name name-style="western"><surname>Matheeussen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moons</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Puyvelde</surname><given-names>S.</given-names></name></person-group><article-title>Horizontally acquired papGII-containing pathogenicity islands underlie the emergence of invasive uropathogenic <italic toggle="yes">Escherichia coli</italic> lineages</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>5968</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-19714-9</pub-id><pub-id pub-id-type="pmid">33235212</pub-id><pub-id pub-id-type="pmcid">PMC7686366</pub-id></element-citation></ref><ref id="B58-ijms-24-10537"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bessaiah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pokharel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Loucif</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kulbay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sasseville</surname><given-names>C.</given-names></name><name name-style="western"><surname>Habouria</surname><given-names>H.</given-names></name><name name-style="western"><surname>Houle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bernier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mass&#233;</surname><given-names>&#201;.</given-names></name><name name-style="western"><surname>Van Grevenynghe</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The RyfA small RNA regulates oxidative and osmotic stress responses and virulence in uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><elocation-id>e1009617</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009617</pub-id><pub-id pub-id-type="pmid">34043736</pub-id><pub-id pub-id-type="pmcid">PMC8205139</pub-id></element-citation></ref><ref id="B59-ijms-24-10537"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>K.B.</given-names></name></person-group><article-title>Urinary tract infection: Clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months</article-title><source>Pediatrics</source><year>2011</year><volume>128</volume><fpage>595</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1542/peds.2011-1330</pub-id><pub-id pub-id-type="pmid">21873693</pub-id></element-citation></ref><ref id="B60-ijms-24-10537"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norinder</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>K&#246;ves</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brauner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Svanborg</surname><given-names>C.</given-names></name></person-group><article-title>Do <italic toggle="yes">Escherichia coli</italic> strains causing acute cystitis have a distinct virulence repertoire?</article-title><source>Microb. Pathog.</source><year>2012</year><volume>52</volume><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2011.08.005</pub-id><pub-id pub-id-type="pmid">22023989</pub-id></element-citation></ref><ref id="B61-ijms-24-10537"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Hannan</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection</article-title><source>Curr. Opin. Infect. Dis.</source><year>2015</year><volume>28</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000130</pub-id><pub-id pub-id-type="pmid">25517222</pub-id><pub-id pub-id-type="pmcid">PMC4365976</pub-id></element-citation></ref><ref id="B62-ijms-24-10537"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishitoya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mitsumori</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>O.</given-names></name><name name-style="western"><surname>Terai</surname><given-names>A.</given-names></name></person-group><article-title>Non-secretor status is associated with female acute uncomplicated pyelonephritis</article-title><source>BJU Int.</source><year>2002</year><volume>89</volume><fpage>851</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1046/j.1464-410X.2002.02782.x</pub-id><pub-id pub-id-type="pmid">12010227</pub-id></element-citation></ref><ref id="B63-ijms-24-10537"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sauer</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Mulvey</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Bacterial pili: Molecular mechanisms of pathogenesis</article-title><source>Curr. Opin. Microbiol.</source><year>2000</year><volume>3</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S1369-5274(99)00053-3</pub-id><pub-id pub-id-type="pmid">10679419</pub-id></element-citation></ref><ref id="B64-ijms-24-10537"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Combe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Clermont</surname><given-names>O.</given-names></name><name name-style="western"><surname>Messika</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eveillard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kouatchet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lasocki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corvec</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lakhal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Billard-Pomares</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Pneumonia-Specific <italic toggle="yes">Escherichia coli</italic> with Distinct Phylogenetic and Virulence Profiles, France, 2012&#8211;2014</article-title><source>Emerg. Infect. Dis.</source><year>2019</year><volume>25</volume><fpage>710</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.3201/eid2504.180944</pub-id><pub-id pub-id-type="pmid">30882313</pub-id><pub-id pub-id-type="pmcid">PMC6433033</pub-id></element-citation></ref><ref id="B65-ijms-24-10537"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werneburg</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Thanassi</surname><given-names>D.G.</given-names></name></person-group><article-title>Pili Assembled by the Chaperone/Usher Pathway in <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Salmonella</italic></article-title><source>EcoSal Plus</source><year>2018</year><volume>8</volume><fpage>1</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1128/ecosalplus.ESP-0007-2017</pub-id><pub-id pub-id-type="pmid">29536829</pub-id><pub-id pub-id-type="pmcid">PMC5940347</pub-id></element-citation></ref><ref id="B66-ijms-24-10537"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic <italic toggle="yes">Escherichia coli</italic> (UPEC) in the mammalian kidney</article-title><source>Kidney Int.</source><year>2007</year><volume>72</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002230</pub-id><pub-id pub-id-type="pmid">17396114</pub-id></element-citation></ref><ref id="B67-ijms-24-10537"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Whittle</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Lockatell</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Donnenberg</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>J.W.</given-names></name></person-group><article-title>Isogenic P-fimbrial deletion mutants of pyelonephritogenic <italic toggle="yes">Escherichia coli</italic>: The role of alpha Gal(1-4) beta Gal binding in virulence of a wild-type strain</article-title><source>Mol. Microbiol.</source><year>1993</year><volume>10</volume><fpage>143</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.1993.tb00911.x</pub-id><pub-id pub-id-type="pmid">7968511</pub-id></element-citation></ref><ref id="B68-ijms-24-10537"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elliott</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Haslam</surname><given-names>D.B.</given-names></name></person-group><article-title>Forssman synthetase expression results in diminished shiga toxin susceptibility: A role for glycolipids in determining host-microbe interactions</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>6543</fpage><lpage>6552</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.11.6543-6552.2003</pub-id><pub-id pub-id-type="pmid">14573676</pub-id><pub-id pub-id-type="pmcid">PMC219581</pub-id></element-citation></ref><ref id="B69-ijms-24-10537"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melican</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sandoval</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Kader</surname><given-names>A.</given-names></name><name name-style="western"><surname>Josefsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Molitoris</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Richter-Dahlfors</surname><given-names>A.</given-names></name></person-group><article-title>Uropathogenic <italic toggle="yes">Escherichia coli</italic> P and Type 1 fimbriae act in synergy in a living host to facilitate renal colonization leading to nephron obstruction</article-title><source>PLoS Pathog.</source><year>2011</year><volume>7</volume><elocation-id>e1001298</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1001298</pub-id><pub-id pub-id-type="pmid">21383970</pub-id><pub-id pub-id-type="pmcid">PMC3044688</pub-id></element-citation></ref><ref id="B70-ijms-24-10537"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#228;ckhed</surname><given-names>F.</given-names></name><name name-style="western"><surname>Als&#233;n</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roche</surname><given-names>N.</given-names></name><name name-style="western"><surname>Angstr&#246;m</surname><given-names>J.</given-names></name><name name-style="western"><surname>von Euler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Westerlund-Wikstr&#246;m</surname><given-names>B.</given-names></name><name name-style="western"><surname>Teneberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richter-Dahlfors</surname><given-names>A.</given-names></name></person-group><article-title>Identification of target tissue glycosphingolipid receptors for uropathogenic, F1C-fimbriated <italic toggle="yes">Escherichia coli</italic> and its role in mucosal inflammation</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>18198</fpage><lpage>18205</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111640200</pub-id><pub-id pub-id-type="pmid">11877427</pub-id></element-citation></ref><ref id="B71-ijms-24-10537"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvarangan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goluszko</surname><given-names>P.</given-names></name><name name-style="western"><surname>Singhal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carnoy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moseley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nowicki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nowicki</surname><given-names>B.</given-names></name></person-group><article-title>Interaction of Dr adhesin with collagen type IV is a critical step in <italic toggle="yes">Escherichia coli</italic> renal persistence</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>4827</fpage><lpage>4835</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.8.4827-4835.2004</pub-id><pub-id pub-id-type="pmid">15271945</pub-id><pub-id pub-id-type="pmcid">PMC470682</pub-id></element-citation></ref><ref id="B72-ijms-24-10537"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Comparison of adhesin genes and antimicrobial susceptibilities between uropathogenic and intestinal commensal <italic toggle="yes">Escherichia coli</italic> strains</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e61169</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0061169</pub-id><pub-id pub-id-type="pmid">23593422</pub-id><pub-id pub-id-type="pmcid">PMC3621879</pub-id></element-citation></ref><ref id="B73-ijms-24-10537"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subashchandrabose</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.T.</given-names></name></person-group><article-title>Virulence and Fitness Determinants of Uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Microbiol. Spectr.</source><year>2015</year><volume>3</volume><fpage>235</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.UTI-0015-2012</pub-id><pub-id pub-id-type="pmid">26350328</pub-id><pub-id pub-id-type="pmcid">PMC4566162</pub-id></element-citation></ref><ref id="B74-ijms-24-10537"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wurpel</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Totsika</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allsopp</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Hartley-Tassell</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Day</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ulett</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tiralongo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>F9 fimbriae of uropathogenic <italic toggle="yes">Escherichia coli</italic> are expressed at low temperature and recognise Gal&#946;1-3GlcNAc-containing glycans</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e93177</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0093177</pub-id><pub-id pub-id-type="pmid">24671091</pub-id><pub-id pub-id-type="pmcid">PMC3966885</pub-id></element-citation></ref><ref id="B75-ijms-24-10537"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spurbeck</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Stapleton</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Walk</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Hooton</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Fimbrial profiles predict virulence of uropathogenic <italic toggle="yes">Escherichia coli</italic> strains: Contribution of ygi and yad fimbriae</article-title><source>Infect. Immun.</source><year>2011</year><volume>79</volume><fpage>4753</fpage><lpage>4763</lpage><pub-id pub-id-type="doi">10.1128/IAI.05621-11</pub-id><pub-id pub-id-type="pmid">21911462</pub-id><pub-id pub-id-type="pmcid">PMC3232662</pub-id></element-citation></ref><ref id="B76-ijms-24-10537"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Kuehn</surname><given-names>M.J.</given-names></name></person-group><article-title>Virulence and immunomodulatory roles of bacterial outer membrane vesicles</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2010</year><volume>74</volume><fpage>81</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00031-09</pub-id><pub-id pub-id-type="pmid">20197500</pub-id><pub-id pub-id-type="pmcid">PMC2832350</pub-id></element-citation></ref><ref id="B77-ijms-24-10537"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiles</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Kulesus</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Mulvey</surname><given-names>M.A.</given-names></name></person-group><article-title>Origins and virulence mechanisms of uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Exp. Mol. Pathol.</source><year>2008</year><volume>85</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2008.03.007</pub-id><pub-id pub-id-type="pmid">18482721</pub-id><pub-id pub-id-type="pmcid">PMC2595135</pub-id></element-citation></ref><ref id="B78-ijms-24-10537"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vigil</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Alteri</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Identification of in vivo-induced antigens including an RTX family exoprotein required for uropathogenic <italic toggle="yes">Escherichia coli</italic> virulence</article-title><source>Infect. Immun.</source><year>2011</year><volume>79</volume><fpage>2335</fpage><lpage>2344</lpage><pub-id pub-id-type="doi">10.1128/IAI.00110-11</pub-id><pub-id pub-id-type="pmid">21422188</pub-id><pub-id pub-id-type="pmcid">PMC3125824</pub-id></element-citation></ref><ref id="B79-ijms-24-10537"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vigil</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Stapleton</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Hooton</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Presence of putative repeat-in-toxin gene tosA in <italic toggle="yes">Escherichia coli</italic> predicts successful colonization of the urinary tract</article-title><source>mBio</source><year>2011</year><volume>2</volume><fpage>e00066-11</fpage><pub-id pub-id-type="doi">10.1128/mBio.00066-11</pub-id><pub-id pub-id-type="pmid">21540363</pub-id><pub-id pub-id-type="pmcid">PMC3088117</pub-id></element-citation></ref><ref id="B80-ijms-24-10537"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engstrom</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Alteri</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>A conserved PapB family member, TosR, regulates expression of the uropathogenic <italic toggle="yes">Escherichia coli</italic> RTX nonfimbrial adhesin TosA while conserved LuxR family members TosE and TosF suppress motility</article-title><source>Infect. Immun.</source><year>2014</year><volume>82</volume><fpage>3644</fpage><lpage>3656</lpage><pub-id pub-id-type="doi">10.1128/IAI.01608-14</pub-id><pub-id pub-id-type="pmid">24935980</pub-id><pub-id pub-id-type="pmcid">PMC4187811</pub-id></element-citation></ref><ref id="B81-ijms-24-10537"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nesta</surname><given-names>B.</given-names></name><name name-style="western"><surname>Spraggon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alteri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moriel</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Rosini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Veggi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bertoldi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pastorello</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ferlenghi</surname><given-names>I.</given-names></name><etal/></person-group><article-title>FdeC, a novel broadly conserved <italic toggle="yes">Escherichia coli</italic> adhesin eliciting protection against urinary tract infections</article-title><source>mBio</source><year>2012</year><volume>3</volume><fpage>e00010-12</fpage><pub-id pub-id-type="doi">10.1128/mBio.00010-12</pub-id><pub-id pub-id-type="pmid">22496310</pub-id><pub-id pub-id-type="pmcid">PMC3324786</pub-id></element-citation></ref><ref id="B82-ijms-24-10537"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mabbett</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Ulett</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Toledo-Arana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wecker</surname><given-names>K.</given-names></name><name name-style="western"><surname>Totsika</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schembri</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ghigo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Beloin</surname><given-names>C.</given-names></name></person-group><article-title>UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Bacteriol.</source><year>2008</year><volume>190</volume><fpage>4147</fpage><lpage>4161</lpage><pub-id pub-id-type="doi">10.1128/JB.00122-08</pub-id><pub-id pub-id-type="pmid">18424525</pub-id><pub-id pub-id-type="pmcid">PMC2446758</pub-id></element-citation></ref><ref id="B83-ijms-24-10537"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Jelacic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schoening</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Clabots</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Tarr</surname><given-names>P.I.</given-names></name></person-group><article-title>The IrgA homologue adhesin Iha is an <italic toggle="yes">Escherichia coli</italic> virulence factor in murine urinary tract infection</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>965</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.2.965-971.2005</pub-id><pub-id pub-id-type="pmid">15664939</pub-id><pub-id pub-id-type="pmcid">PMC546986</pub-id></element-citation></ref><ref id="B84-ijms-24-10537"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnhart</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>M.R.</given-names></name></person-group><article-title>Curli biogenesis and function</article-title><source>Annu. Rev. Microbiol.</source><year>2006</year><volume>60</volume><fpage>131</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1146/annurev.micro.60.080805.142106</pub-id><pub-id pub-id-type="pmid">16704339</pub-id><pub-id pub-id-type="pmcid">PMC2838481</pub-id></element-citation></ref><ref id="B85-ijms-24-10537"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Seol</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name></person-group><article-title>Involvement of curli fimbriae in the biofilm formation of <italic toggle="yes">Enterobacter cloacae</italic></article-title><source>J. Microbiol.</source><year>2012</year><volume>50</volume><fpage>175</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/s12275-012-2044-2</pub-id><pub-id pub-id-type="pmid">22367955</pub-id></element-citation></ref><ref id="B86-ijms-24-10537"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicastro</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>de Anda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Grando</surname><given-names>K.C.M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bessho</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gallucci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.C.L.</given-names></name><name name-style="western"><surname>T&#252;kel</surname><given-names>&#199;.</given-names></name></person-group><article-title>Assembly of ordered DNA-curli fibril complexes during <italic toggle="yes">Salmonella</italic> biofilm formation correlates with strengths of the type I interferon and autoimmune responses</article-title><source>PLoS Pathog.</source><year>2022</year><volume>18</volume><elocation-id>e1010742</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010742</pub-id><pub-id pub-id-type="pmid">35972973</pub-id><pub-id pub-id-type="pmcid">PMC9380926</pub-id></element-citation></ref><ref id="B87-ijms-24-10537"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>T&#252;kel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Raffatellu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Humphries</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Andrews-Polymenis</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Gull</surname><given-names>T.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Michelsen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Ak&#231;elik</surname><given-names>M.</given-names></name><etal/></person-group><article-title>CsgA is a pathogen-associated molecular pattern of <italic toggle="yes">Salmonella enterica</italic> serotype Typhimurium that is recognized by Toll-like receptor 2</article-title><source>Mol. Microbiol.</source><year>2005</year><volume>58</volume><fpage>289</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2005.04825.x</pub-id><pub-id pub-id-type="pmid">16164566</pub-id></element-citation></ref><ref id="B88-ijms-24-10537"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Brauner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Normark</surname><given-names>S.</given-names></name></person-group><article-title>Expression of and cytokine activation by <italic toggle="yes">Escherichia coli</italic> curli fibers in human sepsis</article-title><source>J. Infect. Dis.</source><year>2000</year><volume>181</volume><fpage>602</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1086/315233</pub-id><pub-id pub-id-type="pmid">10669344</pub-id></element-citation></ref><ref id="B89-ijms-24-10537"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kai-Larsen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>L&#252;thje</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chromek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>A.</given-names></name><name name-style="western"><surname>K&#225;das</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hedlund</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Uropathogenic <italic toggle="yes">Escherichia coli</italic> modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37</article-title><source>PLoS Pathog.</source><year>2010</year><volume>6</volume><elocation-id>e1001010</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1001010</pub-id><pub-id pub-id-type="pmid">20661475</pub-id><pub-id pub-id-type="pmcid">PMC2908543</pub-id></element-citation></ref><ref id="B90-ijms-24-10537"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lockatell</surname><given-names>V.</given-names></name><name name-style="western"><surname>Monterosso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lamphier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hebel</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Role of motility in the colonization of uropathogenic <italic toggle="yes">Escherichia coli</italic> in the urinary tract</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>7644</fpage><lpage>7656</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.11.7644-7656.2005</pub-id><pub-id pub-id-type="pmid">16239569</pub-id><pub-id pub-id-type="pmcid">PMC1273871</pub-id></element-citation></ref><ref id="B91-ijms-24-10537"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Seed</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Uropathogenic <italic toggle="yes">Escherichia coli</italic> flagella aid in efficient urinary tract colonization</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>7657</fpage><lpage>7668</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.11.7657-7668.2005</pub-id><pub-id pub-id-type="pmid">16239570</pub-id><pub-id pub-id-type="pmcid">PMC1273872</pub-id></element-citation></ref><ref id="B92-ijms-24-10537"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simms</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>PapX, a P fimbrial operon-encoded inhibitor of motility in uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Infect. Immun.</source><year>2008</year><volume>76</volume><fpage>4833</fpage><lpage>4841</lpage><pub-id pub-id-type="doi">10.1128/IAI.00630-08</pub-id><pub-id pub-id-type="pmid">18710869</pub-id><pub-id pub-id-type="pmcid">PMC2573324</pub-id></element-citation></ref><ref id="B93-ijms-24-10537"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gir&#243;n</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Freer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaper</surname><given-names>J.B.</given-names></name></person-group><article-title>The flagella of enteropathogenic <italic toggle="yes">Escherichia coli</italic> mediate adherence to epithelial cells</article-title><source>Mol. Microbiol.</source><year>2002</year><volume>44</volume><fpage>361</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2002.02899.x</pub-id><pub-id pub-id-type="pmid">11972776</pub-id></element-citation></ref><ref id="B94-ijms-24-10537"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kamei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kurokawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>N.</given-names></name></person-group><article-title>Establishment of a multi-species biofilm model and metatranscriptomic analysis of biofilm and planktonic cell communities</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2016</year><volume>100</volume><fpage>7263</fpage><lpage>7279</lpage><pub-id pub-id-type="doi">10.1007/s00253-016-7532-6</pub-id><pub-id pub-id-type="pmid">27102130</pub-id></element-citation></ref><ref id="B95-ijms-24-10537"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Alteri</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Expression of flagella is coincident with uropathogenic <italic toggle="yes">Escherichia coli</italic> ascension to the upper urinary tract</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>16669</fpage><lpage>16674</lpage><pub-id pub-id-type="doi">10.1073/pnas.0607898104</pub-id><pub-id pub-id-type="pmid">17925449</pub-id><pub-id pub-id-type="pmcid">PMC2034267</pub-id></element-citation></ref><ref id="B96-ijms-24-10537"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosen</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Clegg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Utilization of an intracellular bacterial community pathway in <italic toggle="yes">Klebsiella pneumoniae</italic> urinary tract infection and the effects of FimK on type 1 pilus expression</article-title><source>Infect. Immun.</source><year>2008</year><volume>76</volume><fpage>3337</fpage><lpage>3345</lpage><pub-id pub-id-type="doi">10.1128/IAI.00090-08</pub-id><pub-id pub-id-type="pmid">18411285</pub-id><pub-id pub-id-type="pmcid">PMC2446714</pub-id></element-citation></ref><ref id="B97-ijms-24-10537"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhl&#233;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Laestadius</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jahnukainen</surname><given-names>T.</given-names></name><name name-style="western"><surname>S&#246;derblom</surname><given-names>T.</given-names></name><name name-style="western"><surname>B&#228;ckhed</surname><given-names>F.</given-names></name><name name-style="western"><surname>Celsi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brismar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Normark</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aperia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Richter-Dahlfors</surname><given-names>A.</given-names></name></person-group><article-title>Alpha-haemolysin of uropathogenic <italic toggle="yes">E. coli</italic> induces Ca<sup>2+</sup> oscillations in renal epithelial cells</article-title><source>Nature</source><year>2000</year><volume>405</volume><fpage>694</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1038/35015091</pub-id><pub-id pub-id-type="pmid">10864327</pub-id></element-citation></ref><ref id="B98-ijms-24-10537"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagamatsu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hannan</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Guest</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Kostakioti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hadjifrangiskou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Binkley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raivio</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Dysregulation of <italic toggle="yes">Escherichia coli</italic> &#945;-hemolysin expression alters the course of acute and persistent urinary tract infection</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>E871</fpage><lpage>E880</lpage><pub-id pub-id-type="doi">10.1073/pnas.1500374112</pub-id><pub-id pub-id-type="pmid">25675528</pub-id><pub-id pub-id-type="pmcid">PMC4345586</pub-id></element-citation></ref><ref id="B99-ijms-24-10537"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemonnier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Landraud</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lemichez</surname><given-names>E.</given-names></name></person-group><article-title>Rho GTPase-activating bacterial toxins: From bacterial virulence regulation to eukaryotic cell biology</article-title><source>FEMS Microbiol. Rev.</source><year>2007</year><volume>31</volume><fpage>515</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00078.x</pub-id><pub-id pub-id-type="pmid">17680807</pub-id></element-citation></ref><ref id="B100-ijms-24-10537"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petracchini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hamaoui</surname><given-names>D.</given-names></name><name name-style="western"><surname>Doye</surname><given-names>A.</given-names></name><name name-style="western"><surname>Asnacios</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fage</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vitiello</surname><given-names>E.</given-names></name><name name-style="western"><surname>Balland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lafont</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Optineurin links Hace1-dependent Rac ubiquitylation to integrin-mediated mechanotransduction to control bacterial invasion and cell division</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>6059</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-33803-x</pub-id><pub-id pub-id-type="pmid">36229487</pub-id><pub-id pub-id-type="pmcid">PMC9561704</pub-id></element-citation></ref><ref id="B101-ijms-24-10537"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Le Negrate</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mograbi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>V.</given-names></name><name name-style="western"><surname>Brest</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alliana-Schmid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Flatau</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>B.</given-names></name></person-group><article-title><italic toggle="yes">Escherichia coli</italic> cytotoxic necrotizing factor-1 (CNF-1) increases the adherence to epithelia and the oxidative burst of human polymorphonuclear leukocytes but decreases bacteria phagocytosis</article-title><source>J. Leukoc. Biol.</source><year>2000</year><volume>68</volume><fpage>522</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1189/jlb.68.4.522</pub-id><pub-id pub-id-type="pmid">11037974</pub-id></element-citation></ref><ref id="B102-ijms-24-10537"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pokharel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dhakal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dozois</surname><given-names>C.M.</given-names></name></person-group><article-title>The Diversity of <italic toggle="yes">Escherichia coli</italic> Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen</article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><elocation-id>344</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms11020344</pub-id><pub-id pub-id-type="pmid">36838308</pub-id><pub-id pub-id-type="pmcid">PMC9965155</pub-id></element-citation></ref><ref id="B103-ijms-24-10537"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heimer</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Rasko</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Lockatell</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Autotransporter genes pic and tsh are associated with <italic toggle="yes">Escherichia coli</italic> strains that cause acute pyelonephritis and are expressed during urinary tract infection</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>593</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.1.593-597.2004</pub-id><pub-id pub-id-type="pmid">14688142</pub-id><pub-id pub-id-type="pmcid">PMC343984</pub-id></element-citation></ref><ref id="B104-ijms-24-10537"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guyer</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Radulovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>F.E.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Sat, the secreted autotransporter toxin of uropathogenic <italic toggle="yes">Escherichia coli</italic>, is a vacuolating cytotoxin for bladder and kidney epithelial cells</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>4539</fpage><lpage>4546</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.8.4539-4546.2002</pub-id><pub-id pub-id-type="pmid">12117966</pub-id><pub-id pub-id-type="pmcid">PMC128167</pub-id></element-citation></ref><ref id="B105-ijms-24-10537"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guyer</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Identification of sat, an autotransporter toxin produced by uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Mol. Microbiol.</source><year>2000</year><volume>38</volume><fpage>53</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2000.02110.x</pub-id><pub-id pub-id-type="pmid">11029690</pub-id></element-citation></ref><ref id="B106-ijms-24-10537"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutta</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Cappello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Navarro-Garc&#237;a</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>J.P.</given-names></name></person-group><article-title>Functional comparison of serine protease autotransporters of enterobacteriaceae</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>7105</fpage><lpage>7113</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.12.7105-7113.2002</pub-id><pub-id pub-id-type="pmid">12438392</pub-id><pub-id pub-id-type="pmcid">PMC133081</pub-id></element-citation></ref><ref id="B107-ijms-24-10537"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li&#233;vin-Le Moal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Comenge</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ruby</surname><given-names>V.</given-names></name><name name-style="western"><surname>Amsellem</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Servin</surname><given-names>A.L.</given-names></name></person-group><article-title>Secreted autotransporter toxin (Sat) triggers autophagy in epithelial cells that relies on cell detachment</article-title><source>Cell Microbiol.</source><year>2011</year><volume>13</volume><fpage>992</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2011.01595.x</pub-id><pub-id pub-id-type="pmid">21501364</pub-id></element-citation></ref><ref id="B108-ijms-24-10537"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parham</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>U.</given-names></name><name name-style="western"><surname>Desvaux</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foxman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marrs</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>I.R.</given-names></name></person-group><article-title>PicU, a second serine protease autotransporter of uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>FEMS Microbiol. Lett.</source><year>2004</year><volume>230</volume><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/S0378-1097(03)00862-0</pub-id><pub-id pub-id-type="pmid">14734168</pub-id></element-citation></ref><ref id="B109-ijms-24-10537"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Totsika</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moriel</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wurpel</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Rossiter</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Strugnell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Ulett</surname><given-names>G.C.</given-names></name><etal/></person-group><article-title>Molecular Characterization of the Vacuolating Autotransporter Toxin in Uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Bacteriol.</source><year>2016</year><volume>198</volume><fpage>1487</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1128/JB.00791-15</pub-id><pub-id pub-id-type="pmid">26858103</pub-id><pub-id pub-id-type="pmcid">PMC4859599</pub-id></element-citation></ref><ref id="B110-ijms-24-10537"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Dozois</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Avelar-Gonz&#225;lez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Cuellar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pokharel</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Santiago</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Guerrero-Barrera</surname><given-names>A.L.</given-names></name></person-group><article-title>The Vacuolating Autotransporter Toxin (Vat) of <italic toggle="yes">Escherichia coli</italic> Causes Cell Cytoskeleton Changes and Produces Non-lysosomal Vacuole Formation in Bladder Epithelial Cells</article-title><source>Front. Cell Infect. Microbiol.</source><year>2020</year><volume>10</volume><fpage>299</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2020.00299</pub-id><pub-id pub-id-type="pmid">32670893</pub-id><pub-id pub-id-type="pmcid">PMC7332727</pub-id></element-citation></ref><ref id="B111-ijms-24-10537"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skaar</surname><given-names>E.P.</given-names></name></person-group><article-title>The battle for iron between bacterial pathogens and their vertebrate hosts</article-title><source>PLoS Pathog.</source><year>2010</year><volume>6</volume><elocation-id>e1000949</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000949</pub-id><pub-id pub-id-type="pmid">20711357</pub-id><pub-id pub-id-type="pmcid">PMC2920840</pub-id></element-citation></ref><ref id="B112-ijms-24-10537"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valdebenito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bister</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reissbrodt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hantke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Winkelmann</surname><given-names>G.</given-names></name></person-group><article-title>The detection of salmochelin and yersiniabactin in uropathogenic <italic toggle="yes">Escherichia coli</italic> strains by a novel hydrolysis-fluorescence-detection (HFD) method</article-title><source>Int. J. Med. Microbiol.</source><year>2005</year><volume>295</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2005.02.001</pub-id><pub-id pub-id-type="pmid">15969470</pub-id></element-citation></ref><ref id="B113-ijms-24-10537"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Grady</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Cerami</surname><given-names>A.</given-names></name></person-group><article-title>Low molecular weight iron-binding factor from mammalian tissue that potentiates bacterial growth</article-title><source>J. Exp. Med.</source><year>1980</year><volume>151</volume><fpage>418</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1084/jem.151.2.418</pub-id><pub-id pub-id-type="pmid">6985950</pub-id><pub-id pub-id-type="pmcid">PMC2185783</pub-id></element-citation></ref><ref id="B114-ijms-24-10537"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porcheron</surname><given-names>G.</given-names></name><name name-style="western"><surname>Habib</surname><given-names>R.</given-names></name><name name-style="western"><surname>Houle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caza</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#233;pine</surname><given-names>F.</given-names></name><name name-style="western"><surname>Daigle</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mass&#233;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dozois</surname><given-names>C.M.</given-names></name></person-group><article-title>The small RNA RyhB contributes to siderophore production and virulence of uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Infect. Immun.</source><year>2014</year><volume>82</volume><fpage>5056</fpage><lpage>5068</lpage><pub-id pub-id-type="doi">10.1128/IAI.02287-14</pub-id><pub-id pub-id-type="pmid">25245805</pub-id><pub-id pub-id-type="pmcid">PMC4249264</pub-id></element-citation></ref><ref id="B115-ijms-24-10537"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagan</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Haem acquisition is facilitated by a novel receptor Hma and required by uropathogenic <italic toggle="yes">Escherichia coli</italic> for kidney infection</article-title><source>Mol. Microbiol.</source><year>2009</year><volume>71</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2008.06509.x</pub-id><pub-id pub-id-type="pmid">19019144</pub-id><pub-id pub-id-type="pmcid">PMC2736550</pub-id></element-citation></ref><ref id="B116-ijms-24-10537"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stojiljkovic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Perkins-Balding</surname><given-names>D.</given-names></name></person-group><article-title>Processing of heme and heme-containing proteins by bacteria</article-title><source>DNA Cell Biol.</source><year>2002</year><volume>21</volume><fpage>281</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1089/104454902753759708</pub-id><pub-id pub-id-type="pmid">12042068</pub-id></element-citation></ref><ref id="B117-ijms-24-10537"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Tsukayama</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stamm</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Hooton</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000305</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000305</pub-id><pub-id pub-id-type="pmid">19229321</pub-id><pub-id pub-id-type="pmcid">PMC2637984</pub-id></element-citation></ref><ref id="B118-ijms-24-10537"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raffatellu</surname><given-names>M.</given-names></name><name name-style="western"><surname>George</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hornsby</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Nuccio</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Paixao</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Lipocalin-2 resistance confers an advantage to <italic toggle="yes">Salmonella enterica</italic> serotype Typhimurium for growth and survival in the inflamed intestine</article-title><source>Cell Host Microbe</source><year>2009</year><volume>5</volume><fpage>476</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2009.03.011</pub-id><pub-id pub-id-type="pmid">19454351</pub-id><pub-id pub-id-type="pmcid">PMC2768556</pub-id></element-citation></ref><ref id="B119-ijms-24-10537"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valdebenito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crumbliss</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Winkelmann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hantke</surname><given-names>K.</given-names></name></person-group><article-title>Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in <italic toggle="yes">Escherichia coli</italic> strain Nissle 1917</article-title><source>Int. J. Med. Microbiol.</source><year>2006</year><volume>296</volume><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2006.06.003</pub-id><pub-id pub-id-type="pmid">17008127</pub-id></element-citation></ref><ref id="B120-ijms-24-10537"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sorsa</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Hildinger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>S.</given-names></name></person-group><article-title>The salmochelin siderophore receptor IroN contributes to invasion of urothelial cells by extraintestinal pathogenic <italic toggle="yes">Escherichia coli</italic> in vitro</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>3183</fpage><lpage>3187</lpage><pub-id pub-id-type="doi">10.1128/IAI.00656-06</pub-id><pub-id pub-id-type="pmid">17353289</pub-id><pub-id pub-id-type="pmcid">PMC1932905</pub-id></element-citation></ref><ref id="B121-ijms-24-10537"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Mcfadden</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Carlino-Macdonald</surname><given-names>U.B.</given-names></name><name name-style="western"><surname>Beanan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilding</surname><given-names>G.E.</given-names></name></person-group><article-title>The Siderophore Receptor IroN of Extraintestinal Pathogenic <italic toggle="yes">Escherichia coli</italic> Is a Potential Vaccine Candidate</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>7164</fpage><lpage>7169</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.12.7164-7169.2003</pub-id><pub-id pub-id-type="pmid">14638809</pub-id><pub-id pub-id-type="pmcid">PMC308914</pub-id></element-citation></ref><ref id="B122-ijms-24-10537"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaturvedi</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Stapleton</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>J.P.</given-names></name></person-group><article-title>The siderophore yersiniabactin binds copper to protect pathogens during infection</article-title><source>Nat. Chem. Biol.</source><year>2012</year><volume>8</volume><fpage>731</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1020</pub-id><pub-id pub-id-type="pmid">22772152</pub-id><pub-id pub-id-type="pmcid">PMC3600419</pub-id></element-citation></ref><ref id="B123-ijms-24-10537"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reigstad</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>J.I.</given-names></name></person-group><article-title>Functional genomic studies of uropathogenic <italic toggle="yes">Escherichia coli</italic> and host urothelial cells when intracellular bacterial communities are assembled</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>21259</fpage><lpage>21267</lpage><pub-id pub-id-type="doi">10.1074/jbc.M611502200</pub-id><pub-id pub-id-type="pmid">17504765</pub-id></element-citation></ref><ref id="B124-ijms-24-10537"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watts</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Totsika</surname><given-names>M.</given-names></name><name name-style="western"><surname>Challinor</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Mabbett</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Ulett</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>De Voss</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Schembri</surname><given-names>M.A.</given-names></name></person-group><article-title>Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria <italic toggle="yes">Escherichia coli</italic></article-title><source>Infect. Immun.</source><year>2012</year><volume>80</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1128/IAI.05594-11</pub-id><pub-id pub-id-type="pmid">21930757</pub-id><pub-id pub-id-type="pmcid">PMC3255690</pub-id></element-citation></ref><ref id="B125-ijms-24-10537"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Brumbaugh</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Redundancy and specificity of <italic toggle="yes">Escherichia coli</italic> iron acquisition systems during urinary tract infection</article-title><source>Infect. Immun.</source><year>2011</year><volume>79</volume><fpage>1225</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1128/IAI.01222-10</pub-id><pub-id pub-id-type="pmid">21220482</pub-id><pub-id pub-id-type="pmcid">PMC3067483</pub-id></element-citation></ref><ref id="B126-ijms-24-10537"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Redford</surname><given-names>P.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>S.M.</given-names></name></person-group><article-title>TonB-dependent systems of uropathogenic <italic toggle="yes">Escherichia coli</italic>: Aerobactin and heme transport and TonB are required for virulence in the mouse</article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>6179</fpage><lpage>6185</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.10.6179-6185.2001</pub-id><pub-id pub-id-type="pmid">11553558</pub-id><pub-id pub-id-type="pmcid">PMC98749</pub-id></element-citation></ref><ref id="B127-ijms-24-10537"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Justice</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Theriot</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Footer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Differentiation and developmental pathways of uropathogenic <italic toggle="yes">Escherichia coli</italic> in urinary tract pathogenesis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>1333</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1073/pnas.0308125100</pub-id><pub-id pub-id-type="pmid">14739341</pub-id><pub-id pub-id-type="pmcid">PMC337053</pub-id></element-citation></ref><ref id="B128-ijms-24-10537"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosen</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Hooton</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Stamm</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Humphrey</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Detection of intracellular bacterial communities in human urinary tract infection</article-title><source>PLoS Med.</source><year>2007</year><volume>4</volume><elocation-id>e329</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0040329</pub-id><pub-id pub-id-type="pmid">18092884</pub-id><pub-id pub-id-type="pmcid">PMC2140087</pub-id></element-citation></ref><ref id="B129-ijms-24-10537"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Host subversion by formation of intracellular bacterial communities in the urinary tract</article-title><source>Microbes Infect.</source><year>2004</year><volume>6</volume><fpage>1094</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2004.05.023</pub-id><pub-id pub-id-type="pmid">15380779</pub-id></element-citation></ref><ref id="B130-ijms-24-10537"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eto</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Sundsbak</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Mulvey</surname><given-names>M.A.</given-names></name></person-group><article-title>Actin-gated intracellular growth and resurgence of uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Cell Microbiol.</source><year>2006</year><volume>8</volume><fpage>704</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2006.00691.x</pub-id><pub-id pub-id-type="pmid">16548895</pub-id></element-citation></ref><ref id="B131-ijms-24-10537"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leatham-Jensen</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Mokszycki</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Deering</surname><given-names>R.</given-names></name><name name-style="western"><surname>Camberg</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Sokurenko</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Tchesnokova</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Frimodt-M&#248;ller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Krogfelt</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Leth Nielsen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Uropathogenic <italic toggle="yes">Escherichia coli</italic> Metabolite-Dependent Quiescence and Persistence May Explain Antibiotic Tolerance during Urinary Tract Infection</article-title><source>mSphere</source><year>2016</year><volume>1</volume><fpage>e00055-15</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00055-15</pub-id><pub-id pub-id-type="pmid">27303698</pub-id><pub-id pub-id-type="pmcid">PMC4863606</pub-id></element-citation></ref><ref id="B132-ijms-24-10537"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goetz</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Borregaard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bluhm</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>R.K.</given-names></name></person-group><article-title>The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition</article-title><source>Mol. Cell</source><year>2002</year><volume>10</volume><fpage>1033</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00708-6</pub-id><pub-id pub-id-type="pmid">12453412</pub-id></element-citation></ref><ref id="B133-ijms-24-10537"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischbach</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Abergel</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Wanner</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>C.T.</given-names></name><etal/></person-group><article-title>The pathogen-associated iroA gene cluster mediates bacterial evasion of lipocalin 2</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>16502</fpage><lpage>16507</lpage><pub-id pub-id-type="doi">10.1073/pnas.0604636103</pub-id><pub-id pub-id-type="pmid">17060628</pub-id><pub-id pub-id-type="pmcid">PMC1637611</pub-id></element-citation></ref><ref id="B134-ijms-24-10537"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>K.D.</given-names></name></person-group><article-title>Iron metabolism at the host pathogen interface: Lipocalin 2 and the pathogen-associated iroA gene cluster</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2007</year><volume>39</volume><fpage>1776</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2007.07.003</pub-id><pub-id pub-id-type="pmid">17714976</pub-id><pub-id pub-id-type="pmcid">PMC2695446</pub-id></element-citation></ref><ref id="B135-ijms-24-10537"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simpson</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>May</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kahne</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>N.</given-names></name></person-group><article-title>Lipopolysaccharide transport to the cell surface: Biosynthesis and extraction from the inner membrane</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2015</year><volume>370</volume><fpage>20150029</fpage><pub-id pub-id-type="doi">10.1098/rstb.2015.0029</pub-id><pub-id pub-id-type="pmid">26370941</pub-id><pub-id pub-id-type="pmcid">PMC4632605</pub-id></element-citation></ref><ref id="B136-ijms-24-10537"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maldonado</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>S&#225;-Correia</surname><given-names>I.</given-names></name><name name-style="western"><surname>Valvano</surname><given-names>M.A.</given-names></name></person-group><article-title>Lipopolysaccharide modification in Gram-negative bacteria during chronic infection</article-title><source>FEMS Microbiol. Rev.</source><year>2016</year><volume>40</volume><fpage>480</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuw007</pub-id><pub-id pub-id-type="pmid">27075488</pub-id><pub-id pub-id-type="pmcid">PMC4931227</pub-id></element-citation></ref><ref id="B137-ijms-24-10537"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billips</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Klumpp</surname><given-names>D.J.</given-names></name></person-group><article-title>Molecular basis of uropathogenic <italic toggle="yes">Escherichia coli</italic> evasion of the innate immune response in the bladder</article-title><source>Infect. Immun.</source><year>2008</year><volume>76</volume><fpage>3891</fpage><lpage>3900</lpage><pub-id pub-id-type="doi">10.1128/IAI.00069-08</pub-id><pub-id pub-id-type="pmid">18559433</pub-id><pub-id pub-id-type="pmcid">PMC2519411</pub-id></element-citation></ref><ref id="B138-ijms-24-10537"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunstad</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Justice</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Lauer</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Suppression of bladder epithelial cytokine responses by uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>3999</fpage><lpage>4006</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.7.3999-4006.2005</pub-id><pub-id pub-id-type="pmid">15972487</pub-id><pub-id pub-id-type="pmcid">PMC1168571</pub-id></element-citation></ref><ref id="B139-ijms-24-10537"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ostenson</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Tullus</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brauner</surname><given-names>A.</given-names></name></person-group><article-title>Serum resistance in <italic toggle="yes">Escherichia coli</italic> strains causing acute pyelonephritis and bacteraemia</article-title><source>Apmis</source><year>1992</year><volume>100</volume><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1111/j.1699-0463.1992.tb00854.x</pub-id><pub-id pub-id-type="pmid">1554489</pub-id></element-citation></ref><ref id="B140-ijms-24-10537"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fux</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Costerton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Stoodley</surname><given-names>P.</given-names></name></person-group><article-title>Survival strategies of infectious biofilms</article-title><source>Trends Microbiol.</source><year>2005</year><volume>13</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2004.11.010</pub-id><pub-id pub-id-type="pmid">15639630</pub-id></element-citation></ref><ref id="B141-ijms-24-10537"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costerton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>E.P.</given-names></name></person-group><article-title>Bacterial biofilms: A common cause of persistent infections</article-title><source>Science</source><year>1999</year><volume>284</volume><fpage>1318</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1126/science.284.5418.1318</pub-id><pub-id pub-id-type="pmid">10334980</pub-id></element-citation></ref><ref id="B142-ijms-24-10537"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ejrn&#230;s</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stegger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reisner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferry</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Lundgren</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frimodt-M&#248;ller</surname><given-names>N.</given-names></name></person-group><article-title>Characteristics of <italic toggle="yes">Escherichia coli</italic> causing persistence or relapse of urinary tract infections: Phylogenetic groups, virulence factors and biofilm formation</article-title><source>Virulence</source><year>2011</year><volume>2</volume><fpage>528</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.4161/viru.2.6.18189</pub-id><pub-id pub-id-type="pmid">22030858</pub-id></element-citation></ref><ref id="B143-ijms-24-10537"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norinder</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>L&#252;thje</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kadas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nord</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Brauner</surname><given-names>A.</given-names></name></person-group><article-title>Cellulose and PapG are important for <italic toggle="yes">Escherichia coli</italic> causing recurrent urinary tract infection in women</article-title><source>Infection</source><year>2011</year><volume>39</volume><fpage>571</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1007/s15010-011-0199-0</pub-id><pub-id pub-id-type="pmid">22002732</pub-id></element-citation></ref><ref id="B144-ijms-24-10537"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sevander</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Tapiainen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ik&#228;heimo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pokka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koskela</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uhari</surname><given-names>M.</given-names></name></person-group><article-title>Biofilm formation by <italic toggle="yes">Escherichia coli</italic> isolated from patients with urinary tract infections</article-title><source>Clin. Nephrol.</source><year>2009</year><volume>71</volume><fpage>501</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.5414/CNP71501</pub-id><pub-id pub-id-type="pmid">19473609</pub-id></element-citation></ref><ref id="B145-ijms-24-10537"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tapiainen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hanni</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Salo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ik&#228;heimo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Uhari</surname><given-names>M.</given-names></name></person-group><article-title><italic toggle="yes">Escherichia coli</italic> biofilm formation and recurrences of urinary tract infections in children</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2014</year><volume>33</volume><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1007/s10096-013-1935-4</pub-id><pub-id pub-id-type="pmid">23996047</pub-id></element-citation></ref><ref id="B146-ijms-24-10537"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahrani-Mougeot</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Buckles</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Lockatell</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Hebel</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Donnenberg</surname><given-names>M.S.</given-names></name></person-group><article-title>Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic <italic toggle="yes">Escherichia coli</italic> virulence determinants in the murine urinary tract</article-title><source>Mol. Microbiol.</source><year>2002</year><volume>45</volume><fpage>1079</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2002.03078.x</pub-id><pub-id pub-id-type="pmid">12180926</pub-id></element-citation></ref><ref id="B147-ijms-24-10537"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subashchandrabose</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Spurbeck</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Kole</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Genome-wide detection of fitness genes in uropathogenic <italic toggle="yes">Escherichia coli</italic> during systemic infection</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003788</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003788</pub-id><pub-id pub-id-type="pmid">24339777</pub-id><pub-id pub-id-type="pmcid">PMC3855560</pub-id></element-citation></ref><ref id="B148-ijms-24-10537"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conway</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Dorman</surname><given-names>C.J.</given-names></name></person-group><article-title>The DNA relaxation-dependent OFF-to-ON biasing of the type 1 fimbrial genetic switch requires the Fis nucleoid-associated protein</article-title><source>Microbiology</source><year>2023</year><volume>169</volume><fpage>001283</fpage><pub-id pub-id-type="doi">10.1099/mic.0.001283</pub-id><pub-id pub-id-type="pmid">36748578</pub-id><pub-id pub-id-type="pmcid">PMC9993118</pub-id></element-citation></ref><ref id="B149-ijms-24-10537"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roesch</surname><given-names>P.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moritz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pellett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>R.A.</given-names></name></person-group><article-title>Regulation of type 1 fimbriae by unlinked FimB- and FimE-like recombinases in uropathogenic <italic toggle="yes">Escherichia coli</italic> strain CFT073</article-title><source>Infect. Immun.</source><year>2006</year><volume>74</volume><fpage>1072</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1128/IAI.74.2.1072-1083.2006</pub-id><pub-id pub-id-type="pmid">16428754</pub-id><pub-id pub-id-type="pmcid">PMC1360361</pub-id></element-citation></ref><ref id="B150-ijms-24-10537"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foxman</surname><given-names>B.</given-names></name></person-group><article-title>The epidemiology of urinary tract infection</article-title><source>Nat. Rev. Urol.</source><year>2010</year><volume>7</volume><fpage>653</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2010.190</pub-id><pub-id pub-id-type="pmid">21139641</pub-id></element-citation></ref><ref id="B151-ijms-24-10537"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Grigoryan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Trautner</surname><given-names>B.</given-names></name></person-group><article-title>Urinary Tract Infection</article-title><source>Ann. Intern. Med.</source><year>2017</year><volume>167</volume><fpage>Itc49</fpage><lpage>Itc64</lpage><pub-id pub-id-type="doi">10.7326/AITC201710030</pub-id><pub-id pub-id-type="pmid">28973215</pub-id></element-citation></ref><ref id="B152-ijms-24-10537"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Lowder</surname><given-names>J.L.</given-names></name></person-group><article-title>Diagnosis and treatment of urinary tract infections across age groups</article-title><source>Am. J. Obstet. Gynecol.</source><year>2018</year><volume>219</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.ajog.2017.12.231</pub-id><pub-id pub-id-type="pmid">29305250</pub-id></element-citation></ref><ref id="B153-ijms-24-10537"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Verhaegh</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Harbarth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Huttner</surname><given-names>A.</given-names></name></person-group><article-title>Nitrofurantoin&#8217;s efficacy and safety as prophylaxis for urinary tract infections: A systematic review of the literature and meta-analysis of controlled trials</article-title><source>Clin. Microbiol. Infect.</source><year>2017</year><volume>23</volume><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.08.003</pub-id><pub-id pub-id-type="pmid">27542332</pub-id></element-citation></ref><ref id="B154-ijms-24-10537"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Magee</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Monks</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Geno</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>S.B.</given-names></name></person-group><article-title>Assessment of nationally recommended antibiotics for treatment of UTI in U.S.-Mexico border emergency departments</article-title><source>Am. J. Emerg. Med.</source><year>2022</year><volume>61</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2022.08.023</pub-id><pub-id pub-id-type="pmid">36027632</pub-id></element-citation></ref><ref id="B155-ijms-24-10537"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hooton</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Stamm</surname><given-names>W.E.</given-names></name></person-group><article-title>Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women</article-title><source>Arch. Intern. Med.</source><year>2007</year><volume>167</volume><fpage>2207</fpage><lpage>2212</lpage><pub-id pub-id-type="doi">10.1001/archinte.167.20.2207</pub-id><pub-id pub-id-type="pmid">17998493</pub-id></element-citation></ref><ref id="B156-ijms-24-10537"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moya-Dionisio</surname><given-names>V.</given-names></name><name name-style="western"><surname>D&#237;az-Zabala</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ib&#225;&#241;ez-Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Su&#225;rez-Leiva</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Su&#225;rez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ord&#243;&#241;ez-&#193;lvarez</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Santos-Rodr&#237;guez</surname><given-names>F.</given-names></name></person-group><article-title>Uropathogen pattern and antimicrobial susceptibility in positive urinary cultures isolates from paediatric patients</article-title><source>Rev. Esp. Quimioter.</source><year>2016</year><volume>29</volume><fpage>146</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">27092771</pub-id></element-citation></ref><ref id="B157-ijms-24-10537"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicolle</surname><given-names>L.E.</given-names></name></person-group><article-title>Pivmecillinam in the treatment of urinary tract infections</article-title><source>J. Antimicrob. Chemother.</source><year>2000</year><volume>46</volume><fpage>35</fpage><lpage>65</lpage><page-range>35&#8211;39; discussion 63&#8211;65</page-range><pub-id pub-id-type="doi">10.1093/jac/46.suppl_1.35</pub-id><pub-id pub-id-type="pmid">11051622</pub-id></element-citation></ref><ref id="B158-ijms-24-10537"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bader</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Loeb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>A.A.</given-names></name></person-group><article-title>Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents</article-title><source>Postgrad. Med.</source><year>2020</year><volume>132</volume><fpage>234</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1080/00325481.2019.1680052</pub-id><pub-id pub-id-type="pmid">31608743</pub-id></element-citation></ref><ref id="B159-ijms-24-10537"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quek</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lye</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>T.M.</given-names></name></person-group><article-title>Outcomes of Fosfomycin Use in Ceftriaxone-Resistant Enterobacteriaceae Urinary Tract Infection in the Elderly</article-title><source>Int. J. Antimicrob. Agents</source><year>2019</year><volume>53</volume><fpage>195</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.10.008</pub-id><pub-id pub-id-type="pmid">30722963</pub-id></element-citation></ref><ref id="B160-ijms-24-10537"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peretz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naamneh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tkhawkho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nitzan</surname><given-names>O.</given-names></name></person-group><article-title>High Rates of Fosfomycin Resistance in Gram-Negative Urinary Isolates from Israel</article-title><source>Microb. Drug. Resist.</source><year>2019</year><volume>25</volume><fpage>408</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1089/mdr.2018.0393</pub-id><pub-id pub-id-type="pmid">30724694</pub-id></element-citation></ref><ref id="B161-ijms-24-10537"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hooton</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Naber</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Wullt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Colgan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Nicolle</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Raz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases</article-title><source>Clin. Infect. Dis.</source><year>2011</year><volume>52</volume><fpage>e103</fpage><lpage>e120</lpage><pub-id pub-id-type="doi">10.1093/cid/ciq257</pub-id><pub-id pub-id-type="pmid">21292654</pub-id></element-citation></ref><ref id="B162-ijms-24-10537"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>P.R.</given-names></name></person-group><article-title>Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections</article-title><source>Expert Opin. Pharm.</source><year>2013</year><volume>14</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1517/14656566.2013.778827</pub-id><pub-id pub-id-type="pmid">23480061</pub-id></element-citation></ref><ref id="B163-ijms-24-10537"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paterson</surname><given-names>D.L.</given-names></name></person-group><article-title>Resistance in gram-negative bacteria: <italic toggle="yes">Enterobacteriaceae</italic></article-title><source>Am. J. Med.</source><year>2006</year><volume>34</volume><fpage>S20</fpage><lpage>S70</lpage><page-range>S20&#8211;S28; discussion S62&#8211;S70</page-range><pub-id pub-id-type="doi">10.1016/j.amjmed.2006.03.013</pub-id><pub-id pub-id-type="pmid">16735147</pub-id></element-citation></ref><ref id="B164-ijms-24-10537"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pendleton</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>B.F.</given-names></name></person-group><article-title>Clinical relevance of the ESKAPE pathogens</article-title><source>Expert Rev. Anti. Infect. Ther.</source><year>2013</year><volume>11</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1586/eri.13.12</pub-id><pub-id pub-id-type="pmid">23458769</pub-id></element-citation></ref><ref id="B165-ijms-24-10537"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhadelia</surname><given-names>N.</given-names></name></person-group><article-title>Management of urinary tract infections from multidrug-resistant organisms</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2014</year><volume>28</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2013.10.002</pub-id><pub-id pub-id-type="pmid">24484574</pub-id></element-citation></ref><ref id="B166-ijms-24-10537"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bader</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Loeb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>A.A.</given-names></name></person-group><article-title>An update on the management of urinary tract infections in the era of antimicrobial resistance</article-title><source>Postgrad. Med.</source><year>2017</year><volume>129</volume><fpage>242</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1080/00325481.2017.1246055</pub-id><pub-id pub-id-type="pmid">27712137</pub-id></element-citation></ref><ref id="B167-ijms-24-10537"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garau</surname><given-names>J.</given-names></name></person-group><article-title>Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: Fosfomycin, nitrofurantoin and tigecycline</article-title><source>Clin. Microbiol. Infect.</source><year>2008</year><volume>14</volume><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2007.01852.x</pub-id><pub-id pub-id-type="pmid">18154548</pub-id></element-citation></ref><ref id="B168-ijms-24-10537"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paterson</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Bonomo</surname><given-names>R.A.</given-names></name></person-group><article-title>Extended-spectrum beta-lactamases: A clinical update</article-title><source>Clin. Microbiol. Rev.</source><year>2005</year><volume>18</volume><fpage>657</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1128/CMR.18.4.657-686.2005</pub-id><pub-id pub-id-type="pmid">16223952</pub-id><pub-id pub-id-type="pmcid">PMC1265908</pub-id></element-citation></ref><ref id="B169-ijms-24-10537"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradford</surname><given-names>P.A.</given-names></name></person-group><article-title>Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat</article-title><source>Clin. Microbiol. Rev.</source><year>2001</year><volume>14</volume><fpage>933</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1128/CMR.14.4.933-951.2001</pub-id><pub-id pub-id-type="pmid">11585791</pub-id><pub-id pub-id-type="pmcid">PMC89009</pub-id></element-citation></ref><ref id="B170-ijms-24-10537"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>U.I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Wie</surname><given-names>S.H.</given-names></name></person-group><article-title>Use of cefuroxime for women with community-onset acute pyelonephritis caused by cefuroxime-susceptible or -resistant <italic toggle="yes">Escherichia coli</italic></article-title><source>Korean J. Intern. Med.</source><year>2016</year><volume>31</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.3904/kjim.2016.31.1.145</pub-id><pub-id pub-id-type="pmid">26767868</pub-id><pub-id pub-id-type="pmcid">PMC4712418</pub-id></element-citation></ref><ref id="B171-ijms-24-10537"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whelan</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Grady</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Finn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lucey</surname><given-names>B.</given-names></name></person-group><article-title>Effect of Sub-Inhibitory Concentrations of Nitrofurantoin, Ciprofloxacin, and Trimethoprim on In Vitro Biofilm Formation in Uropathogenic <italic toggle="yes">Escherichia coli</italic> (UPEC)</article-title><source>Med. Sci</source><year>2022</year><volume>11</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.3390/medsci11010001</pub-id><pub-id pub-id-type="pmcid">PMC9844298</pub-id><pub-id pub-id-type="pmid">36649038</pub-id></element-citation></ref><ref id="B172-ijms-24-10537"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Suyemoto</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Hull</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Gall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Borst</surname><given-names>L.B.</given-names></name></person-group><article-title>Genomic Characterization of a Nalidixic Acid-Resistant Salmonella Enteritidis Strain Causing Persistent Infections in Broiler Chickens</article-title><source>Front. Vet. Sci.</source><year>2021</year><volume>8</volume><fpage>725737</fpage><pub-id pub-id-type="doi">10.3389/fvets.2021.725737</pub-id><pub-id pub-id-type="pmid">34540936</pub-id><pub-id pub-id-type="pmcid">PMC8440904</pub-id></element-citation></ref><ref id="B173-ijms-24-10537"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jabeen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>N.U.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Shareef</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sarwar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yahya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Comparative efficacy of cephradine-loaded silver and gold nanoparticles against resistant human pathogens</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><year>2022</year><volume>50</volume><fpage>312</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1080/21691401.2022.2144340</pub-id><pub-id pub-id-type="pmid">36380462</pub-id></element-citation></ref><ref id="B174-ijms-24-10537"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Becknell</surname><given-names>B.</given-names></name></person-group><article-title>Urinary Tract Infections</article-title><source>Pediatr. Clin. N. Am.</source><year>2019</year><volume>66</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.pcl.2018.08.002</pub-id><pub-id pub-id-type="pmid">30454735</pub-id></element-citation></ref><ref id="B175-ijms-24-10537"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zalewska-Pi&#261;tek</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Pi&#261;tek</surname><given-names>R.J.</given-names></name></person-group><article-title>Alternative treatment approaches of urinary tract infections caused by uropathogenic <italic toggle="yes">Escherichia coli</italic> strains</article-title><source>Acta Biochim. Pol.</source><year>2019</year><volume>66</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.18388/abp.2018_2787</pub-id><pub-id pub-id-type="pmid">31136644</pub-id></element-citation></ref><ref id="B176-ijms-24-10537"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saatchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>McCormack</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marra</surname><given-names>F.</given-names></name></person-group><article-title>Quantifying the Gap between Expected and Actual Rates of Antibiotic Prescribing in British Columbia, Canada</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>1428</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10111428</pub-id><pub-id pub-id-type="pmid">34827366</pub-id><pub-id pub-id-type="pmcid">PMC8615253</pub-id></element-citation></ref><ref id="B177-ijms-24-10537"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLellan</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Hunstad</surname><given-names>D.A.</given-names></name></person-group><article-title>Urinary Tract Infection: Pathogenesis and Outlook</article-title><source>Trends Mol. Med.</source><year>2016</year><volume>22</volume><fpage>946</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2016.09.003</pub-id><pub-id pub-id-type="pmid">27692880</pub-id><pub-id pub-id-type="pmcid">PMC5159206</pub-id></element-citation></ref><ref id="B178-ijms-24-10537"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grischke</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>R&#252;ttgers</surname><given-names>H.</given-names></name></person-group><article-title>Treatment of bacterial infections of the female urinary tract by immunization of the patients</article-title><source>Urol. Int.</source><year>1987</year><volume>42</volume><fpage>338</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1159/000281988</pub-id><pub-id pub-id-type="pmid">3324441</pub-id></element-citation></ref><ref id="B179-ijms-24-10537"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopkins</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Elkahwaji</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beierle</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Leverson</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Uehling</surname><given-names>D.T.</given-names></name></person-group><article-title>Vaginal mucosal vaccine for recurrent urinary tract infections in women: Results of a phase 2 clinical trial</article-title><source>J. Urol.</source><year>2007</year><volume>177</volume><fpage>1349</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2006.11.093</pub-id><pub-id pub-id-type="pmid">17382730</pub-id></element-citation></ref><ref id="B180-ijms-24-10537"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beerepoot</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Geerlings</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>van Haarst</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>van Charante</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>ter Riet</surname><given-names>G.</given-names></name></person-group><article-title>Nonantibiotic prophylaxis for recurrent urinary tract infections: A systematic review and meta-analysis of randomized controlled trials</article-title><source>J. Urol.</source><year>2013</year><volume>190</volume><fpage>1981</fpage><lpage>1989</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2013.04.142</pub-id><pub-id pub-id-type="pmid">23867306</pub-id></element-citation></ref><ref id="B181-ijms-24-10537"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kochiashvili</surname><given-names>D.</given-names></name><name name-style="western"><surname>Khuskivadze</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kochiashvili</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koberidze</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kvakhajelidze</surname><given-names>V.</given-names></name></person-group><article-title>Role of the bacterial vaccine Solco-Urovac&#174; in treatment and prevention of recurrent urinary tract infections of bacterial origin</article-title><source>Georgian. Med. News</source><year>2014</year><volume>231</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">25020163</pub-id></element-citation></ref><ref id="B182-ijms-24-10537"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wade</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Derry</surname><given-names>F.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.</given-names></name></person-group><article-title>Uro-Vaxom<sup>&#174;</sup> versus placebo for the prevention of recurrent symptomatic urinary tract infections in participants with chronic neurogenic bladder dysfunction: A randomised controlled feasibility study</article-title><source>Trials</source><year>2019</year><volume>20</volume><fpage>223</fpage><pub-id pub-id-type="doi">10.1186/s13063-019-3275-x</pub-id><pub-id pub-id-type="pmid">30992071</pub-id><pub-id pub-id-type="pmcid">PMC6469220</pub-id></element-citation></ref><ref id="B183-ijms-24-10537"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magasi</surname><given-names>P.</given-names></name><name name-style="western"><surname>P&#225;novics</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ill&#233;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>M.</given-names></name></person-group><article-title>Uro-Vaxom and the management of recurrent urinary tract infection in adults: A randomized multicenter double-blind trial</article-title><source>Eur. Urol.</source><year>1994</year><volume>26</volume><fpage>137</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1159/000475363</pub-id><pub-id pub-id-type="pmid">7957468</pub-id></element-citation></ref><ref id="B184-ijms-24-10537"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dambros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Naber</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Cozma</surname><given-names>G.</given-names></name></person-group><article-title>Recurrent Urinary Tract Infections: Uro-Vaxom, a New Alternative</article-title><source>Eur. Urol. Suppl.</source><year>2009</year><volume>8</volume><fpage>762</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/j.eursup.2009.07.002</pub-id></element-citation></ref><ref id="B185-ijms-24-10537"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Paick</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Son</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Park</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Choo</surname><given-names>M.S.</given-names></name></person-group><article-title>A prospective multi-center trial of <italic toggle="yes">Escherichia coli</italic> extract for the prophylactic treatment of patients with chronically recurrent cystitis</article-title><source>J. Korean Med. Sci.</source><year>2010</year><volume>25</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.3346/jkms.2010.25.3.435</pub-id><pub-id pub-id-type="pmid">20191044</pub-id><pub-id pub-id-type="pmcid">PMC2826739</pub-id></element-citation></ref><ref id="B186-ijms-24-10537"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magistro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stief</surname><given-names>C.G.</given-names></name></person-group><article-title>Vaccine Development for Urinary Tract Infections: Where Do We Stand?</article-title><source>Eur. Urol. Focus.</source><year>2019</year><volume>5</volume><fpage>39</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.euf.2018.07.034</pub-id><pub-id pub-id-type="pmid">30093359</pub-id></element-citation></ref><ref id="B187-ijms-24-10537"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marinova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nenkov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Markova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nikolaeva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kostadinova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mitov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vretenarska</surname><given-names>M.</given-names></name></person-group><article-title>Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections</article-title><source>Int. J. Immunopathol. Pharmacol.</source><year>2005</year><volume>18</volume><fpage>457</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1177/039463200501800306</pub-id><pub-id pub-id-type="pmid">16164822</pub-id></element-citation></ref><ref id="B188-ijms-24-10537"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Bino</surname><given-names>L.</given-names></name><name name-style="western"><surname>&#216;sterlid</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Nonne</surname><given-names>F.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Cod&#233;e</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name></person-group><article-title>Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance</article-title><source>Chem. Rev.</source><year>2022</year><volume>122</volume><fpage>15672</fpage><lpage>15716</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.2c00021</pub-id><pub-id pub-id-type="pmid">35608633</pub-id><pub-id pub-id-type="pmcid">PMC9614730</pub-id></element-citation></ref><ref id="B189-ijms-24-10537"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Beanan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>R.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>U.</given-names></name><name name-style="western"><surname>Cope</surname><given-names>J.J.</given-names></name></person-group><article-title>Capsular polysaccharide and the O-specific antigen impede antibody binding: A potential obstacle for the successful development of an extraintestinal pathogenic <italic toggle="yes">Escherichia coli</italic> vaccine</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>388</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.10.082</pub-id><pub-id pub-id-type="pmid">19014988</pub-id></element-citation></ref><ref id="B190-ijms-24-10537"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billips</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Yaggie</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Cashy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Klumpp</surname><given-names>D.J.</given-names></name></person-group><article-title>A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Infect. Dis.</source><year>2009</year><volume>200</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1086/599839</pub-id><pub-id pub-id-type="pmid">19522648</pub-id></element-citation></ref><ref id="B191-ijms-24-10537"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horvath</surname><given-names>D.J.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Patel</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koff</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Jayanthi</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Association of O-Antigen Serotype with the Magnitude of Initial Systemic Cytokine Responses and Persistence in the Urinary Tract</article-title><source>J. Bacteriol.</source><year>2016</year><volume>198</volume><fpage>964</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1128/JB.00664-15</pub-id><pub-id pub-id-type="pmid">26755631</pub-id><pub-id pub-id-type="pmcid">PMC4772593</pub-id></element-citation></ref><ref id="B192-ijms-24-10537"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uehling</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Dahmer</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Balish</surname><given-names>E.</given-names></name></person-group><article-title>Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection</article-title><source>J. Urol.</source><year>1994</year><volume>152</volume><fpage>2308</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(17)31664-6</pub-id><pub-id pub-id-type="pmid">7966729</pub-id></element-citation></ref><ref id="B193-ijms-24-10537"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uehling</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Elkahwaji</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Leverson</surname><given-names>G.E.</given-names></name></person-group><article-title>Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections</article-title><source>J. Urol.</source><year>2003</year><volume>170</volume><fpage>867</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000075094.54767.6e</pub-id><pub-id pub-id-type="pmid">12913718</pub-id></element-citation></ref><ref id="B194-ijms-24-10537"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Beanan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Genagon</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>U.</given-names></name><name name-style="western"><surname>Cope</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.R.</given-names></name></person-group><article-title>A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic <italic toggle="yes">E. coli</italic> strain is a vaccine candidate</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>3859</fpage><lpage>3870</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.100</pub-id><pub-id pub-id-type="pmid">17306426</pub-id><pub-id pub-id-type="pmcid">PMC1913199</pub-id></element-citation></ref><ref id="B195-ijms-24-10537"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billips</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Forrestal</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Rycyk</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Klumpp</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>A.J.</given-names></name></person-group><article-title>Modulation of host innate immune response in the bladder by uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Infect Immun.</source><year>2007</year><volume>75</volume><fpage>5353</fpage><lpage>5360</lpage><pub-id pub-id-type="doi">10.1128/IAI.00922-07</pub-id><pub-id pub-id-type="pmid">17724068</pub-id><pub-id pub-id-type="pmcid">PMC2168307</pub-id></element-citation></ref><ref id="B196-ijms-24-10537"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>William</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Darren</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oscar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wouter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tiziano</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Kellen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stefan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ibarra</surname><given-names>D.</given-names></name></person-group><article-title>2712. Safety and Immunogenicity of two Doses of ExPEC4V Vaccine Against Extraintestinal Pathogenic <italic toggle="yes">Escherichia coli</italic> Disease in Healthy Adult Participants</article-title><source>Open Forum Infect. Dis.</source><year>2019</year><volume>6</volume><fpage>S954</fpage></element-citation></ref><ref id="B197-ijms-24-10537"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frenck</surname><given-names>R.W.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Ervin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abbanat</surname><given-names>D.</given-names></name><name name-style="western"><surname>Spiessens</surname><given-names>B.</given-names></name><name name-style="western"><surname>Go</surname><given-names>O.</given-names></name><name name-style="western"><surname>Haazen</surname><given-names>W.</given-names></name><name name-style="western"><surname>van den Dobbelsteen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Poolman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thoelen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a vaccine for extra-intestinal pathogenic <italic toggle="yes">Escherichia coli</italic> (ESTELLA): A phase 2 randomised controlled trial</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>631</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30803-X</pub-id><pub-id pub-id-type="pmid">31079947</pub-id></element-citation></ref><ref id="B198-ijms-24-10537"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asadi Karam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Oloomi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S.</given-names></name></person-group><article-title>Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>1210</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.12.059</pub-id><pub-id pub-id-type="pmid">23306365</pub-id></element-citation></ref><ref id="B199-ijms-24-10537"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasanzadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shokrgozar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ahangari Cohan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Asadi Karam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S.</given-names></name></person-group><article-title>In silico analysis and in vivo assessment of a novel epitope-based vaccine candidate against uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>16258</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-73179-w</pub-id><pub-id pub-id-type="pmid">33004862</pub-id><pub-id pub-id-type="pmcid">PMC7530722</pub-id></element-citation></ref><ref id="B200-ijms-24-10537"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asadi Karam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S.</given-names></name></person-group><article-title>Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Mol. Immunol.</source><year>2019</year><volume>108</volume><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2019.02.007</pub-id><pub-id pub-id-type="pmid">30784763</pub-id></element-citation></ref><ref id="B201-ijms-24-10537"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savar</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Jahanian-Najafabadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shokrgozar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S.</given-names></name></person-group><article-title>In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative <italic toggle="yes">Escherichia coli</italic> fused to FimH from uropathogenic <italic toggle="yes">Escherichia coli</italic> as a vaccine candidate against urinary tract infections</article-title><source>J. Biotechnol.</source><year>2014</year><volume>175</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2014.01.037</pub-id><pub-id pub-id-type="pmid">24530504</pub-id></element-citation></ref><ref id="B202-ijms-24-10537"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asadi Karam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S.</given-names></name></person-group><article-title>Use of flagellin and cholera toxin as adjuvants in intranasal vaccination of mice to enhance protective immune responses against uropathogenic <italic toggle="yes">Escherichia coli</italic> antigens</article-title><source>Biologicals</source><year>2016</year><volume>44</volume><fpage>378</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2016.06.006</pub-id><pub-id pub-id-type="pmid">27461240</pub-id></element-citation></ref><ref id="B203-ijms-24-10537"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asadi Karam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S.</given-names></name></person-group><article-title>Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic <italic toggle="yes">Escherichia coli</italic> isolates as a vaccine target against urinary tract infection</article-title><source>Microb. Pathog.</source><year>2017</year><volume>110</volume><fpage>477</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2017.07.037</pub-id><pub-id pub-id-type="pmid">28754265</pub-id></element-citation></ref><ref id="B204-ijms-24-10537"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brumbaugh</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection</article-title><source>Infect. Immun.</source><year>2013</year><volume>81</volume><fpage>3309</fpage><lpage>3316</lpage><pub-id pub-id-type="doi">10.1128/IAI.00470-13</pub-id><pub-id pub-id-type="pmid">23798537</pub-id><pub-id pub-id-type="pmcid">PMC3754202</pub-id></element-citation></ref><ref id="B205-ijms-24-10537"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huttner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hatz</surname><given-names>C.</given-names></name><name name-style="western"><surname>van den Dobbelsteen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Abbanat</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hornacek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fr&#246;lich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dreyer</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fae</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic <italic toggle="yes">Escherichia coli</italic> in women with a history of recurrent urinary tract infection: A randomised, single-blind, placebo-controlled phase 1b trial</article-title><source>Lancet Infect. Dis.</source><year>2017</year><volume>17</volume><fpage>528</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30108-1</pub-id><pub-id pub-id-type="pmid">28238601</pub-id></element-citation></ref><ref id="B206-ijms-24-10537"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langermann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palaszynski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barnhart</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auguste</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Burlein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barren</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>Prevention of mucosal <italic toggle="yes">Escherichia coli</italic> infection by FimH-adhesin-based systemic vaccination</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>607</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1126/science.276.5312.607</pub-id><pub-id pub-id-type="pmid">9110982</pub-id></element-citation></ref><ref id="B207-ijms-24-10537"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poggio</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>La Torre</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Scodeller</surname><given-names>E.A.</given-names></name></person-group><article-title>Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic <italic toggle="yes">Escherichia coli</italic> challenge</article-title><source>Can. J. Microbiol.</source><year>2006</year><volume>52</volume><fpage>1093</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1139/w06-065</pub-id><pub-id pub-id-type="pmid">17215901</pub-id></element-citation></ref><ref id="B208-ijms-24-10537"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Oloomi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S.</given-names></name></person-group><article-title>Assessment of immune responses of the flagellin (FliC) fused to FimH adhesin of Uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Mol. Immunol.</source><year>2013</year><volume>54</volume><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2012.11.002</pub-id><pub-id pub-id-type="pmid">23220068</pub-id></element-citation></ref><ref id="B209-ijms-24-10537"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagherpour</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fooladi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Mehrabadi</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Nourani</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Einollahi</surname><given-names>B.</given-names></name></person-group><article-title>Evaluation of mammalian codon usage of fimH in DNA vaccine design</article-title><source>Acta Microbiol. Immunol. Hung.</source><year>2011</year><volume>58</volume><fpage>259</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1556/amicr.58.2011.4.2</pub-id><pub-id pub-id-type="pmid">22207284</pub-id></element-citation></ref><ref id="B210-ijms-24-10537"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferraro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Hutnick</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Lucke</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name></person-group><article-title>Clinical applications of DNA vaccines: Current progress</article-title><source>Clin. Infect. Dis.</source><year>2011</year><volume>53</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1093/cid/cir334</pub-id><pub-id pub-id-type="pmid">21765081</pub-id><pub-id pub-id-type="pmcid">PMC3202319</pub-id></element-citation></ref><ref id="B211-ijms-24-10537"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imani Fooladi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bagherpour</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khoramabadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fallah Mehrabadi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halabian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Izadi Mobarakeh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Einollahi</surname><given-names>B.</given-names></name></person-group><article-title>Cellular immunity survey against urinary tract infection using pVAX/fimH cassette with mammalian and wild type codon usage as a DNA vaccine</article-title><source>Clin. Exp. Vaccine Res.</source><year>2014</year><volume>3</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.7774/cevr.2014.3.2.185</pub-id><pub-id pub-id-type="pmid">25003092</pub-id><pub-id pub-id-type="pmcid">PMC4083071</pub-id></element-citation></ref><ref id="B212-ijms-24-10537"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kaack</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Baskin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hunstad</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>S.J.</given-names></name></person-group><article-title>Antibody responses and protection from pyelonephritis following vaccination with purified <italic toggle="yes">Escherichia coli</italic> PapDG protein</article-title><source>J. Urol.</source><year>2004</year><volume>171</volume><fpage>1682</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000116123.05160.43</pub-id><pub-id pub-id-type="pmid">15017266</pub-id><pub-id pub-id-type="pmcid">PMC2838480</pub-id></element-citation></ref><ref id="B213-ijms-24-10537"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mike</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Sumner</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Siderophore vaccine conjugates protect against uropathogenic <italic toggle="yes">Escherichia coli</italic> urinary tract infection</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>13468</fpage><lpage>13473</lpage><pub-id pub-id-type="doi">10.1073/pnas.1606324113</pub-id><pub-id pub-id-type="pmid">27821778</pub-id><pub-id pub-id-type="pmcid">PMC5127358</pub-id></element-citation></ref><ref id="B214-ijms-24-10537"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wieser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Romann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Magistro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>N&#246;renberg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>S.</given-names></name></person-group><article-title>A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic <italic toggle="yes">Escherichia coli</italic> in mice</article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>3432</fpage><lpage>3442</lpage><pub-id pub-id-type="doi">10.1128/IAI.00174-10</pub-id><pub-id pub-id-type="pmid">20498257</pub-id><pub-id pub-id-type="pmcid">PMC2916271</pub-id></element-citation></ref><ref id="B215-ijms-24-10537"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wieser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Magistro</surname><given-names>G.</given-names></name><name name-style="western"><surname>N&#246;renberg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>S.</given-names></name></person-group><article-title>First multi-epitope subunit vaccine against extraintestinal pathogenic <italic toggle="yes">Escherichia coli</italic> delivered by a bacterial type-3 secretion system (T3SS)</article-title><source>Int. J. Med. Microbiol.</source><year>2012</year><volume>302</volume><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2011.09.012</pub-id><pub-id pub-id-type="pmid">22000741</pub-id></element-citation></ref><ref id="B216-ijms-24-10537"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alteri</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Sivick</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>H.L.</given-names></name></person-group><article-title>Mucosal immunization with iron receptor antigens protects against urinary tract infection</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000586</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000586</pub-id><pub-id pub-id-type="pmid">19806177</pub-id><pub-id pub-id-type="pmcid">PMC2736566</pub-id></element-citation></ref><ref id="B217-ijms-24-10537"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>S.T.</given-names></name></person-group><article-title>Who will develop new antibacterial agents?</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2014</year><volume>369</volume><fpage>20130430</fpage><pub-id pub-id-type="doi">10.1098/rstb.2013.0430</pub-id><pub-id pub-id-type="pmid">24821916</pub-id><pub-id pub-id-type="pmcid">PMC4024223</pub-id></element-citation></ref><ref id="B218-ijms-24-10537"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marouf</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Mbarga</surname><given-names>J.A.M.</given-names></name><name name-style="western"><surname>Ermolaev</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Podoprigora</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Smirnova</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Yashina</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Zhigunova</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Martynenkova</surname><given-names>A.V.</given-names></name></person-group><article-title>Antibacterial Activity of Medicinal Plants against Uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Pharm. Bioallied. Sci.</source><year>2022</year><volume>14</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.4103/jpbs.jpbs_124_21</pub-id><pub-id pub-id-type="pmid">35784103</pub-id><pub-id pub-id-type="pmcid">PMC9245916</pub-id></element-citation></ref><ref id="B219-ijms-24-10537"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaheen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Akram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jabeen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ali Shah</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Munir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Daniyal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tahir</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Ghauri</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Therapeutic potential of medicinal plants for the management of urinary tract infection: A systematic review</article-title><source>Clin. Exp. Pharmacol. Physiol.</source><year>2019</year><volume>46</volume><fpage>613</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1111/1440-1681.13092</pub-id><pub-id pub-id-type="pmid">30932202</pub-id></element-citation></ref><ref id="B220-ijms-24-10537"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#193;lvarez-Mart&#237;nez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Barraj&#243;n-Catal&#225;n</surname><given-names>E.</given-names></name><name name-style="western"><surname>Encinar</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-D&#237;az</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Micol</surname><given-names>V.</given-names></name></person-group><article-title>Antimicrobial Capacity of Plant Polyphenols against Gram-positive Bacteria: A Comprehensive Review</article-title><source>Curr. Med. Chem.</source><year>2020</year><volume>27</volume><fpage>2576</fpage><lpage>2606</lpage><pub-id pub-id-type="doi">10.2174/0929867325666181008115650</pub-id><pub-id pub-id-type="pmid">30295182</pub-id></element-citation></ref><ref id="B221-ijms-24-10537"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#193;lvarez-Mart&#237;nez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Borr&#225;s-Rocher</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barraj&#243;n-Catal&#225;n</surname><given-names>E.</given-names></name><name name-style="western"><surname>Micol</surname><given-names>V.</given-names></name></person-group><article-title>The antimicrobial capacity of Cistus salviifolius and Punica granatum plant extracts against clinical pathogens is related to their polyphenolic composition</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>588</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-80003-y</pub-id><pub-id pub-id-type="pmid">33436818</pub-id><pub-id pub-id-type="pmcid">PMC7803989</pub-id></element-citation></ref><ref id="B222-ijms-24-10537"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upadhyay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Upadhyaya</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kollanoor-Johny</surname><given-names>A.</given-names></name><name name-style="western"><surname>Venkitanarayanan</surname><given-names>K.</given-names></name></person-group><article-title>Combating pathogenic microorganisms using plant-derived antimicrobials: A minireview of the mechanistic basis</article-title><source>Biomed. Res. Int.</source><year>2014</year><volume>2014</volume><fpage>761741</fpage><pub-id pub-id-type="doi">10.1155/2014/761741</pub-id><pub-id pub-id-type="pmid">25298964</pub-id><pub-id pub-id-type="pmcid">PMC4178913</pub-id></element-citation></ref><ref id="B223-ijms-24-10537"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khameneh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Iranshahy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soheili</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fazly Bazzaz</surname><given-names>B.S.</given-names></name></person-group><article-title>Review on plant antimicrobials: A mechanistic viewpoint</article-title><source>Antimicrob. Resist. Infect. Control.</source><year>2019</year><volume>8</volume><fpage>118</fpage><pub-id pub-id-type="doi">10.1186/s13756-019-0559-6</pub-id><pub-id pub-id-type="pmid">31346459</pub-id><pub-id pub-id-type="pmcid">PMC6636059</pub-id></element-citation></ref><ref id="B224-ijms-24-10537"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deipenbrock</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hensel</surname><given-names>A.</given-names></name></person-group><article-title>Polymethoxylated flavones from Orthosiphon stamineus leaves as antiadhesive compounds against uropathogenic <italic toggle="yes">E. coli</italic></article-title><source>Fitoterapia</source><year>2019</year><volume>139</volume><fpage>104387</fpage><pub-id pub-id-type="doi">10.1016/j.fitote.2019.104387</pub-id><pub-id pub-id-type="pmid">31678632</pub-id></element-citation></ref><ref id="B225-ijms-24-10537"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarshar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sendker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Goycoolea</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Asadi Karam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dobrindt</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hensel</surname><given-names>A.</given-names></name></person-group><article-title>Antiadhesive hydroalcoholic extract from Apium graveolens fruits prevents bladder and kidney infection against uropathogenic <italic toggle="yes">E. coli</italic></article-title><source>Fitoterapia</source><year>2018</year><volume>127</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2018.02.029</pub-id><pub-id pub-id-type="pmid">29496563</pub-id></element-citation></ref><ref id="B226-ijms-24-10537"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scharf</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sendker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dobrindt</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hensel</surname><given-names>A.</given-names></name></person-group><article-title>Influence of Cranberry Extract on Tamm-Horsfall Protein in Human Urine and its Antiadhesive Activity Against Uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Planta Med.</source><year>2019</year><volume>85</volume><fpage>126</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1055/a-0755-7801</pub-id><pub-id pub-id-type="pmid">30312973</pub-id></element-citation></ref><ref id="B227-ijms-24-10537"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutters</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Mampel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kropidlowski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Biehler</surname><given-names>K.</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>F.</given-names></name><name name-style="western"><surname>B&#259;lu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Malek</surname><given-names>V.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>U.</given-names></name></person-group><article-title>Treating urinary tract infections due to MDR <italic toggle="yes">E. coli</italic> with Isothiocyanates&#8212;A phytotherapeutic alternative to antibiotics?</article-title><source>Fitoterapia</source><year>2018</year><volume>129</volume><fpage>237</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2018.07.012</pub-id><pub-id pub-id-type="pmid">30031115</pub-id></element-citation></ref><ref id="B228-ijms-24-10537"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabadash</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shulyak</surname><given-names>A.</given-names></name></person-group><article-title>Canephron<sup>&#174;</sup> N in the treatment of recurrent cystitis in women of child-bearing Age: A randomised controlled study</article-title><source>Clin. Phyt.</source><year>2017</year><volume>3</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s40816-017-0046-7</pub-id></element-citation></ref><ref id="B229-ijms-24-10537"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacheva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>B.</given-names></name><name name-style="western"><surname>Staneva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marhova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kostadinova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Todorova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stoitsova</surname><given-names>S.</given-names></name></person-group><article-title>Effects of Extracts from Medicinal Plants on Biofilm Formation by <italic toggle="yes">Escherichia coli</italic> Urinary Tract Isolates</article-title><source>Biotechnol. Biotechnol. Equip.</source><year>2011</year><volume>25</volume><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.5504/BBEQ.2011.0111</pub-id></element-citation></ref><ref id="B230-ijms-24-10537"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#381;itek</surname><given-names>T.</given-names></name><name name-style="western"><surname>Postru&#382;nik</surname><given-names>V.</given-names></name><name name-style="western"><surname>Knez</surname><given-names>&#381;.</given-names></name><name name-style="western"><surname>Golle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dari&#353;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Knez Marevci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arnica Montana</surname><given-names>L.</given-names></name></person-group><article-title>Supercritical Extraction Optimization for Antibiotic and Anticancer Activity</article-title><source>Front. Bioeng. Biotechnol.</source><year>2022</year><volume>10</volume><fpage>897185</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2022.897185</pub-id><pub-id pub-id-type="pmid">35620474</pub-id><pub-id pub-id-type="pmcid">PMC9127360</pub-id></element-citation></ref><ref id="B231-ijms-24-10537"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hidalgo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tufenkji</surname><given-names>N.</given-names></name></person-group><article-title>Inhibition of <italic toggle="yes">Escherichia coli</italic> CFT073 fliC expression and motility by cranberry materials</article-title><source>Appl. Environ. Microbiol.</source><year>2011</year><volume>77</volume><fpage>6852</fpage><lpage>6857</lpage><pub-id pub-id-type="doi">10.1128/AEM.05561-11</pub-id><pub-id pub-id-type="pmid">21821749</pub-id><pub-id pub-id-type="pmcid">PMC3187111</pub-id></element-citation></ref><ref id="B232-ijms-24-10537"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranfaing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunyach-Remy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lavigne</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Sotto</surname><given-names>A.</given-names></name></person-group><article-title>Propolis potentiates the effect of cranberry (<italic toggle="yes">Vaccinium macrocarpon</italic>) in reducing the motility and the biofilm formation of uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0202609</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0202609</pub-id><pub-id pub-id-type="pmid">30138443</pub-id><pub-id pub-id-type="pmcid">PMC6107218</pub-id></element-citation></ref><ref id="B233-ijms-24-10537"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Horowitz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coppenhagen-Glazer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pizov</surname><given-names>G.</given-names></name><name name-style="western"><surname>Elia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gofrit</surname><given-names>O.N.</given-names></name><name name-style="western"><surname>Ginsburg</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pode</surname><given-names>D.</given-names></name></person-group><article-title>Intravesical administration of green tea extract attenuates the inflammatory response of bacterial cystitis&#8211;a rat model</article-title><source>BJU Int.</source><year>2014</year><volume>114</volume><fpage>601</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1111/bju.12544</pub-id><pub-id pub-id-type="pmid">24712880</pub-id></element-citation></ref><ref id="B234-ijms-24-10537"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>C.Z.</given-names></name></person-group><article-title>Anti-inflammatory effects of <italic toggle="yes">Abelmoschus manihot</italic> (L.) Medik. on LPS-induced cystitis in mice: Potential candidate for cystitis treatment based on classic use</article-title><source>Chin. J. Nat. Med.</source><year>2022</year><volume>20</volume><fpage>321</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/S1875-5364(22)60140-7</pub-id><pub-id pub-id-type="pmid">35551768</pub-id></element-citation></ref><ref id="B235-ijms-24-10537"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rafsanjany</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lechtenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petereit</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hensel</surname><given-names>A.</given-names></name></person-group><article-title>Antiadhesion as a functional concept for protection against uropathogenic <italic toggle="yes">Escherichia coli</italic>: In vitro studies with traditionally used plants with antiadhesive activity against uropathognic <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Ethnopharmacol.</source><year>2013</year><volume>145</volume><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2012.11.035</pub-id><pub-id pub-id-type="pmid">23211661</pub-id></element-citation></ref><ref id="B236-ijms-24-10537"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bortolami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Matteo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rocco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Feroci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petrucci</surname><given-names>R.</given-names></name></person-group><article-title>Metabolic Profile of <italic toggle="yes">Agropyron repens</italic> (L.) P. Beauv. Rhizome Herbal Tea by HPLC-PDA-ESI-MS/MS Analysis</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>4962</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27154962</pub-id><pub-id pub-id-type="pmid">35956912</pub-id><pub-id pub-id-type="pmcid">PMC9370816</pub-id></element-citation></ref><ref id="B237-ijms-24-10537"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noundou</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>van Vuuren</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Ndinteh</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>D.K.</given-names></name></person-group><article-title>Antibacterial effects of Alchornea cordifolia (Schumach. and Thonn.) M&#252;ll. Arg extracts and compounds on gastrointestinal, skin, respiratory and urinary tract pathogens</article-title><source>J. Ethnopharmacol.</source><year>2016</year><volume>179</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2015.12.043</pub-id><pub-id pub-id-type="pmid">26724423</pub-id></element-citation></ref><ref id="B238-ijms-24-10537"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.Y.</given-names></name></person-group><article-title>Andrographolide acts as an anti-inflammatory agent in LPS-stimulated RAW264.7 macrophages by inhibiting STAT3-mediated suppression of the NF-&#954;B pathway</article-title><source>J. Ethnopharmacol.</source><year>2011</year><volume>135</volume><fpage>678</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.03.068</pub-id><pub-id pub-id-type="pmid">21497192</pub-id></element-citation></ref><ref id="B239-ijms-24-10537"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Arriba</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Naser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nolte</surname><given-names>K.U.</given-names></name></person-group><article-title>Risk assessment of free hydroquinone derived from Arctostaphylos Uva-ursi folium herbal preparations</article-title><source>Int. J. Toxicol.</source><year>2013</year><volume>32</volume><fpage>442</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1177/1091581813507721</pub-id><pub-id pub-id-type="pmid">24296864</pub-id></element-citation></ref><ref id="B240-ijms-24-10537"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietz</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Hajirahimkhan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dunlap</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>J.L.</given-names></name></person-group><article-title>Botanicals and Their Bioactive Phytochemicals for Women&#8217;s Health</article-title><source>Pharmacol. Rev.</source><year>2016</year><volume>68</volume><fpage>1026</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1124/pr.115.010843</pub-id><pub-id pub-id-type="pmid">27677719</pub-id><pub-id pub-id-type="pmcid">PMC5050441</pub-id></element-citation></ref><ref id="B241-ijms-24-10537"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatadri</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arunagirinathan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rameshkumar</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dhanasezhian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agastian</surname><given-names>P.</given-names></name></person-group><article-title>In vitro Antibacterial Activity of Aqueous and Ethanol Extracts of <sup>Aristolochia indica</sup> and <italic toggle="yes">Toddalia asiatica</italic> Against Multidrug-Resistant Bacteria</article-title><source>Indian J. Pharm. Sci.</source><year>2015</year><volume>77</volume><fpage>788</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">26997710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0250-474X.174991</pub-id><pub-id pub-id-type="pmcid">PMC4778242</pub-id></element-citation></ref><ref id="B242-ijms-24-10537"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Kite</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Ingrouille</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Simmonds</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Heinrich</surname><given-names>M.</given-names></name></person-group><article-title>Is aristolochic acid nephropathy a widespread problem in developing countries? A case study of <italic toggle="yes">Aristolochia indica</italic> L. in Bangladesh using an ethnobotanical-phytochemical approach</article-title><source>J. Ethnopharmacol.</source><year>2013</year><volume>149</volume><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2013.06.028</pub-id><pub-id pub-id-type="pmid">23806867</pub-id></element-citation></ref><ref id="B243-ijms-24-10537"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albrecht</surname><given-names>U.</given-names></name><name name-style="western"><surname>Goos</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>B.</given-names></name></person-group><article-title>A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing <italic toggle="yes">Tropaeoli majoris herba</italic> (Nasturtium) and <italic toggle="yes">Armoraciae rusticanae radix</italic> (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections</article-title><source>Curr. Med. Res. Opin.</source><year>2007</year><volume>23</volume><fpage>2415</fpage><lpage>2422</lpage><pub-id pub-id-type="pmid">17723159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1185/030079907X233089</pub-id></element-citation></ref><ref id="B244-ijms-24-10537"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conrad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Biehler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nobis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Engels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Biehler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>U.</given-names></name></person-group><article-title>Broad spectrum antibacterial activity of a mixture of isothiocyanates from nasturtium (<italic toggle="yes">Tropaeoli majoris herba</italic>) and horseradish (<italic toggle="yes">Armoraciae rusticanae radix</italic>)</article-title><source>Drug. Res.</source><year>2013</year><volume>63</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1331754</pub-id><pub-id pub-id-type="pmid">23447075</pub-id></element-citation></ref><ref id="B245-ijms-24-10537"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajkumar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Devi</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Beenish</surname><given-names>T.K.</given-names></name></person-group><article-title>Detection of Antibacterial Compound of <italic toggle="yes">Avicennia marina</italic> Against Pathogens Isolated from Urinary Tract Infected Patients</article-title><source>Asian J. Chem.</source><year>2014</year><volume>26</volume><fpage>458</fpage><lpage>460</lpage></element-citation></ref><ref id="B246-ijms-24-10537"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wojnicz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kucharska</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Sok&#243;&#322;-&#321;&#281;towska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kicia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tichaczek-Goska</surname><given-names>D.</given-names></name></person-group><article-title>Medicinal plants extracts affect virulence factors expression and biofilm formation by the uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Urol. Res.</source><year>2012</year><volume>40</volume><fpage>683</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1007/s00240-012-0499-6</pub-id><pub-id pub-id-type="pmid">22915095</pub-id><pub-id pub-id-type="pmcid">PMC3495101</pub-id></element-citation></ref><ref id="B247-ijms-24-10537"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Swain</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chand</surname><given-names>P.K.</given-names></name></person-group><article-title>Agrobacterium rhizogenes-mediated transformation of a multi-medicinal herb, <italic toggle="yes">Boerhaavia diffusa</italic> L.: Optimization of the process and anti-microbial activity against bacterial pathogens causing urinary tract infections</article-title><source>Front. Life Sci.</source><year>2013</year><volume>7</volume><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1080/21553769.2013.879266</pub-id></element-citation></ref><ref id="B248-ijms-24-10537"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreres</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Justin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valent&#227;o</surname><given-names>P.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Llorach</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seabra</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Leit&#227;o</surname><given-names>A.</given-names></name></person-group><article-title>Characterisation of the phenolic profile of <italic toggle="yes">Boerhaavia diffusa</italic> L. by HPLC-PAD-MS/MS as a tool for quality control</article-title><source>Phytochem. Anal.</source><year>2005</year><volume>16</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1002/pca.869</pub-id><pub-id pub-id-type="pmid">16315490</pub-id></element-citation></ref><ref id="B249-ijms-24-10537"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adetutu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>O.</given-names></name></person-group><article-title>Ethnopharmacological survey and in vitro evaluation of wound-healing plants used in South-western Nigeria</article-title><source>J. Ethnopharmacol.</source><year>2011</year><volume>137</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.03.073</pub-id><pub-id pub-id-type="pmid">21501678</pub-id></element-citation></ref><ref id="B250-ijms-24-10537"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeboah</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Owusu</surname><given-names>F.W.A.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kyene</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Kumadoh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ayertey</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mintah</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Atta-Adjei Junior</surname><given-names>P.</given-names></name><name name-style="western"><surname>Appiah</surname><given-names>A.A.</given-names></name></person-group><article-title><italic toggle="yes">Bridelia ferruginea</italic> Benth.; An ethnomedicinal, phytochemical, pharmacological and toxicological review</article-title><source>Heliyon</source><year>2022</year><volume>8</volume><fpage>e10366</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e10366</pub-id><pub-id pub-id-type="pmid">36082325</pub-id><pub-id pub-id-type="pmcid">PMC9445295</pub-id></element-citation></ref><ref id="B251-ijms-24-10537"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vu&#269;i&#263;</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Petkovi&#263;</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Rodi&#263;-Grabovac</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Stefanovi&#263;</surname><given-names>O.D.</given-names></name><name name-style="western"><surname>Vasi&#263;</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Comi&#263;</surname><given-names>L.R.</given-names></name></person-group><article-title>In vitro activity of heather [<italic toggle="yes">Calluna vulgaris</italic> (L.) Hull] extracts on selected urinary tract pathogens</article-title><source>Bosn. J. Basic Med. Sci.</source><year>2014</year><volume>14</volume><fpage>234</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.17305/bjbms.2014.4.40</pub-id><pub-id pub-id-type="pmid">25428676</pub-id><pub-id pub-id-type="pmcid">PMC4333975</pub-id></element-citation></ref><ref id="B252-ijms-24-10537"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vollmerhausen</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Dzung</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Brauner</surname><given-names>A.</given-names></name></person-group><article-title>Decoctions from <italic toggle="yes">Citrus reticulata</italic> Blanco seeds protect the uroepithelium against <italic toggle="yes">Escherichia coli</italic> invasion</article-title><source>J. Ethnopharmacol.</source><year>2013</year><volume>150</volume><fpage>770</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2013.09.050</pub-id><pub-id pub-id-type="pmid">24120518</pub-id></element-citation></ref><ref id="B253-ijms-24-10537"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.H.</given-names></name></person-group><article-title>Discrimination of <italic toggle="yes">Citrus reticulata</italic> Blanco and <italic toggle="yes">Citrus reticulata</italic> &#8216;Chachi&#8217; by gas chromatograph-mass spectrometry based metabolomics approach</article-title><source>Food Chem.</source><year>2016</year><volume>212</volume><fpage>123</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2016.05.141</pub-id><pub-id pub-id-type="pmid">27374515</pub-id></element-citation></ref><ref id="B254-ijms-24-10537"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uliana</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.G.D.</given-names></name><name name-style="western"><surname>Fronza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>R.</given-names></name></person-group><article-title>In vitro Antioxidant and Antimicrobial Activities of <italic toggle="yes">Costus spicatus</italic> Swartz used in Folk Medicine for Urinary Tract Infection in Brazil</article-title><source>Latin. Am. J. Pharm.</source><year>2015</year><volume>34</volume><fpage>766</fpage><lpage>772</lpage></element-citation></ref><ref id="B255-ijms-24-10537"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>C.P.</given-names></name></person-group><article-title>Antibacterial activity of medicinal plant <italic toggle="yes">Crateava nurvala</italic> (bark) against bacterial strains causing urinary tract infection</article-title><source>Asian J. Chem.</source><year>2001</year><volume>13</volume><fpage>1181</fpage><lpage>1186</lpage></element-citation></ref><ref id="B256-ijms-24-10537"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shashidhara</surname><given-names>S.C.</given-names></name></person-group><article-title>Aswathanarayana, Phytochemical and ethno-pharmacological profile of <italic toggle="yes">Crataeva nurvala</italic> Buch-Hum (Varuna): A review</article-title><source>Asian Pac. J. Trop. Biomed.</source><year>2012</year><volume>2</volume><fpage>S1162</fpage><lpage>S1168</lpage><pub-id pub-id-type="doi">10.1016/S2221-1691(12)60379-7</pub-id></element-citation></ref><ref id="B257-ijms-24-10537"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Packiavathy</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Priya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pandian</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ravi</surname><given-names>A.V.</given-names></name></person-group><article-title>Inhibition of biofilm development of uropathogens by curcumin&#8212;An anti-quorum sensing agent from <italic toggle="yes">Curcuma longa</italic></article-title><source>Food Chem.</source><year>2014</year><volume>148</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2012.08.002</pub-id><pub-id pub-id-type="pmid">24262582</pub-id></element-citation></ref><ref id="B258-ijms-24-10537"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Sumita</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Furlan</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Jorge</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>M.</given-names></name></person-group><article-title>Antibacterial activity of essential oils on microorganisms isolated from urinary tract infection</article-title><source>Rev. Saude Publica</source><year>2004</year><volume>38</volume><fpage>326</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1590/S0034-89102004000200025</pub-id><pub-id pub-id-type="pmid">15122392</pub-id></element-citation></ref><ref id="B259-ijms-24-10537"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramteke</surname><given-names>P.</given-names></name></person-group><article-title><italic toggle="yes">Cyperus rotundus</italic>: A potential novel source of therapeutic compound against urinary tract pathogens</article-title><source>J. Herb. Med.</source><year>2014</year><volume>4</volume><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.hermed.2014.01.003</pub-id></element-citation></ref><ref id="B260-ijms-24-10537"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Dendrobium officinale</italic> polysaccharides attenuate uropathogenic <italic toggle="yes">Escherichia coli</italic> (UPEC)-induced pyroptosis in macrophage cells</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>151</volume><fpage>113098</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113098</pub-id><pub-id pub-id-type="pmid">35594714</pub-id></element-citation></ref><ref id="B261-ijms-24-10537"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#252;thje</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lokman</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Sandstr&#246;m</surname><given-names>C.</given-names></name><name name-style="western"><surname>&#214;stenson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brauner</surname><given-names>A.</given-names></name></person-group><article-title><italic toggle="yes">Gynostemma pentaphyllum</italic> exhibits anti-inflammatory properties and modulates antimicrobial peptide expression in the urinary bladder</article-title><source>J. Funct. Food.</source><year>2015</year><volume>17</volume><fpage>283</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.jff.2015.03.028</pub-id></element-citation></ref><ref id="B262-ijms-24-10537"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fazliana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>L&#252;thje</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sekikubo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wan Nazaimoon</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Brauner</surname><given-names>A.</given-names></name></person-group><article-title><italic toggle="yes">Labisia pumila</italic> var. alata reduces bacterial load by inducing uroepithelial cell apoptosis</article-title><source>J. Ethnopharmacol.</source><year>2011</year><volume>136</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.04.018</pub-id><pub-id pub-id-type="pmid">21524700</pub-id></element-citation></ref><ref id="B263-ijms-24-10537"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#252;thje</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dzung</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Brauner</surname><given-names>A.</given-names></name></person-group><article-title><italic toggle="yes">Lactuca indica</italic> extract interferes with uroepithelial infection by <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Ethnopharmacol.</source><year>2011</year><volume>135</volume><fpage>672</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.03.069</pub-id><pub-id pub-id-type="pmid">21497191</pub-id></element-citation></ref><ref id="B264-ijms-24-10537"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.R.</given-names></name></person-group><article-title>Terpene and phenolic constituents of <italic toggle="yes">Lactuca indica</italic> L.</article-title><source>Arch. Pharm. Res.</source><year>2008</year><volume>31</volume><fpage>983</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1007/s12272-001-1256-8</pub-id><pub-id pub-id-type="pmid">18787785</pub-id></element-citation></ref><ref id="B265-ijms-24-10537"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashraf</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>A.</given-names></name></person-group><article-title><italic toggle="yes">Orthosiphon stamineus</italic> Benth. is an Outstanding Food Medicine: Review of Phytochemical and Pharmacological Activities</article-title><source>J. Pharm. Bioallied. Sci.</source><year>2018</year><volume>10</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.4103/JPBS.JPBS_253_17</pub-id><pub-id pub-id-type="pmid">30237681</pub-id><pub-id pub-id-type="pmcid">PMC6142889</pub-id></element-citation></ref><ref id="B266-ijms-24-10537"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmahmood</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ameh</surname><given-names>J.M.</given-names></name></person-group><article-title>In vitro antibacterial activity of <italic toggle="yes">Parkia biglobosa</italic> (Jacq.) root bark extract against some microorganisms associated with urinary tract infections</article-title><source>Afr. J. Biotechnol.</source><year>2007</year><volume>6</volume><fpage>1272</fpage><lpage>1275</lpage></element-citation></ref><ref id="B267-ijms-24-10537"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamfu</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Roland</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mfifen</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kucukaydin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gaye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Botezatu</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Duru</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Dinica</surname><given-names>R.M.</given-names></name></person-group><article-title>Phenolic composition, antioxidant and enzyme inhibitory activities of <italic toggle="yes">Parkia biglobosa</italic> (Jacq.) Benth., <italic toggle="yes">Tithonia diversifolia</italic> (Hemsl) A. Gray, and <italic toggle="yes">Crossopteryx febrifuga</italic> (Afzel.) Benth</article-title><source>Arab. J. Chem.</source><year>2022</year><volume>15</volume><fpage>103675</fpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2021.103675</pub-id></element-citation></ref><ref id="B268-ijms-24-10537"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeidi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amini Boroujeni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hassanshahian</surname><given-names>M.</given-names></name></person-group><article-title>Antibacterial Activity of Some Plant Extracts Against Extended- Spectrum Beta-Lactamase Producing <italic toggle="yes">Escherichia coli</italic> Isolates</article-title><source>Jundishapur. J. Microbiol.</source><year>2015</year><volume>8</volume><fpage>e15434</fpage><pub-id pub-id-type="doi">10.5812/jjm.15434</pub-id><pub-id pub-id-type="pmid">25793093</pub-id><pub-id pub-id-type="pmcid">PMC4353063</pub-id></element-citation></ref><ref id="B269-ijms-24-10537"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mina</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Farzaei</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Gholamreza</surname><given-names>A.</given-names></name></person-group><article-title>Medicinal properties of <italic toggle="yes">Peganum harmala</italic> L. in traditional Iranian medicine and modern phytotherapy: A review</article-title><source>J. Tradit. Chin. Med.</source><year>2015</year><volume>35</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">25842736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0254-6272(15)30016-9</pub-id></element-citation></ref><ref id="B270-ijms-24-10537"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fri&#353;&#269;i&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jerkovi&#263;</surname><given-names>I.</given-names></name><name name-style="western"><surname>Marijanovi&#263;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dragovi&#263;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hazler&#8197;Pilepi&#263;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Male&#353;</surname><given-names>&#381;.</given-names></name></person-group><article-title>Essential Oil Composition of Different Plant Parts from Croatian <italic toggle="yes">Petasites albus</italic> (L.) Gaertn. and <italic toggle="yes">Petasites hybridus</italic> (L.) G.Gaertn., B.Mey. &amp; Scherb. (<italic toggle="yes">Asteraceae</italic>)</article-title><source>Chem. Biodivers</source><year>2019</year><volume>16</volume><fpage>e1800531</fpage><pub-id pub-id-type="pmid">30600899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbdv.201800531</pub-id></element-citation></ref><ref id="B271-ijms-24-10537"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrolini</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>Lucarini</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>C.H.</given-names></name></person-group><article-title>Evaluation of the antibacterial potential of <italic toggle="yes">Petroselinum crispum</italic> and <italic toggle="yes">Rosmarinus officinalis</italic> against bacteria that cause urinary tract infections</article-title><source>Braz. J. Microbiol.</source><year>2013</year><volume>44</volume><fpage>829</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1590/S1517-83822013005000061</pub-id><pub-id pub-id-type="pmid">24516424</pub-id><pub-id pub-id-type="pmcid">PMC3910196</pub-id></element-citation></ref><ref id="B272-ijms-24-10537"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tintino</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guedes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Pess&#244;a</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>C.A.</given-names></name></person-group><article-title>Modulatory antimicrobial activity of <italic toggle="yes">piper arboreum</italic> extracts</article-title><source>Acta Bot. Croat.</source><year>2014</year><volume>73</volume><fpage>281</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.2478/botcro-2013-0026</pub-id></element-citation></ref><ref id="B273-ijms-24-10537"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva</surname><given-names>A.C.A.</given-names></name><name name-style="western"><surname>Matias</surname><given-names>E.F.F.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>A.C.J.</given-names></name><name name-style="western"><surname>de Freitas</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Campina</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>M.D.S.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Maia</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Gas chromatography coupled to mass spectrometry (GC-MS) characterization and evaluation of antibacterial bioactivities of the essential oils from <italic toggle="yes">Piper arboreum</italic> Aubl., <italic toggle="yes">Piper aduncum</italic> L. e <italic toggle="yes">Piper gaudichaudianum</italic> Kunth</article-title><source>Z. Naturforsch. C J. Biosci.</source><year>2021</year><volume>76</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1515/znc-2020-0045</pub-id><pub-id pub-id-type="pmid">32673283</pub-id></element-citation></ref><ref id="B274-ijms-24-10537"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Antibacterial and anti-inflammatory effects of extracts and fractions from <italic toggle="yes">Polygonum capitatum</italic></article-title><source>J. Ethnopharmacol.</source><year>2011</year><volume>134</volume><fpage>1006</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.01.050</pub-id><pub-id pub-id-type="pmid">21296143</pub-id></element-citation></ref><ref id="B275-ijms-24-10537"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seifi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abbasalizadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohammad-Alizadeh-Charandabi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khodaie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mirghafourvand</surname><given-names>M.</given-names></name></person-group><article-title>The effect of Rosa (L. <italic toggle="yes">Rosa canina</italic>) on the incidence of urinary tract infection in the puerperium: A randomized placebo-controlled trial</article-title><source>Phytother. Res.</source><year>2018</year><volume>32</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1002/ptr.5950</pub-id><pub-id pub-id-type="pmid">29024081</pub-id></element-citation></ref><ref id="B276-ijms-24-10537"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name></person-group><article-title>The pharmacological activities of Compound <italic toggle="yes">Salvia Plebeia</italic> Granules on treating urinary tract infection</article-title><source>J. Ethnopharmacol.</source><year>2010</year><volume>129</volume><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.02.029</pub-id><pub-id pub-id-type="pmid">20211234</pub-id></element-citation></ref><ref id="B277-ijms-24-10537"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>F.-J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.-Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.-Z.</given-names></name></person-group><article-title><italic toggle="yes">Salvia plebeia</italic> R. Br.: An overview about its traditional uses, chemical constituents, pharmacology and modern applications</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>121</volume><fpage>109589</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109589</pub-id><pub-id pub-id-type="pmid">31810130</pub-id></element-citation></ref><ref id="B278-ijms-24-10537"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sittiwet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Puangpronpitag</surname><given-names>D.</given-names></name><name name-style="western"><surname>Niamsa</surname><given-names>N.</given-names></name></person-group><article-title>In vitro Antimicrobial Activity of <italic toggle="yes">Schefflera leucantha</italic>: The Potential of Respiratory Tract and Urinary Tract Infection Treatment</article-title><source>Int. J. Pharmacol.</source><year>2009</year><volume>5</volume><fpage>240</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.3923/ijp.2009.240.243</pub-id></element-citation></ref><ref id="B279-ijms-24-10537"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>F.-A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.-F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.-Y.</given-names></name><name name-style="western"><surname>Choudhary</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.-Q.</given-names></name></person-group><article-title>Chemical constituents from <italic toggle="yes">Schefflera leucantha</italic> R.Vig. (<italic toggle="yes">Araliaceae</italic>)</article-title><source>Biochem. Syst. Ecol.</source><year>2020</year><volume>91</volume><fpage>104076</fpage><pub-id pub-id-type="doi">10.1016/j.bse.2020.104076</pub-id></element-citation></ref><ref id="B280-ijms-24-10537"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karunai Raj</surname><given-names>M.</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duraipandiyan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Agastian</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ignacimuthu</surname><given-names>S.</given-names></name></person-group><article-title>Antimicrobial activity of Ulopterol isolated from <italic toggle="yes">Toddalia asiatica</italic> (L.) Lam.: A traditional medicinal plant</article-title><source>J. Ethnopharmacol.</source><year>2012</year><volume>140</volume><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2012.01.005</pub-id><pub-id pub-id-type="pmid">22265751</pub-id></element-citation></ref><ref id="B281-ijms-24-10537"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Crude polysaccharides from the seeds of <italic toggle="yes">Vaccaria segetalis</italic> prevent the urinary tract infection through the stimulation of kidney innate immunity</article-title><source>J. Ethnopharmacol.</source><year>2020</year><volume>260</volume><fpage>112578</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2020.112578</pub-id><pub-id pub-id-type="pmid">31962152</pub-id></element-citation></ref><ref id="B282-ijms-24-10537"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uzoigwe</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Agwa</surname><given-names>O.K.</given-names></name></person-group><article-title>Antimicrobial activity of <italic toggle="yes">Vernonia amygdalina</italic> on selected urinary tract pathogens</article-title><source>Afr. J. Microbiol. Res.</source><year>2011</year><volume>5</volume><fpage>1467</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.5897/AJMR10.866</pub-id></element-citation></ref><ref id="B283-ijms-24-10537"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chandraker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Ramteke</surname><given-names>P.</given-names></name></person-group><article-title>Antibacterial Activity of Medicinal Plants Against Pathogens causing Complicated Urinary Tract Infections</article-title><source>Indian J. Pharm. Sci.</source><year>2009</year><volume>71</volume><fpage>136</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.4103/0250-474X.54279</pub-id><pub-id pub-id-type="pmid">20336211</pub-id><pub-id pub-id-type="pmcid">PMC2839399</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-24-10537-f001" orientation="portrait"><label>Figure 1</label><caption><p>Epidemiology of urinary tract infections (UTIs). UTIs are multispecies; the type of infection can be caused by Gram-negative bacteria, Gram-positive bacteria, or fungi. Among them, uropathogenic <italic toggle="yes">E. coli</italic> (UPEC) are the main pathogenic factor for UTIs, accounting for about 75% of uncomplicated UTI cases and more than half of complicated UTI cases.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10537-g001.jpg"/></fig><fig position="float" id="ijms-24-10537-f002" orientation="portrait"><label>Figure 2</label><caption><p>Pathogenesis of UTIs and uropathogenic <italic toggle="yes">E. coli</italic> (UPEC) adhesin structure. UTIs begin when UPEC induce periurethral invasion and colonization. Subsequent UPEC ascension into the bladder and expression of fimbriae and adhesins result in colonization and invasion of host cells and interaction with the defensive system of the bladder epithelium. UPEC produce toxins that induce host cell damage, releasing essential nutrients that promote bacterial survival and ascension to the kidneys. Kidney colonization further leads to bacterial toxin production and host tissue damage. In severe cases, it can lead to the occurrence of diseases such as bacteremia. In the abovementioned process, the structure of UPEC, including type 1 fimbriae, P fimbriae, and other fimbriae and non-fimbrial adhesins, plays an important role in the pathogenic process of UPEC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10537-g002.jpg"/></fig><fig position="float" id="ijms-24-10537-f003" orientation="portrait"><label>Figure 3</label><caption><p>Adhesins of uropathogenic bacteria (orange: organism; blue: assembly pathway; green: adhesins).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10537-g003.jpg"/></fig><fig position="float" id="ijms-24-10537-f004" orientation="portrait"><label>Figure 4</label><caption><p>Schematic structure of type 1 fimbrial and P fimbrial organelles in UPEC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10537-g004.jpg"/></fig><fig position="float" id="ijms-24-10537-f005" orientation="portrait"><label>Figure 5</label><caption><p>The formation of intracellular bacterial communities (IBCs). <italic toggle="yes">E. coli</italic> enter the cytoplasm of urothelial cells and then form IBCs. The rapidly multiplying <italic toggle="yes">E. coli</italic> initially adopt a coccoid morphology and then change back to a rod-like shape as the IBC mature. Finally, <italic toggle="yes">E. coli</italic> protrude from the original cells and colonize and invade nearby cells in the form of filaments, initiating a second round of IBC formation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10537-g005.jpg"/></fig><fig position="float" id="ijms-24-10537-f006" orientation="portrait"><label>Figure 6</label><caption><p>Resistance profiles for uropathogens.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10537-g006.jpg"/></fig><fig position="float" id="ijms-24-10537-f007" orientation="portrait"><label>Figure 7</label><caption><p>Structural formulae of some UPEC-resistant and UPEC-susceptible antibiotics (orange: UPEC resistant; purple: UPEC susceptible).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10537-g007.jpg"/></fig><table-wrap position="float" id="ijms-24-10537-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-24-10537-t001_Table 1</object-id><label>Table 1</label><caption><p>Oral treatment regimens for acute uncomplicated cystitis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose and Duration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Common Adverse Effects</th></tr></thead><tbody><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nitrofurantoin monohydrate<break/>macrocrystals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 mg twice daily for 5 d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nausea, headache, gastrointestinal effects</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Pivmecillinam</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">400 mg twice daily for 5 d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rash and gastrointestinal upset, including nausea and vomiting</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Trimethoprim-<break/>sulfamethoxazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160/800 mg twice daily for 3 d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rash, urticaria, nausea,<break/>vomiting, hematologic signs</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Fosfomycin tromethamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 g single-dose sachet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diarrhea, nausea, headache</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><italic toggle="yes">&#946;</italic>-Lactams</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The dose varies by agent from 5 to 7 d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diarrhea, nausea, vomiting, rash, urticaria</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Fluoroquinolones</td><td align="center" valign="middle" rowspan="1" colspan="1">Ciprofloxacin</td><td align="center" valign="middle" rowspan="1" colspan="1">500 mg twice daily or<break/>1000 mg once daily for 3 d</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nausea, vomiting, diarrhea, headache, drowsiness, insomnia, tendon rupture, neuropathy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Norfloxacin</td><td align="center" valign="middle" rowspan="1" colspan="1">400 mg twice daily for 3&#8211;7 d</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ofloxacin</td><td align="center" valign="middle" rowspan="1" colspan="1">200&#8211;400 mg twice daily</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Levofloxacin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">750 mg once daily for 3 d</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-24-10537-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-24-10537-t002_Table 2</object-id><label>Table 2</label><caption><p>Reports describing vaccines against <italic toggle="yes">E. coli</italic>, especially UPEC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Type of Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Component of Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comments</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Whole-cell vaccines</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inactivated vaccines</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Solco-Urovac: 10 strains of heat-inactivated uropathogens (6 from <italic toggle="yes">E. coli</italic> of different serotypes and 1 each from <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">P. mirabilis</italic>, <italic toggle="yes">M. morganii</italic>, and <italic toggle="yes">E. faecalis</italic>).</p></list-item></list>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Causes the prophylaxis of recurrent UTIs and major side effects, such as fever, bleeding, burning, nausea, and vaginal itching.</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B179-ijms-24-10537" ref-type="bibr">179</xref>,<xref rid="B192-ijms-24-10537" ref-type="bibr">192</xref>,<xref rid="B193-ijms-24-10537" ref-type="bibr">193</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>StroVac: the same 10 strains in a different formulation.</p></list-item></list>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Causes the prophylaxis of recurrent UTIs.</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B181-ijms-24-10537" ref-type="bibr">181</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Uro-vaxom: 18 UPEC strains.</p></list-item></list>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Prevents recurrent UTIs in women.</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B182-ijms-24-10537" ref-type="bibr">182</xref>,<xref rid="B183-ijms-24-10537" ref-type="bibr">183</xref>,<xref rid="B184-ijms-24-10537" ref-type="bibr">184</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Urvakol: a mixture of inactivated bacterial pathogens including <italic toggle="yes">E. coli</italic>, <italic toggle="yes">P. mirabilis</italic>, <italic toggle="yes">E. faecalis</italic>, <italic toggle="yes">K. pneumoniae</italic>, and <italic toggle="yes">P. aeruginosa</italic>.</p></list-item></list>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Promotes immunogenicity in animals and humans.</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B186-ijms-24-10537" ref-type="bibr">186</xref>,<xref rid="B187-ijms-24-10537" ref-type="bibr">187</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Urostim: a mixture of inactivated bacterial pathogens including <italic toggle="yes">E. coli</italic>, <italic toggle="yes">P. mirabilis</italic>, <italic toggle="yes">E. faecalis</italic>, and <italic toggle="yes">K. pneumoniae</italic>.</p></list-item></list>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Promotes immunogenicity in animals and humans.</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B186-ijms-24-10537" ref-type="bibr">186</xref>,<xref rid="B187-ijms-24-10537" ref-type="bibr">187</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>ExPEC9V (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04899336">NCT04899336</ext-link>).</p></list-item></list>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Targets invasive extraintestinal pathogenic <italic toggle="yes">Escherichia coli</italic> disease (IED).</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B188-ijms-24-10537" ref-type="bibr">188</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Intranasal vaccination with formalin-inactivated CP923.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Shows stronger systemic antibody response.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B194-ijms-24-10537" ref-type="bibr">194</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Attenuated vaccines</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>NU14 &#916;<italic toggle="yes">waaL</italic>: a mutation of O antigens of UPEC strains.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Protects against NU14, CFT073, and four UPEC isolates.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B195-ijms-24-10537" ref-type="bibr">195</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Antigen-specific vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Capsular- or LPS-based vaccines</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>ExPEC4V (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03500679">NCT03500679</ext-link>): O antigens specific to serogroups O1A, O2, O6A, and O25B.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Prevents UTIs even with high bacterial doses and low bacteremia.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B196-ijms-24-10537" ref-type="bibr">196</xref>,<xref rid="B197-ijms-24-10537" ref-type="bibr">197</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Fimbrial and non-fimbrial adhesin vaccines</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>FimCH vaccine with Freund&#8217;s adjuvants; FimH vaccine with Alum and MF59 adjuvants.</p></list-item></list>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Promotes an immune response against UPEC and prevents colonization in murine and primate models; ineffective in humans.</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B198-ijms-24-10537" ref-type="bibr">198</xref>,<xref rid="B199-ijms-24-10537" ref-type="bibr">199</xref>,<xref rid="B200-ijms-24-10537" ref-type="bibr">200</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>TLR ligand-based vaccine with the fusion of FimH adhesin; vaccination with admixed FimH, FliC, and Montanide ISA 206 adjuvants.</p></list-item></list>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Induces an immune response and protects mice against UTIs.</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B198-ijms-24-10537" ref-type="bibr">198</xref>,<xref rid="B201-ijms-24-10537" ref-type="bibr">201</xref>,<xref rid="B202-ijms-24-10537" ref-type="bibr">202</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>PapDG vaccines with Freund&#8217;s adjuvants.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Generates immune responses and reduces UPEC colonization in a mouse model.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-ijms-24-10537" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iron-scavenger-receptor-based vaccines</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Salmochelin receptor IroN or IroN with Freund&#8217;s adjuvant; aerobactin receptor IutA conjugated with cholera toxin; yersiniabactin receptor FyuA with alum as an adjuvant.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Generates strong immune responses and protection against UPEC infection in murine models.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-ijms-24-10537" ref-type="bibr">121</xref>,<xref rid="B200-ijms-24-10537" ref-type="bibr">200</xref>,<xref rid="B203-ijms-24-10537" ref-type="bibr">203</xref>,<xref rid="B204-ijms-24-10537" ref-type="bibr">204</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toxin-based vaccines</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Vaccine containing antigens such as hemolysin HlyA, recombinant hemolysin, mutated CNF1, and HlyA toxins.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Reduces UTI symptoms in murine experimental infection models.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-ijms-24-10537" ref-type="bibr">2</xref>,<xref rid="B200-ijms-24-10537" ref-type="bibr">200</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-24-10537-t003" orientation="portrait"><object-id pub-id-type="pii">ijms-24-10537-t003_Table 3</object-id><label>Table 3</label><caption><p>Reports describing medicinal plants against <italic toggle="yes">E. coli</italic>, especially UPEC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Botanical Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Part Used</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Compound Class</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect and Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proof <break/>Obtained</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Abelmoschus manihot</italic> (L.) Medik.</td><td align="center" valign="middle" rowspan="1" colspan="1">Flowers</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Acts against LPS-induced cystitis; attributed to its anti-inflammatory profile by suppressing TLR4/MYD88/NF-<italic toggle="yes">&#954;</italic>B pathways.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vivo</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B234-ijms-24-10537" ref-type="bibr">234</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Agropyron repens</italic> (L.) P. Beauv.</td><td align="center" valign="middle" rowspan="1" colspan="1">Rhizome</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics, flavonoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Decreased bacterial adhesion; interaction with bacterial outer-membrane proteins.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vivo</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B235-ijms-24-10537" ref-type="bibr">235</xref>,<xref rid="B236-ijms-24-10537" ref-type="bibr">236</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Alchornea cordifolia</italic> (Schumach. and Thonn.) M&#252;ll.Arg.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves, stem bark</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids, <break/>phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity on ESBL-producing <italic toggle="yes">E. coli</italic> isolates.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B237-ijms-24-10537" ref-type="bibr">237</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Andrographis paniculate</italic> (Burm. F.) Nees</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoid</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of LPS-induced iNOS and COX-2 protein expression; negative regulation involving STAT3 phosphorylation and NF-&#954;B activation.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B238-ijms-24-10537" ref-type="bibr">238</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Arctostaphylos uva-ursi</italic> (L.) Spreng.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">UTI control; shrinking and tightening of mucous membranes.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B239-ijms-24-10537" ref-type="bibr">239</xref>,<xref rid="B240-ijms-24-10537" ref-type="bibr">240</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Aristolochia indica</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Whole plant</td><td align="center" valign="middle" rowspan="1" colspan="1">Aristolochic acid analogs</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity against MDR UPEC.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B241-ijms-24-10537" ref-type="bibr">241</xref>,<xref rid="B242-ijms-24-10537" ref-type="bibr">242</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Armoracia rusticana</italic> (Lam.) P. Gaertner et Schreb.</td><td align="center" valign="middle" rowspan="1" colspan="1">Roots</td><td align="center" valign="middle" rowspan="1" colspan="1">Isothiocyanates</td><td align="center" valign="middle" rowspan="1" colspan="1">Possible damage to the cell membrane.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro, <break/>in vivo, <break/>clinical</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B243-ijms-24-10537" ref-type="bibr">243</xref>,<xref rid="B244-ijms-24-10537" ref-type="bibr">244</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Arnica montana</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Flowers</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Biofilm-modulating activity on UPEC.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B229-ijms-24-10537" ref-type="bibr">229</xref>,<xref rid="B230-ijms-24-10537" ref-type="bibr">230</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Avicennia marina</italic> (Forsk.) Vierh.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B245-ijms-24-10537" ref-type="bibr">245</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Betula pendula</italic> Roth.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Bactericidal activity; modifications to the bacterial surface structures responsible for binding to the occupied surface.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B246-ijms-24-10537" ref-type="bibr">246</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Boerhaavia diffusa</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Hairy root, root</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Active against UPEC MDR strains.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B247-ijms-24-10537" ref-type="bibr">247</xref>,<xref rid="B248-ijms-24-10537" ref-type="bibr">248</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Bridelia ferruginea</italic> Benth.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Flavonoids, phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B249-ijms-24-10537" ref-type="bibr">249</xref>,<xref rid="B250-ijms-24-10537" ref-type="bibr">250</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Calluna vulgaris</italic> Salisb.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves, flowers</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B251-ijms-24-10537" ref-type="bibr">251</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Citrus reticulata</italic> Blanco</td><td align="center" valign="middle" rowspan="1" colspan="1">Seeds</td><td align="center" valign="middle" rowspan="1" colspan="1">Flavonoids, volatile oils</td><td align="center" valign="middle" rowspan="1" colspan="1">Reduction in UPEC invasion; decreased &#946;1 integrin expression.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B252-ijms-24-10537" ref-type="bibr">252</xref>,<xref rid="B253-ijms-24-10537" ref-type="bibr">253</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Costus spicatus</italic> (Jacq.) Sw.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antimicrobial activity; correlation between the antioxidant and antimicrobial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B254-ijms-24-10537" ref-type="bibr">254</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Crateava nurvala</italic> Buch-Hum (Varuna)</td><td align="center" valign="middle" rowspan="1" colspan="1">Bark</td><td align="center" valign="middle" rowspan="1" colspan="1">Alkaloids, saponins</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro, <break/>clinical</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B255-ijms-24-10537" ref-type="bibr">255</xref>,<xref rid="B256-ijms-24-10537" ref-type="bibr">256</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Curcuma longa</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Rhizome</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibiofilm activity; the inhibition of swimming and swarming behavior; the enhanced susceptibility of UPEC to antibiotics; alterations to biofilm morphology, including a reduction in thickness.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B257-ijms-24-10537" ref-type="bibr">257</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Cymbopogon citratus</italic> (DC.) Stapf</td><td align="center" valign="middle" rowspan="1" colspan="1">Whole plant</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Antimicrobial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B258-ijms-24-10537" ref-type="bibr">258</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Cyperus rotundus</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Rhizome</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B259-ijms-24-10537" ref-type="bibr">259</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Dendrobium officinale</italic> Kimura et Migo</td><td align="center" valign="middle" rowspan="1" colspan="1">Rhizome</td><td align="center" valign="middle" rowspan="1" colspan="1">Polysaccharides</td><td align="center" valign="middle" rowspan="1" colspan="1">The mitigation of UPEC-promoted pyroptosis in macrophage cells; the inhibition of the NLRP3/caspase-1/GSDMD pathway and ROS signal activation.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B260-ijms-24-10537" ref-type="bibr">260</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Equisetum arvense</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antimicrobial activity; the inhibition of biofilm mass production; antiadhesive action; modifications to the bacterial surface structures responsible for binding to the occupied surface.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B235-ijms-24-10537" ref-type="bibr">235</xref>,<xref rid="B246-ijms-24-10537" ref-type="bibr">246</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Galium odoratum</italic> (L.) Scop.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Modifications to the bacterial surface structures responsible for binding to the occupied surface.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B246-ijms-24-10537" ref-type="bibr">246</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Gynostemma pentaphyllum</italic> (Thunb.) Makino</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids, dammarane-type saponins</td><td align="center" valign="middle" rowspan="1" colspan="1">Reduction in pro-inflammatory response of BECs to UPEC; the modulation of antimicrobial peptides; NF-&#954;B inhibition and ERK activation.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B261-ijms-24-10537" ref-type="bibr">261</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Herniaria glabra</italic> Linnaeus.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">High bactericidal activity; the inhibition of biofilm mass production; modifications to the bacterial surface structures responsible for binding to the occupied surface.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B246-ijms-24-10537" ref-type="bibr">246</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Labisia pumila var. alata</italic> (Scheff.) Mez</td><td align="center" valign="middle" rowspan="1" colspan="1">Herbal</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Reduction in uroepithelial apoptosis and the number of intracellular UPEC cells in BECs; reduction in the expression of &#946;1 integrin</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B262-ijms-24-10537" ref-type="bibr">262</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Lactuca indica</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids, phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Reduction in the bacterial colonization of bladder epithelial cells; the inhibition of FAK, significantly decreasing bacterial adherence.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B263-ijms-24-10537" ref-type="bibr">263</xref>,<xref rid="B264-ijms-24-10537" ref-type="bibr">264</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Lawsonia inermis</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Xanthones</td><td align="center" valign="middle" rowspan="1" colspan="1">Antimicrobial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B249-ijms-24-10537" ref-type="bibr">249</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Ocimum gratissimum</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves, flowers</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Antimicrobial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B258-ijms-24-10537" ref-type="bibr">258</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Orthosiphon stamineus</italic> Benth.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Flavonoids, terpenoids, essential oils</td><td align="center" valign="middle" rowspan="1" colspan="1">Antiadhesive effects; direct interaction between compounds from the extract and the bacterial adhesins.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vivo</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B235-ijms-24-10537" ref-type="bibr">235</xref>,<xref rid="B265-ijms-24-10537" ref-type="bibr">265</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Parkia biglobosa</italic> (Jacq.) Benth</td><td align="center" valign="middle" rowspan="1" colspan="1">Roots, bark</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B266-ijms-24-10537" ref-type="bibr">266</xref>,<xref rid="B267-ijms-24-10537" ref-type="bibr">267</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Peganum. Harmala</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Seeds</td><td align="center" valign="middle" rowspan="1" colspan="1">Alkaloids, <break/>quinazoline derivatives</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial Activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B268-ijms-24-10537" ref-type="bibr">268</xref>,<xref rid="B269-ijms-24-10537" ref-type="bibr">269</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Petasites albus</italic> (L.) Gaertn.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves, flower stems, rhizomes</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Biofilm-modulating activity on UPEC.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B229-ijms-24-10537" ref-type="bibr">229</xref>,<xref rid="B270-ijms-24-10537" ref-type="bibr">270</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Petasites hybridus</italic> (L.) G.Gaertn., B.Mey. and Schreb.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves, flower stems, rhizomes</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Biofilm-modulating activity on UPEC.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B229-ijms-24-10537" ref-type="bibr">229</xref>,<xref rid="B270-ijms-24-10537" ref-type="bibr">270</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Petroselinum crispum</italic> (Mill.) Hill</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B271-ijms-24-10537" ref-type="bibr">271</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Piper arboreum</italic> Aubl.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Modulatory activity, synergistic activity with antibiotic drugs.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B272-ijms-24-10537" ref-type="bibr">272</xref>,<xref rid="B273-ijms-24-10537" ref-type="bibr">273</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Persicaria capitata</italic> (Buch.-Ham. ex D. Don) H. Gross</td><td align="center" valign="middle" rowspan="1" colspan="1">Whole plant</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids, <break/>phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-inflammatory and moderate antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro, <break/>in vivo</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B274-ijms-24-10537" ref-type="bibr">274</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">37</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Punica granatum</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Seed</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B259-ijms-24-10537" ref-type="bibr">259</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">38</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Rhodiola rosea</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Roots, rhizomes</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Biofilm-modulating activity on UPEC.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B229-ijms-24-10537" ref-type="bibr">229</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Rosa canina</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Fruit</td><td align="center" valign="middle" rowspan="1" colspan="1">Vitamins, minerals</td><td align="center" valign="middle" rowspan="1" colspan="1">The prevention of UTIs.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro, <break/>clinical</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B275-ijms-24-10537" ref-type="bibr">275</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Rosmarinus officinalis</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B271-ijms-24-10537" ref-type="bibr">271</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Salvia officinalis</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Antimicrobial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B258-ijms-24-10537" ref-type="bibr">258</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">42</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Salvia plebeia</italic> R. Br.</td><td align="center" valign="middle" rowspan="1" colspan="1">Whole plant</td><td align="center" valign="middle" rowspan="1" colspan="1">Flavonoids, terpenoids, Phenolic acids</td><td align="center" valign="middle" rowspan="1" colspan="1">Diuretic activity; UPEC susceptibility.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro, <break/>in vivo</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B276-ijms-24-10537" ref-type="bibr">276</xref>,<xref rid="B277-ijms-24-10537" ref-type="bibr">277</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">43</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Schefflera leucantha</italic> R. Viguier</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">terpenoids, saponins</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B278-ijms-24-10537" ref-type="bibr">278</xref>,<xref rid="B279-ijms-24-10537" ref-type="bibr">279</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">44</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Toddalia asiatica</italic> (L.) Lam.</td><td align="center" valign="middle" rowspan="1" colspan="1">Whole plant, leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics alkaloids</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial activity against MDR UPEC.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B241-ijms-24-10537" ref-type="bibr">241</xref>,<xref rid="B280-ijms-24-10537" ref-type="bibr">280</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Tropaeoli majoris</italic> herba</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Isothiocyanates</td><td align="center" valign="middle" rowspan="1" colspan="1">Intermediate susceptibility; possible damage to the cell membrane.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro, <break/>in vivo, <break/>clinical</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B243-ijms-24-10537" ref-type="bibr">243</xref>,<xref rid="B244-ijms-24-10537" ref-type="bibr">244</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Urtica dioica</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Antimicrobial activity; antiadhesive effects; modifications to the bacterial surface structures responsible for binding to the occupied surface, and the direct interaction between compounds from the extract and the bacterial adhesins.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro, <break/>in vivo</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B235-ijms-24-10537" ref-type="bibr">235</xref>,<xref rid="B246-ijms-24-10537" ref-type="bibr">246</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">47</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Vaccaria segetalis</italic> (Neck.) Garcke</td><td align="center" valign="middle" rowspan="1" colspan="1">Seeds</td><td align="center" valign="middle" rowspan="1" colspan="1">Polysaccharides</td><td align="center" valign="middle" rowspan="1" colspan="1">The upregulation of innate immunity in the kidney.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vivo</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B281-ijms-24-10537" ref-type="bibr">281</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Vaccinium macrocarpon</italic> Aiton</td><td align="center" valign="middle" rowspan="1" colspan="1">Fruit</td><td align="center" valign="middle" rowspan="1" colspan="1">polyphenols</td><td align="center" valign="middle" rowspan="1" colspan="1">The obstruction of bacterial adhesion to bladder cells; downregulation or interference with several bacterial virulence factors. <break/>The repression of the inflammatory cascades triggered by the immune system; the inhibition of UPEC motility.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro, <break/>in vivo</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B218-ijms-24-10537" ref-type="bibr">218</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Vaccinium vitis-idaea</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">High bactericidal activity; the inhibition of biofilm mass production; modifications to the bacterial surface structures responsible for binding to the occupied surface.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B246-ijms-24-10537" ref-type="bibr">246</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Vernonia amygdalina</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Leaves stems</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" rowspan="1" colspan="1">Antimicrobial activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B249-ijms-24-10537" ref-type="bibr">249</xref>,<xref rid="B282-ijms-24-10537" ref-type="bibr">282</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">51</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Zea mays</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Stigmata</td><td align="center" valign="middle" rowspan="1" colspan="1">Phenolics</td><td align="center" valign="middle" rowspan="1" colspan="1">Decreased bacterial adhesion; interaction with bacterial outer-membrane proteins.</td><td align="center" valign="middle" rowspan="1" colspan="1">In vivo, <break/>in vitro</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B235-ijms-24-10537" ref-type="bibr">235</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Zingiber officinale</italic> Roscoe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rhizomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibacterial activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B283-ijms-24-10537" ref-type="bibr">283</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>